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Abstract 
Human Papillomavirus (HPV) is the most common sexually transmitted infection (STI) 
in the US. Infection with low-risk HPV (i.e., 6 and 11) can cause genital warts, and persistent 
infection with high-risk HPV types (i.e., HPV 16 and 18) can progress to cancer. Currently, there 
is an HPV vaccine that is recommended for boys and girls, aged 11 to 12. Healthy People 2020 
established a national objective of 80% completion of HPV vaccination among children aged 13 
to 15 years old. Although the HPV vaccine is proven to be a safe and effective primary 
prevention strategy, uptake and completion rates remain low in the US.  
Vaccination mandates for school entrance are an effective strategy to improve 
vaccination coverage. In the US, HPV vaccine policies vary; some legislate in favor of 
educational campaigns, while others require health insurance to cover the HPV vaccine or 
require it for middle-school entry. Currently, only Virginia, Rhode Island, and Washington DC 
require the HPV vaccine for school entrance. In Puerto Rico (PR) the Department of Health 
recently approved the HPV vaccine school-entry requirement for children 11 to 12 years old, 
starting in fall 2018.  
Despite HPV vaccination’s cancer-preventive properties and vaccine mandates’ 
effectiveness, HPV vaccine school-entry requirements have not been widely adopted in the US. 
Guided by the Multiple Streams Approach, the purpose of this study was to understand the 
adoption process of PR’s HPV vaccine school-entry requirement. Phase 1 consisted of a 
qualitative study in PR using in-depth interviews. Participants included stakeholders in the PR 
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HPV vaccine school-entry approval process (in favor/against). Purposive sampling was used to 
recruit stakeholders identified from online sources, by consulting local experts, and utilizing 
snowball sampling. Interviews were audio-recorded and transcribed. Data were analyzed using 
applied thematic analysis. Phase 2 consisted of a content analysis of PR’s newspapers from 
January 1st, 2015 to July 31st, 2018. Data were described quantitatively and qualitatively.   
From 21 stakeholders that were interviewed, only one person expressed views against the 
HPV vaccine school-entry requirement. The stakeholders highlighted problems such as, the high 
incidence of HPV and HPV-related cancers in PR (e.g., cervical/oropharyngeal) that needed to 
be resolved. Social factors such as the case of Rhaiza López Plumey, a young mother, who died 
of cervical cancer in 2015, and the VOCES HPV Advisory Panel Report served as focusing 
events that motivated the adoption process. Stakeholders also discussed other policy initiatives, 
such as changes to the current immunization law. The political turn-over in key government 
positions facilitated the adoption process. During the summer of 2017, a policy window opened, 
and the HPV vaccine school-entry requirement was adopted in the summer of 2018. The policy 
entrepreneurs worked on what was needed for the HPV vaccine school-entry requirement to be 
adopted through collaborations among different sectors.  
A total of 286 news articles included the key terms “HPV” or “human papillomavirus” in 
Spanish. Thirty-four articles mentioned the HPV vaccine school-entry requirement. The highest 
number of publications that mentioned the HPV vaccine school-entry requirement in PR 
occurred in 2017, and during the first seven months of 2018. The arguments listed in the articles 
included concerns related to the side effects of the HPV vaccine, the sexual nature of the 
transmission of the virus, and that it should be the parents’ right to choose to vaccinate their 
children. Other areas such as the HPV clears by itself and that there is no consensus regarding 
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the HPV vaccine, were mentioned less frequently. Findings from this study can inform other 
states and public health practitioners interested in adopting HPV vaccine policy initiatives to 
improve HPV vaccination rates across the US and target the prevention of HPV-related cancers.
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Chapter 1: Introduction 
 
Background 
The Human Papillomavirus (HPV) is the most common sexually transmitted infection 
(STI) in the United States (Centers for Disease Control and Prevention, 2015; Satterwhite et al., 
2013), with around 18 million adolescents between the ages of 15 and 24 currently infected 
(Satterwhite et al., 2013). New cases of HPV are estimated to be around 14 million a year, half of 
which occur among this age group (Satterwhite et al., 2013). Common risk factors for HPV 
infection include a higher number of sexual partners (concurrently or sequentially), early sexual 
initiation, lacking or inconsistent condom use, young age, partner’s sexual behavior, immune 
system status, and biological susceptibility (Burchell, Winer, de Sanjose, & Franco, 2006; 
Centers for Disease Control Prevention, 2015; Markowitz et al., 2014; Ratanasiripong, 2012; 
Trottier & Franco, 2006). Infection with low-risk HPV types, HPV 6 and 11, causes anogenital 
warts (Garland et al., 2009), and persistent infection with high-risk types 16 and 18 can cause 
cancers such as cervical, vulvar, vaginal, penile, anal, and oropharyngeal (Forman et al., 2012; 
Markowitz et al., 2014; zur Hausen, 2002). 
Currently, there is an HPV vaccine that is mainly targeted for boys and girls 11 to 12 
years old (Centers for Disease and Control Prevention, 2016c), due to a better immune response 
before children become sexually active (Block et al., 2006). This segment of the population only 
requires two doses of the HPV vaccine (Centers for Disease and Control Prevention, 2016c). 
Catch-up vaccination is recommended for females between the ages of 13 and 26 years and for 
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males between the ages of 13 and 21 years, who will need three doses of the HPV vaccine 
(Markowitz et al., 2014; Petrosky et al., 2015). Furthermore, the nine-valent and the quadri-
valent versions are also recommended up to age 26 years of age for men who have sex with men 
(Markowitz et al., 2014; Petrosky et al., 2015), transgender young adults and people with 
immunocompromised conditions (Centers for Disease and Control Prevention, 2016c). 
During 2015, coverage with at least one dose of the HPV vaccine was 56.1%, and three 
doses were 34.9% among 13 to 17-year-old adolescents (Reagan-Steiner et al., 2016). Thus, 
uptake and completion rates of the HPV vaccine remain low in the US. Furthermore, there is 
state variation in the initiation and completion rates of the HPV vaccine among this age group. 
For example, Florida had a 62.5% initiation rate among females and 45.3% among males. 
Completion rates were 36.8% and 19.8%, for females and males respectively (Reagan-Steiner et 
al., 2016). Puerto Rico had overall initiation and completion rates estimated to be 75.8% and 
52.8% respectively. Among females, the initiation rate was 80.8% and among males was 71.1%. 
Completion rates were 61.9% and 44.1%, for females and males respectively (Walker et al., 
2017). 
This low uptake and completion rates are due to a combination of multi-level factors. 
Factors such as young age, gender, low parental awareness of the HPV vaccine, parental 
concerns about their children’s sexual behavior, vaccine side effects and safety have been noted 
at the individual level (Berenson, 2015; Holman et al., 2014). At the interpersonal level factors 
such as lack of physician recommendation (Dorell, Yankey, Kennedy, & Stokley, 2013) and 
communication between mother and child (Gross, Laz, Rahman, & Berenson, 2015) have been 
found to impact HPV vaccine initiation and completion. Ethnicity is a factor at the community 
level, with Hispanic minorities usually having higher rates of HPV vaccine initiation (Henry, 
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Warner, Ding, & Kepka, 2015). At the organizational level, the HPV vaccine has received an 
endorsement from many important professional organizations such as the American Academy of 
Pediatrics, the American Academy of Family Physicians, the American College of Obstetricians 
and Gynecologists, among others (Byington et al., 2016). Lastly at the societal level, issues such 
as the social perception of HPV as a female only issue (Daley et al., 2016), news media messages 
(Gollust, LoRusso, Nagler, & Fowler, 2016), and the variation of state-level policies regarding 
the HPV vaccine (Laugesen et al., 2014), also impact HPV vaccine uptake and completion.   
Vaccines interventions have contributed to the improvement of the overall health of our 
society. Consequently, the reduction of vaccine-preventable diseases through vaccination is 
celebrated as one of the ten greatest public health achievements (Centers for Disease and Control 
Prevention, 1999; Centers for Disease Control and Prevention, 2011; Dube et al., 2013; Larson, 
Jarrett, Eckersberger, Smith, & Paterson, 2014). Vaccines were instrumental in the eradication of 
diseases such as polio and smallpox (Centers for Disease and Control Prevention, 1999; Dube et 
al., 2013), and have aided in lowering the incidence of pneumococcal infections and rotavirus 
hospitalizations in the US during the last decade (Centers for Disease Control and Prevention, 
2011).  
Vaccine interventions, mainly vaccination mandates, are an effective strategy to improve 
vaccination coverage. Based on the Community Preventive Services Task Force (GCPS, 2016) 
definitions, ‘school-entry requirements’ refer to laws that require vaccination and documentation 
as a condition to school attendance. The states create these laws; thus, there is variation across 
jurisdictions in the vaccinations included, the evidence required as documentation, the opt-out 
options (reasons parents can choose not to vaccinate their children), and how they are 
implemented (GCPS, 2016). ‘Vaccine mandates’ can be defined as a broad term that refers to 
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any law requiring vaccination. These can include school-entry requirements, or laws requiring 
hospital employees to be vaccinated (Cole & Swendiman, 2014). On the other hand, ‘school-
based programs’ are defined as vaccination programs where immunization is delivered at the 
schools. These programs usually include education and promotion, tracking of vaccination status, 
and referral components (GCPS, 2016). 
School-entry requirements are a highly effective strategy commonly used in the US to 
increase adolescent uptake of vaccines (Averhoff et al., 2004; Field & Caplan, 2008; Hinman, 
Orenstein, Williamson, & Darrington, 2002). Unfortunately, HPV vaccine policies have 
encountered a lot of resistance due to the intersection of vaccine safety and adolescent sexuality  
(Colgrove, Abiola, & Mello, 2010). Overall, arguments in favor and against of the HPV vaccine 
mandates have been previously debated. In 2006, when the HPV vaccine was approved by the 
FDA,  arguments in support for HPV vaccine mandates was influenced by framing the issue 
under the umbrella of women’s health and children’s welfare (Colgrove, 2006). Additional 
arguments in favor of a school vaccine mandate note the vaccine cost-effectiveness, the 
appropriate age range for inoculation, the importance of preventing and reducing cervical cancer, 
and parental involvement in health decisions (Vamos, McDermott, & Daley, 2008). Arguments 
against the HPV vaccine mandates included concerns related to the lack of transmission of the 
virus through casual contact, interfering with parental autonomy, public distrust due to 
pharmaceutical lobbying during policy development, and the potential economic burden on the 
government, health departments, and private physicians (Gostin & DeAngelis, 2007; Javitt, 
Berkowitz, & Gostin, 2008; Mello, Abiola, & Colgrove, 2012).  
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Public Health Significance  
In 1988, the Institute of Medicine (IOM) established in its seminal report ‘The Future of 
Public Health’ the core functions of public health as assessment, policy development, and 
assurance. These functions apply to all levels of the government (i.e., local, state, and federal), 
each level with its unique responsibilities (Institute of Medicine, 1988). The assessment core 
function includes the recommendation for public health agencies to “collect, assemble, analyze, 
and make available information on the on the health of the community, including statistics on 
health status, community health needs, and epidemiologic and other studies of health problems.” 
(Institute of Medicine, 1988, p. 7). Governmental and agencies cooperation was recommended to 
accomplish this function.  
 Policy development refers to “the development of comprehensive public health policies 
by promoting the use of the scientific knowledge base in decision-making about public health 
and by leading in developing public health policy” within the context of the democratic political 
process (Institute of Medicine, 1988, p. 8). Finally, assurance is a recommendation for public 
health agencies to guarantee their citizens the services that are needed “to achieve agreed upon 
goals are provided, either by encouraging actions by other entities (private or public sector), by 
requiring such action through regulation, or by providing services directly” (Institute of 
Medicine, 1988, p.8). Additionally, public health agencies should “involve key policymakers and 
the general public in determining a set of high-priority personal and communitywide health 
services that governments will guarantee” (Institute of Medicine, 1988, p. 8).  
In 1994, the US Public Health Service operationalized the core functions; and the Ten 
Essential Public Health Services were created (Novick & Morrow, 2008). In the IOM’s 2003 
follow-up report ‘The Future of the Public’s Health in the 21st Century’, the emphasis was on 
strengthening the public health infrastructures, and the importance of partnerships to enhance the 
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system (Novick & Morrow, 2008). Thus, six areas were identified to assure the conditions for 
population health. These include community, healthcare delivery system, employers and 
business, the media, academia, and government public health infrastructure (Institute of 
Medicine, 2003, as cited in Novick & Morrow, 2008).  
In addition to the core functions and the essential services, public health is based on 
overarching tenets. These include an understanding that protecting the health of entire 
communities may sometimes be in conflict with the individuals’ autonomy, the idea that health 
depends on social, behavioral, and biological factors that affect all the population, and that 
prevention (i.e., primary, secondary and tertiary) is the desirable approach (Novick & Morrow, 
2008; Schneider, 2016). Thus, the core functions, the ten essential services, and public health 
overarching tenets have contributed to the formation of the discipline and its current 
achievements.   
The Centers for Disease Control and Prevention (2011) has identified ten areas in which 
public health has achieved significant accomplishments in lives and money saved during the first 
decade of the 21st century. These endeavors are in the areas of 1) vaccine-preventable diseases, 
2) prevention and control of infectious diseases, 3) tobacco control, 4) maternal and infant 
health, 5) motor vehicle safety, 6) cardiovascular disease prevention, 7) occupational safety, 8) 
cancer prevention, 9) childhood lead poisoning prevention, and 10) public health preparedness 
and response (Centers for Disease Control and Prevention, 2011).  
The present study falls under the policy development core function of public health by 
contributing to the overall science and creation of evidence. The study addresses issues related to 
the promotion of public health policy, the HPV vaccine school-entry requirement. The study’s 
research focus overlaps with two areas, vaccine-preventable diseases, and cancer prevention. The 
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research, practice, and policy implications that result from the study have been considered under 
this framework and will be discussed in Chapter 5.    
Statement of Need  
Healthy People 2020 established a national objective of 80% completion of the HPV 
vaccination among females and males aged 13 to 15 years old (U.S. Department of Health and 
Human Services & Office of Disease Prevention and Health Promotion, 2015). Despite research 
demonstrating the safety and effectiveness of the HPV vaccine as a primary prevention strategy 
(Petrosky et al., 2015; Stokley et al., 2014), HPV vaccination rates among adolescents remain far 
below the Healthy People 2020 goal. 
HPV is the cause of most cervical, vulvar, vaginal, anal, and penile cancers, and is also 
associated with anogenital warts and recurrent respiratory papillomatosis (Markowitz et al., 
2014). The HPV vaccine affords the opportunity to successfully prevent these types of cancers 
and HPV-related diseases (Markowitz et al., 2014; Petrosky et al., 2015). Moreover, the annual 
medical direct cost of the prevention and treatment of HPV-associated diseases in the US has 
been estimated to be around $8 billion (2010 US dollars) (Chesson et al., 2012). Thus, an overall 
reduction of the infection of HPV would significantly reduce the morbidity and mortality of 
these diseases and their associated economic costs. 
In the US, provider recommendation and parental education have been widely used the 
strategies to promote HPV vaccination; thus, a call has been made to consider HPV vaccine 
school-entry requirements as part of the approaches to increase HPV vaccination rates (Daley, 
Thompson, & Zimet, 2019). Recommendations are based on the available evidence of the 
effectiveness and previous experience in the US with vaccination mandates for school entrance 
(Averhoff et al., 2004).  
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Currently, the policies related to the HPV vaccine vary in content; some legislate in favor 
of educational campaigns while others require health insurances to cover the HPV vaccine or 
require the HPV vaccine for middle school entrance (Abiola, Colgrove, & Mello, 2013; Colgrove 
et al., 2010; Laugesen et al., 2014). Virginia, Rhode Island, Washington DC (Barraza, 
Weidenaar, Campos-Outcalt, & Yang, 2016), and Puerto Rico (PR) are the only states/territories 
currently requiring the HPV vaccine for school-entry.  
Despite cancer-preventive properties of HPV vaccination and the effectiveness of prior 
vaccine mandates, there is a need to understand why HPV vaccine school-entry requirements 
have not been widely adopted in the US. Thus, guided by the Multiple Streams Approach, the 
purpose of this study is to understand the macro level factors that influenced the adoption of the 
HPV vaccine school-entry requirement in PR. This purpose will be achieved via the following 
research questions:  
1. How did the problems, politics, and policy streams intersect to inform the HPV vaccine 
school-entry requirement in Puerto Rico? 
2. Who were the policy entrepreneurs involved in the adoption process and what were their 
roles? 
3. What were the arguments in favor of and against the HPV vaccine school-entry 
requirement? 
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Key Terms  
 HPV – human papillomavirus  
 STI – sexually transmitted infection 
 US – United States  
PR – Puerto Rico  
MSA – Multiple Streams Approach/Theory/Framework 
DOH – Puerto Rico’s Department of Health  
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Chapter 2: Literature Review 
 
The Human Papillomavirus  
The Human Papillomavirus (HPV) is the most common sexually transmitted infection 
(STI) in the United States (Centers for Disease Control and Prevention, 2015; Satterwhite et al., 
2013). Around 79 million people aged 15 to 59 are currently infected with the HPV, 18 million 
of them between the ages of 15 and 24 (Satterwhite et al., 2013). New cases of HPV are 
estimated to be around 14 million a year, half of those among youth 15 to 24 years old 
(Satterwhite et al., 2013). Most of all sexually active individuals will contract the virus at least 
once during their lifetime. For instance, it was estimated that among heterosexual individuals 
with at least one sexual partner, 84.6% of women and 91.3% of men, will contract HPV by age 
45 (Chesson, Dunne, Hariri, & Markowitz, 2014).  
The HPV belongs to the Papillomaviridae family a group of non-enveloped DNA viruses 
that can cause tumors in the epithelium tissue (Morshed, Polz-Gruszka, Szymanski, & Polz-
Dacewicz, 2014). In particular, HPV has an 8,000 base-pair long circular DNA wrapped in a 
protein shell composed of two molecules (L1 and L2) (Gattoc, Nair, & Ault, 2013; Munoz, 
Castellsague, de Gonzalez, & Gissmann, 2006). These two proteins (L1 and L2) and six early 
proteins (E1, E2, E4-E7) are necessary for the viral DNA replication within the infected cells 
(Morshed et al., 2014; Munoz et al., 2006). Currently, 170 types of HPV have been identified, 40 
of which infect the genital tract (de Villiers, 2013).  
An HPV infection is mostly asymptomatic and localized and can occur via various routes 
of transmission. HPV’s infections primarily occur via genital contact during sexual intercourse, 
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but other means of sexual contagion include oral-genital and anal-genital contact (Moscicki et 
al., 2012).  Evidence also indicates other routes of transmission, such as skin-to-skin contact, 
vertical transmission from mother to infant during vaginal delivery, hands to genitals or genitals 
to hands, and/or by contaminated fomites – objects that could carry the virus (e.g., sonography 
probes, speculum) (Liu, Rashid, & Nyitray, 2015; Tay, 1995). 
Common risk factors for HPV infection include higher number of sexual partners 
(concurrently or sequentially), early sexual initiation, lack or inconsistent condom use, young 
age, partner’s sexual behavior, immune status, and biological susceptibility (Burchell et al., 
2006; Centers for Disease Control Prevention, 2015; Markowitz et al., 2014; Ratanasiripong, 
2012; Trottier & Franco, 2006). Most HPV infections are transient and will clear within one to 
two years without clinical repercussions (Burchell et al., 2006; Trottier & Franco, 2006). 
Nevertheless, persistent infection can lead to diseases such as respiratory papillomatosis, genital 
warts, and some types of cancers (Centers for Disease Control Prevention, 2015; Jemal et al., 
2013; Markowitz et al., 2014; Molano et al., 2003; Moscicki, 1998; zur Hausen, 2002). Among 
women, HPV infection can be tested during a routine Papanicolaou test; however, there are no 
HPV tests approved for men (Markowitz et al., 2014).  
Low-risk HPV types 6 and 11 cause more than 90% of anogenital warts (Garland et al., 
2009). It has been reported that anogenital warts or condylomata acuminate, can develop clinical 
symptoms as early as two to three months after infection with HPV (Garland et al., 2009; Winer 
et al., 2005). It is difficult to estimate the incidence of anogenital warts because in the US this is 
not required to be reported (Park, Introcaso, & Dunne, 2015). Based on data from the US 
National Health and Nutrition Examination survey from 1999 to 2004, among 18 to 56-year-old 
adults, 5.6% of reported having a prior genital warts diagnosis (Dinh, Sternberg, Dunne, & 
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Markowitz, 2008). Additionally, this study found that diagnosis of anogenital warts was higher 
among 25 to 34-year-old women and 35 to 44-year-old men, 10.4% and 6.0% respectively. 
Factors associated with having genital warts include sex, age, race/ethnicity, the number of 
lifetime sexual partners, and illegal drug use (Dinh et al., 2008). 
Another less prevalent condition caused by HPV types 6 and 11 is recurrent respiratory 
papillomatosis (Lacey, Lowndes, & Shah, 2006; Markowitz et al., 2014). Infection with the HPV 
virus typically during childbirth, causes the growth of benign tumors in the respiratory tract (i.e., 
nose, mouth, larynx, lungs) (National Institute on Deafness and Other Communication Disorders, 
2010). These tumors can be removed through surgery but often grow back causing respiratory 
obstruction (Lacey et al., 2006). Due to its rare occurrence, incidence and prevalence rates are 
difficult to evaluate, but some estimates indicate 80 to 1,500 incident cases and 700 to 3,000 
prevalent cases among individuals younger than 18 years old in the US (Armstrong et al., 2000).  
HPV-related cancers include cervical, vulvar, vaginal, penile, anal, and oropharyngeal 
(Forman et al., 2012; Markowitz et al., 2014; zur Hausen, 2002). From 2008 to 2012, 
approximately 30,700 HPV-associated cancers were diagnosed annually in the US (Viens et al., 
2016). Specifically, 91% of cervical and anal cancers, 72% of oropharyngeal cancers, 63% of 
penile cancers, 75% of vaginal cancers, and 69% of vulvar cancers were attributable to HPV 
(Markowitz et al., 2014). Moreover, approximately 64% of these cancers are caused by HPV 
types 16 and 18 (Centers for Disease Control Prevention, 2015; Markowitz et al., 2014). This is 
because persistent biological infections with high-risk HPV types (i.e., HPV 16 and 18) are more 
likely to progress to cancer (Jemal et al., 2013; Markowitz et al., 2014; Schiffman, Castle, 
Jeronimo, Rodriguez, & Wacholder, 2007). Additionally, about 10% of the HPV-associated 
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cancers are attributed to HPV types 31, 33, 45, 52, and 58 (Centers for Disease Control and 
Prevention, 2015; Markowitz et al., 2014; Petrosky et al., 2015).  
The HPV Vaccine   
Currently, there are three approved HPV vaccines. The first two vaccines developed and 
later approved by the Food and Drug Administration (FDA) were the bivalent (Cervarix®) – 
only recommended for females – and the quadri-valent (Gardasil®) – recommended for both 
males and females. The Advisory Committee on Immunization Practices (ACIP) first 
recommended the HPV vaccine for routine vaccination for females in 2006 and males in 2011 
(Markowitz et al., 2014). The third vaccine that was approved by the FDA in 2014 was the nine-
valent version (Gardasil 9®). ACIP made it part of its recommended vaccines for both sexes in 
2015 (Petrosky et al., 2015). Table 1 contains a detailed description of the HPV vaccines 
available.  
The current ACIP recommendations indicate vaccinating children at 11 to 12 years of 
age, due to a better immune response before children become sexually active (Block et al., 
2006). Additionally, the HPV vaccine is recommended for females between the ages of 13 and 
26 years, and for males between the ages of 13 and 21 years, also as the known catch-up group, 
(Markowitz et al., 2014; Petrosky et al., 2015). Other populations to which the nine-valent and 
the quadri-valent versions of the HPV vaccine are also recommended include men who have sex 
with men (Markowitz et al., 2014; Petrosky et al., 2015), transgender individuals and people with 
immunocompromised conditions, all groups through age 26 (Centers for Disease and Control 
Prevention, 2016c). 
Until recently, all approved vaccines required three intramuscular shots over a six-month 
period (scheduled at zero, two, and six months after the first shot) (Petrosky et al., 2015).  The 
HPV vaccine series costs between $390 and $450, and additional fees may be charged by the 
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clinics and providers for administration costs (Association of Reproductive Health Professionals, 
n.d.). Research pointed to non-inferiority of two doses of the HPV vaccine (Dobson et al., 2013; 
Kreimer et al., 2015); thus in 2016, there was change to a two-dose/shots regime in the 
recommended number of dosages in the US. All 11 to 12 years old children should get two shots 
of the HPV vaccine six to 12 months apart. A third dose is required if the children received the 
two shots less than five months apart or if adolescents are older than 14 years or for 9 to 26-year-
old individuals with immunocompromised conditions (Centers for Disease and Control 
Prevention, 2016c). Currently, the World Health Organization (WHO) recommends a two-dose 
schedule for females younger than 15, and a three-dose schedule for females older than 15, and 
immunocompromised or HIV-infected individuals (World Health Organization, 2014).  
The vaccines are made of HPV L1 protein, which produces virus-like particles by using 
recombinant DNA technology; thus, making the vaccines not infectious (Markowitz et al., 2014). 
Common mild side effects associated with the HPV vaccine include pain and swelling at the 
injection site, headache, nausea, and muscle or joint pain (Centers for Disease and Control 
Prevention, 2015).  Nonetheless, a recent review of nine years (up to the year 2015) of 
worldwide data from active and passive post-licensure safety surveillance of the 4valent HPV 
vaccine, found that only syncope (i.e., fainting) and possible skin infection were associated with 
vaccination. Furthermore, the review found that there was no higher incidence of serious adverse 
events, such as anaphylaxis, stroke, and autoimmune diseases, compared to background rates 
(Vichnin et al., 2015). 
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HPV vaccine uptake and completion rates in the US.  
For 2016, it was estimated that only 56.0% of males between the ages of 13 and 17 years 
had received at least one dose of the HPV vaccine, in contrast to 65.1% of females in the same 
age group (Walker et al., 2017). For that same year, only 49.5% of females and 37.5% of males 
13 to 17 years old had three doses of the HPV vaccine. Among both male and female 
adolescents, coverage with at least one dose of the HPV vaccine was 60.4%, and three doses 
coverage was 43.4% (Walker et al., 2017). These coverage rates are 28% points lower than at 
least one dose of the Tdap and 22% lower than at least one dose of the meningococcal vaccine 
(Walker et al., 2017). Lower rates are observed among the catch-up population. In 2012, the 
HPV vaccine uptake among females between the ages of 18 and 26 (considered catch-up group) 
was around 34.1% (Schmidt & Parsons, 2014). During the 2011 to 2012 period, the uptake rate 
among males 18 to 26 years old was 5.5% (Pierre-Victor, Mukherjee, Bahelah, & Madhivanan, 
2014). 
There is state variation in the initiation and completion rates of the HPV vaccine among 
adolescents 13 to 17 years old. During 2016, Rhode Island had the highest rate of initiation 
among females (90.1%) and males (87.8%). Mississippi had the lowest initiation rates for 
females (47.8%), while Indiana and Wyoming had the lowest initiation rates for males (36.9%). 
HPV vaccine three dose completion among females ranged from 30.8% in South Carolina to 
73.0% in Rhode Island. Among males, completion rates ranged from 19.3% in Wyoming to 
68.7% in Rhode Island. Overall initiation and completion rates in Puerto Rico were estimated to 
be 75.8% and 52.8% respectively. Among females, the initiation rate was 80.8% and among 
males was 71.1%. Completion rates were 61.9% and 44.1%, for females and males, respectively 
(Walker et al., 2017). 
 
 
16 
 
There are also racial/ethnic differences in HPV vaccination, as well as differences based 
on poverty level. In 2014, HPV vaccination initiation and completion were higher among 
Hispanic adolescents compared to non-Hispanic White adolescents (Reagan-Steiner et al., 2016). 
Non-Hispanic Black adolescents and American Indian/Alaska Native males had a higher HPV 
vaccine initiation rates compared to non-Hispanic Whites. Additionally, compared with 
adolescents living at or above the poverty level, HPV vaccination initiation was higher among 
adolescents living below the poverty level (Reagan-Steiner et al., 2016). 
Healthy People 2020 established a national objective of 80% completion of the HPV 
vaccination among females and males aged 13 to 15 years old (Reagan-Steiner et al., 2016; U.S. 
Department of Health and Human Services & Office of Disease Prevention and Health 
Promotion, 2015). Despite research demonstrating the safety and effectiveness of the HPV 
vaccine as a primary prevention strategy (Petrosky et al., 2015; Stokley et al., 2014), the 
initiation and completion rates previously presented show HPV vaccination rates among 
adolescents remain far below the Healthy People 2020 goal.   
Health implications of increasing HPV vaccination rates.  
There are important health implications for increasing HPV vaccination. Research has 
reported findings regarding the reduction in the prevalence of HPV in the US population. A 
recent study found a 64% reduction in the prevalence of the HPV types covered by the 4valent 
vaccine among females between the ages of 14 and 19, within six years of the vaccine 
introduction in the US (Markowitz et al., 2016).  
As discussed before, HPV is the cause of most cervical, vulvar, vaginal, anal, and penile 
cancers, and is also associated with anogenital warts and recurrent respiratory papillomatosis 
(Markowitz et al., 2014). Thus, an overall reduction of the infection of HPV would significantly 
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reduce the morbidity and mortality of these diseases. Moreover, HPV is also the cause of 72% of 
all oropharyngeal cancers; however, the HPV vaccine is not currently recommended for the 
prevention of this type of cancer because of lack of clinical trial data (Chaturvedi et al., 2011; 
Markowitz et al., 2014). Nonetheless, the vaccine includes HPV types 16 and 18, associated with 
62% of the HPV-related oropharyngeal cancers (Gillison, Chaturvedi, & Lowy, 2008; Markowitz 
et al., 2014; Steinau et al., 2014). Therefore, increasing HPV vaccination rates could also have an 
impact on the reduction of oropharyngeal cancer rates. 
It is important to note that, there are some disparities in the distribution of HPV-
associated cancer incidence and mortality among race/ethnicities in the US (Jemal et al., 2013). 
For instance, data from 2008 to 2012 showed that cervical cancer rates were higher among 
Blacks compared to their White counterparts (9.2% and 7.1% respectively) (Viens et al., 2016). 
This same study found that cervical cancer rates were higher among Hispanics (9.7%) compared 
to non-Hispanics (7.1%) (Viens et al., 2016). Recent simulation models have been conducted to 
project changes in HPV-associated cancer burden. Findings suggest that HPV vaccination could 
not only decrease the morbidity and mortality of HPV-related cancers among all 
races/ethnicities, but it could also reduce the absolute degree of disparities (Burger et al., 2016). 
Nonetheless, some relative differences could worsen. For example, among males, the lifetime 
risk of dying of HPV-associated cancer lowered by 60%, but relative disparities increased when 
high uptake of the second generation of the HPV vaccine was assumed (Burger et al., 2016). 
Thus, the authors conclude that if the fundamental causes of disparities are not addressed (e.g., 
limited access to health care and cancer treatments) the relative disparities will likely continue 
and may even broaden (Burger et al., 2016).  
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Globally there is evidence in the reduction of HPV-related disease. A recent meta-
analysis of female HPV vaccination programs in nine high-income countries (Australia, Canada, 
Denmark, England, Germany, New Zealand, Scotland, Sweden, and the US), was conducted to 
assess the population-level effects of these programs on the rates of genital warts (Drolet et al., 
2015). Findings demonstrated significant reductions of HPV 16 and 18 infections, and of 
anogenital warts among 13 to 19-year-old girls when female vaccination coverage was at least 
50% (Drolet et al., 2015). Among this age group, a significant reduction of HPV types 31, 33 and 
45 was seen; thus, indicating some level of cross-protection. Among males under 20 years and 
women between 20 and 39 years old, a significant decrease of anogenital warts was also found 
indicating herd immunity effects (Drolet et al., 2015). In places with female vaccination 
coverage less than 50%, there were still significant decreases in HPV 16 and 18 infections and 
anogenital warts; however, no signs of cross-protection or herd immunity effects were found 
(Drolet et al., 2015).  
Reductions in the rates of genital warts in the US has also been reported. For example, 
among female members of private health insurance 15 to 19 years old, the prevalence of genital 
warts significantly decreased during the years of 2007 to 2010 compared to 2003 to 2006, 
indicating some effect of the HPV vaccine after its introduction (Flagg, Schwartz, & Weinstock, 
2013). Furthermore, Bauer, Wright, and Chow (2012) found a 35% and 19% significant 
reduction in genital warts diagnoses among females and males younger than 21 years, 
respectively, using a claims data from a California public family planning clinic. More recently, 
in a group of low-income and minority adolescents, rates of genital warts significantly decreased 
from pre- to post-vaccination periods from 3.5% to 1.5% in females and from 3.6% to 2.9% in 
males (Perkins, Legler, & Hanchate, 2015). 
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Economic implications of increasing HPV vaccination rates.  
Besides the health implications, there are economic consequences of improving HPV 
vaccination. The annual medical direct cost of the prevention and treatment of HPV-associated 
diseases in the US has been estimated to be around $8 billion (2010 US dollars) (Chesson et al., 
2012). Routine cervical cancer screening and follow-up accounted for about $6.6 billion, cervical 
and oropharyngeal cancers cost were around $1 billion, anogenital warts accounted for $288 
million, and recurrent respiratory papillomatosis accounted for 171 million dollars (Chesson et 
al., 2012). Furthermore, women bear about two-thirds of the annual costs of HPV-associated 
diseases (Chesson et al., 2012). Therefore, increasing the HPV vaccination rates could save 
billions of dollars to the US health care system, and could result in a decrease in the burden of 
HPV-related diseases among women. Additionally, routine HPV vaccination of 12-year-old 
females, “in the context of current screening and assuming lifelong vaccine-induced immunity, 
had an incremental cost-effectiveness ratio of $43,600 per QALY gained, as compared with 
screening alone” (Kim & Goldie, 2008, p. 825). 
In the US, recent data showed a 64% and a 34% decrease in the prevalence of HPV 6, 11, 
16, and 18 after the HPV vaccine introduction among 14 to 19-year-olds and 20 to 24 years old 
females, respectively (Markowitz et al., 2016). Thus, in addition to the reduction of the 
prevalence of anogenital warts (i.e., HPV 6 and 11) by the uptake of the HPV vaccine, this could 
also mean the savings of around 167.4 million dollars; which was the estimated direct costs 
associated with genital warts among 15 to 24 year old young adults (Chesson, Blandford, Gift, 
Tao, & Irwin, 2004).  
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Factors that impact HPV vaccine rates. 
 Many barriers and facilitators influence HPV vaccine acceptance among stakeholders, 
which affect HPV vaccination rates in the US.1 In this section, common barriers and facilitators 
to HPV vaccine uptake and completion will be presented following the levels of the Socio-
Ecological Model (SEM). The SEM is a framework commonly used in public health to identify, 
organize, and analyze factors that can impact/influence a public health issue or/in a population. 
This framework consists of the following levels of influence: intrapersonal, interpersonal, 
organizational, community, and societal (Coreil, 2010). Because of this multilevel perspective, 
the SEM is useful for understanding health problems, identifying needs or areas for public health 
intervention, and for developing interventions.  
Individual level.  
Factors such as age, sex, beliefs, attitudes, and knowledge are usually considered at the 
individual level. In the case of the HPV vaccine, the adolescent’s sex is a factor that influences 
vaccination rates. A study using data from the National Immunization Survey-Teen 2013 (NIS-
Teen 2013), showed that girls were more likely to be vaccinated and had completed the three 
doses compared to boys between the ages of 13 and 17 years (Lindley et al., 2016). This is also 
the case among the college student population. A recent study noted that, although the difference 
between males and females decreased in comparison to rates of fall 2009 to 2011, HPV 
                                                            
 
1 There are two systematic reviews that summarize barriers to HPV vaccination among adolescents aged 
11 to 17 living in the US Holman et al. (2014) included studies from 2009 to 2012. Berenson (2015) 
followed-up Holman’s review by looking at studies from 2013 to 2015. Therefore, some of the factors 
presented in the following sections are based on the studies included in these reviews. 
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vaccination rates in years 2012 and 2013 were still higher among females than males college 
students (Thompson et al., 2016).  
Age is another factor that influences HPV vaccination. In most studies identified by 
Holman et al. (2014), younger age was a reason for not vaccinating or for delaying vaccination 
(Baldwin, Bruce, & Tiro, 2013; Bastani et al., 2011a; Control & Prevention, 2012; Dorell, 
Yankey, Santibanez, & Markowitz, 2011; Gilkey, Moss, McRee, & Brewer, 2012; Hoffman et 
al., 2012; Laz, Rahman, & Berenson, 2012; Reynolds & O'connell, 2012). However, among 
males, this age difference was not observed in either HPV vaccine initiation or completion 
(Control & Prevention, 2012; Curtis et al., 2013).  
Parents, including caregivers, also report individual-level barriers to HPV vaccination. 
Holman et al. (2014) and Berenson (2015) noted in their reviews of studies that parents report 
the need for more information about the HPV vaccine. Additionally, in a recent study, parents of 
children 11 to 17 years old who decide to delay the HPV vaccine, have also reported the need for 
more information about the vaccine (Gilkey, Calo, Marciniak, & Brewer, 2017). Parents have 
also mentioned the cost of the HPV vaccine as a barrier to uptake in most studies summarized by 
Holman et al. (2014). Moreover, Berenson (2015) highlighted the cost of the HPV vaccine is a 
barrier to adolescent vaccination. This perception of the cost of the HPV vaccine is a barrier to 
HPV vaccination among parents even when they could get the vaccine through the Vaccines for 
Children program (Vadaparampil, Staras, et al., 2013). 
As reported by Holman et al. (2014) and Berenson (2015), research has found that some 
parents also think that the HPV vaccine will cause their children to initiate sexual activity and/or 
engage in risky sexual behavior. For instance, in a qualitative study with Puerto Rican mothers 
one of the themes related to HPV vaccination uptake was the idea that the vaccine would indicate 
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to their daughters that it would be fine to engage in sexual activity (Fernandez et al., 2014). This 
phenomenon is known as sexual risk compensation or sexual disinhibition (Zimet, Rosberger, 
Fisher, Perez, & Stupiansky, 2013). Nonetheless, two systematic reviews have concluded that 
there is no evidence for these concerns (Kasting, Shapiro, Rosberger, Kahn, & Zimet, 2016; 
Madhivanan et al., 2016). Furthermore, among college students no association between 
inconsistent condom use and HPV vaccination was found (Vazquez-Otero et al., 2016), further 
providing evidence that the HPV vaccine does not promote risky sexual behaviors.  
Holman et al. 2014 noted that studies’ findings of parental worries related to side effects 
and safety, and concerns about the newness of the vaccine did not clearly indicate if HPV 
vaccine uptake was affected (Laz et al., 2012; Litton, Desmond, Gilliland, Huh, & Franklin, 
2011; Sanders-Thompson, Arnold, & Notaro, 2011). Berenson (2015) also identified studies in 
which parents expressed concerns about the possibility of long-term health effects associated 
with the vaccine as a reason for not vaccinating their children (Blackman et al., 2013; Dorell et 
al., 2014). For example, in a sample of African American and Bahamian parents, most agreed 
needing more assurance on the HPV vaccine safety (Blackman et al. 2013). Concerns about 
adverse events were also found to be among the most common factors against  HPV vaccination 
among parents from Georgia  (Gargano et al., 2013). 
Parental religiosity or religious beliefs influence HPV vaccination uptake is a contested 
factor. Holman et al. (2014) found two studies in which religious affiliation was associated with 
disapproval in getting the vaccine (Pierre-Joseph et al., 2012; Thomas, Strickland, DiClemente, 
Higgins, & Haber, 2012), whereas in two other studies there was no association to HPV vaccine 
acceptance (Litton et al., 2011; Sanders-Thompson et al., 2011). For example, Litton et al., 
(2011), conducted a survey among female caregivers of 10 and 14-year-old girls, and found that 
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religious attendance as well as factors such as perceived susceptibility and severity of the 
infection were not associated with intention to vaccinate their children. On the other hand, 
among African American parents of young children, religious affiliation was correlated with 
planning and getting the HPV vaccine (Thompson et al., 2011).  
Furthermore, Berenson (2015) found studies that reported that among parents there is a 
lack of awareness and knowledge of the HPV likelihood of infection, of the risks or 
understanding that transmission of the virus can be prevented with the vaccine; resulting in some 
parents choosing not to vaccinate their children. For example, in a recent qualitative study guided 
by the HBM, most of the participants of a sample of African American parents perceived that 
their adolescent daughters were not susceptible to the virus. These parents believed their 
daughters were not sexually active (Galbraith‐Gyan et al., 2019). Similarly, Berenson (2015) 
reported on studies that found that among adolescents there is lack of knowledge about the virus, 
cervical cancer, and the HPV vaccine.  
Overall these barriers and concerns contribute to HPV vaccine hesitancy among 
parents/caregivers (Patel & Berenson, 2013). Additionally, health care providers may not 
recommend the HPV vaccine if they perceive parental vaccine hesitancy (Allison et al., 2016). 
Vaccine hesitancy (VH) has emerged as a concept to describe the phenomena of individuals 
deciding to delay or refuse vaccination. VH was defined by the SAGE Working Group as “delay 
in acceptance or refusal of vaccination despite the availability of vaccination services. Vaccine 
hesitancy is complex and context specific, varying across time, place and vaccines. It is 
influenced by factors such as complacency, convenience, and confidence” (MacDonald, 2015, p. 
3). This definition integrates the concepts ‘complacency’, ‘convenience’ and ‘confidence’ all 
part of the “3 C’s” model previously developed by the WHO EURO Vaccine Communications 
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Working Group in 2011 (MacDonald, 2015). The first C, ‘complacency,’ occurs when there is a 
perception of low risk of vaccine-preventable diseases and people think vaccines are not needed 
(MacDonald, 2015, p. 2). The second C, ‘convenience’ covers the accessibility and affordability 
factors related to vaccination services (MacDonald, 2015, p. 2). Finally, ‘confidence,’ refers to 
the trust people have in vaccine safety, in the health care system and health care providers, and in 
the policymakers who create the mandates related to which vaccines are required (MacDonald, 
2015, p. 2). 
Another critical characteristic of VH is that it is considered along a continuum with 
individuals who accept and those who refuse vaccines at the extremes, and the ‘vaccine-hesitant 
individuals’ standing as a heterogeneous group in the middle (Benin, Wisler-Scher, Colson, 
Shapiro, & Holmboe, 2006; Dube et al., 2013; Kestenbaum & Feemster, 2015; Larson et al., 
2014; MacDonald, 2015). Vaccine-hesitant individuals are heterogeneous because their 
indecision varies depending on the type of vaccine; they might refuse some, accept some and/or 
delay others (Dube et al., 2013; Larson et al., 2014).  
Despite these barriers, there are facilitators to HPV vaccine acceptance and initiation 
among parents. In Holman et al. (2014) review of the literature, some facilitators included in the 
summarized studies were parents’ interest in protecting their children before the initiation of 
sexual activities, perceived risk of diseases associated to HPV, and parental preventive-care 
seeking behaviors. Among adolescents, the promotion of health, prevention of STIs, and cancer 
prevention were mentioned as common reasons for accepting the HPV vaccine among high 
school, college, and graduate health students, respectively (Suryadevara et al., 2016). 
Among health care providers Holman et al. (2014) identified studies in their review that 
found individual-level barriers. Some of these studies noted barriers such as low knowledge 
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about the relationship of HPV with genital warts (Perkins & Clark, 2012a; Saraiya, Rosser, & 
Cooper, 2012), providers offering too much or too little information about the vaccine to parents 
(Goff, Mazor, Gagne, Corey, & Blake, 2011; Hughes, Jones, Feemster, & Fiks, 2011), assessing 
their patients based on perceived risk factors (Goff et al., 2011; Hughes et al., 2011; Perkins & 
Clark, 2012a), and concerns about parental attitudes towards vaccination (Perkins & Clark, 
2012a, 2012b; Quinn, Murphy, Malo, Christie, & Vadaparampil, 2012).  
Additional factors noted by Holman et al. (2014) among this group of stakeholders 
included concerns about the cost of the vaccine and issues with insurance coverage and 
reimbursement (Luque, Raychowdhury, & Weaver, 2012; Quinn et al., 2012). Berenson (2015) 
also reported findings from studies on the cost associated with the storage of the HPV vaccine, 
and inadequate reimbursement mentioned as barriers to HPV vaccination by physicians (Allison 
et al., 2013; Luque, Tarasenko, Dixon, Vogel, & Tedders, 2014; Malo et al., 2013; 
Vadaparampil, Murphy, Rodriguez, Malo, & Quinn, 2013).   
Interpersonal level.  
At the interpersonal level, factors such as family, peer, and partner and other relationships 
are common influences. Relationships with health care providers are essential. Physician 
recommendation is the most significant predictor of HPV vaccination among women (Rosenthal 
et al., 2011),  as well as among adolescents (Dorell et al., 2013; Dorell et al., 2011). However, a 
recent systematic review of the literature by Gilkey and colleagues (2016), found that providers 
still confront barriers to recommendation such as feeling uncomfortable when talking about sex, 
perceiving parental hesitancy to get the vaccine, or believing their patients at are at low risk of 
contracting HPV. Additionally, the authors found that if patients were young, male or from a 
racial/ethnic minority, providers would be less likely to recommend the HPV vaccine (Gilkey & 
 
 
26 
 
McRee, 2016). For example, data from the NIS-Teen 2013, showed that parents of boys 13 to 17 
years old were less likely to report provider recommendation compared to parents of girls in that 
age group (Lindley et al., 2016). Lack of physician recommendation has also been cited as a 
reason for not receiving the HPV vaccine in a study including high school, college, and graduate 
health students (Suryadevara et al., 2016), and among parents as reported in the literature 
reviews by Holman et al. (2014) and Berenson (2015).  
Another factor that can be listed at this level is the communication between mother and 
child. In a survey with mothers of children 9 to 17 years old, communication about STI’s, and 
contraception and condom use were positively associated with HPV vaccine initiation (Gross et 
al., 2015). This is an important factor because mothers are usually the ones deciding to vaccinate 
their children against HPV (Berenson, Laz, Hirth, McGrath, & Rahman, 2014; Gross et al., 
2015). 
Community level. 
 Some factors considered at the community level are geographical and/or cultural 
influence. The concept of community can include geographical locations, as well as 
cultural/ethnic groups. For instance, among low-income immigrant ethnic minority women 
concerns about locating a place for vaccinating their daughters was a barrier to HPV vaccination 
(Bastani et al., 2011b). Parents from Latino communities have mentioned the lack of provider 
recommendation as the main barrier to HPV vaccination for their sons and daughters (Aragones, 
Genoff, Gonzalez, Shuk, & Gany, 2015; Warner et al., 2015). In terms of geographical factors, a 
study looking at community-level factors associated with HPV vaccine uptake among female 
adolescents found that communities composed of mostly Hispanics and urban residence were 
associated with higher vaccine initiation (Henry et al., 2015). Among boys, having public health 
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insurance, lower income, education, and being Hispanic are factors associated with HPV 
vaccination (Kepka, Ding, Hawkins, Warner, & Boucher, 2016).  
Organizational level.  
The organization level includes experiences with the health care system, schools, and/or 
the workplace. For instance, Holman et al. (2014) found that across studies preventive care 
appointments, frequent contact with the medical system, and have received other vaccines were 
all associated with receiving at least one dose of the HPV vaccine. Additionally, Berenson 
(2015) identified the need to access the health care system at three different occasions as a 
barrier for HPV vaccination.   
Professional associations can also play a role in promoting the HPV vaccine. The HPV 
vaccine has received endorsement and support from multiple influential organizations such as the 
ACIP, the American Academy of Pediatrics, the American Academy of Family Physicians, the 
American College of Obstetricians and Gynecologists, and the WHO (Byington et al., 2016; 
World Health Organization, 2014). Nonetheless, research indicates that vaccine 
recommendations alone, by institutions such as ACIP, do not increase immunization rates 
(Askelson et al., 2010; Rosenthal, Kottenhahn, Biro, & Succop, 1995). 
Societal level.  
At this level, factors such as federal and state policies and programs, social norms, and 
the media can influence HPV vaccination rates. For example, Holman et al. 2014 found a study 
indicating a positive association between HPV vaccine intention with the belief it agreed with 
social norms regarding the vaccination of children (Reynolds & O'connell, 2012). This study 
used the Health Belief Model and the Theory of Reasoned Action to predict intention to HPV 
vaccination in a sample of parents/legal guardians of girls 9 to 18 years old (Reynolds & 
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O’Connell, 2012). Additionally, a more recent study looking at social norm’s beliefs among 
parents of boys also found that parents who thought other parents were also vaccinating their 
children were more likely to have the intention to vaccinate their sons compare to those who did 
not agree to vaccinating (Schuler & Coyne-Beasley, 2016).  
Another common social perception is that the HPV is a female issue; this notion, known 
as the “feminization of HPV”, is largely the result of the intersection between sexism and the 
vaccine’s scientific evolution (i.e., the known science) (Daley et al., 2016).  Furthermore, on a 
review of studies about the US news media coverage of the HPV vaccine since 2006, Gollust and 
colleagues (2016) found two common themes: “a rising focus on political controversy and a 
consistent emphasis on the vaccine as for girls, even beyond the point when the vaccine was 
recommended for boys” (p. 1). These messages influence stakeholders such as parents, 
providers, and policymakers. Additionally, network and word cluster analyses of online 
presentation of HPV information suggest that compared to boys, HPV vaccine information for 
women and girls is usually presented in sexual terms (Ruiz & Barnett, 2015). 
At the federal level, the Vaccines for Children program provides the HPV vaccine – and 
other required and recommended vaccines – at no cost to providers for use among uninsured or 
underinsured, Medicaid-eligible, and to American Indian/Alaska Native children up to 18 years 
old (Smith, Hinman, & Pickering, 2014). The Patient Protection and Affordable Care Act of 
2010 also requires insurances to cover vaccines recommended by the ACIP with no cost to the 
beneficiary (Markowitz et al., 2014). Using data from the National Health Interview Survey, a 
recent study estimated that 1.1 million and 854,000 women between the ages of 19 and 25 
initiated and completed the HPV vaccine, respectively, based on this ACA provision (Lipton & 
Decker, 2015).  
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At the state level, the introduced legislation related to the HPV vaccine is varied in 
content.  Some states, such as Colorado, New Jersey, North Carolina, have legislated in favor of 
awareness campaigns, while other states (e.g., Illinois, Maine, Nevada, and New Mexico) require 
health insurances to cover the HPV vaccine (Laugesen et al., 2014). The National Conference of 
State Legislatures reports that at least 25 states and territories have passed some type of 
legislation regarding the HPV vaccine. From those, only the states of Virginia and Rhode Island, 
and Washington DC require the HPV vaccine for school entrance (National Conference of State 
Legislatures, 2016). Details of the HPV vaccine school-entry policies are described in the 
School-entry requirements section (p. 38).  
Vaccine Interventions  
Vaccines interventions have contributed to the improvement of the overall health of our 
society. Consequently, the reduction of vaccine-preventable diseases through vaccination is 
celebrated as one of the ten greatest public health achievements (Centers for Disease and Control 
Prevention, 1999; Centers for Disease Control and Prevention, 2011; Dube et al., 2013; Larson et 
al., 2014). Vaccines were instrumental in the eradication of diseases such as polio and smallpox 
(Centers for Disease and Control Prevention, 1999; Dube et al., 2013), and have aided in 
lowering the incidence of pneumococcal infections and rotavirus hospitalizations in the US 
during the last decade (Centers for Disease Control and Prevention, 2011). 
The Community Preventive Services Task Force (CPSTF, 2016) has identified and 
organized vaccine interventions into three major categories: 1) enhancing access to vaccination 
services, 2) increasing community demand for vaccines, and 3) provider- or system-based 
interventions. Reducing out-of-pocket costs, and vaccine programs in schools and organized 
childcare centers, are examples of recommended vaccine interventions under the first category 
(CPSTF, 2016). Examples under the second category include client reminder and recall systems, 
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and vaccination requirements for childcare, school, and college attendance (CPSTF, 2016). 
Under the third category, recommended interventions include immunization information systems 
and provider reminders (CPSTF, 2016).  
It is important to note that school-based programs, school-entry requirements, and 
vaccine mandates are different concepts. To differentiate between school-based programs and 
school-entry requirements, the definitions provided by the CPSTF (2016) will be used and are 
presented below.  
School-based programs are defined as:  
“Vaccination programs in schools or organized child care centers are multicomponent 
interventions delivered on-site to improve immunization rates in children and 
adolescents. These programs include two or more of the following components: 1) 
Immunization education and promotion, 2) Assessment and tracking of vaccination 
status, 3) Referral of under-immunized school or child care center attendees to 
vaccination providers, 4) Provision of vaccinations. […] Vaccination programs are often 
collaborations between the school or child care center and local health departments, 
private healthcare providers, or community healthcare services.” (CPSTF, 2016) 
“Potential barriers to implementation of vaccination programs in schools might include 
difficulties coordinating between different programs, need for staff training, disruption of 
school routines, and concerns regarding confidentiality” (Briss et al., 2000, p. 112). 
School-entry requirements are defined as:  
“Vaccination requirements are laws or policies requiring vaccinations or other 
documentation of immunity as a condition of child care, school, and college attendance. 
Their purpose is to reduce the incidence of vaccine-preventable disease and associated 
morbidity and mortality by increasing vaccination rates. Laws are created by states, with 
the specific vaccines required established by the legislature and embodied in statutes or 
adopted as administrative rules by health or education departments. Institutions such as 
colleges and private schools may establish additional vaccination policies for attendance 
or residence. Vaccination requirements vary across jurisdictions by comprehensiveness, 
acceptable documentation of immunity, access to exemptions (especially nonmedical 
exemptions), and the type and consistency of enforcement.” (CPSTF, 2016) 
“Potential barriers to implementation of vaccination requirements for child care, school, 
and college attendance include administrative burden, difficulty coordinating various 
programs, and difficulty passing legislation” (Briss et al., 2000, p. 104). 
 
 
31 
 
The last concept, vaccine mandates can be defined as a broad term that refers to any law 
requiring vaccination. These can include school-entry requirements, or laws requiring hospital 
employees to be vaccinated (Cole & Swendiman, 2014). In a recent systematic review looking at 
the economics of vaccine interventions from 1980 to 2012, it was reported that school-based 
interventions are considered cost-effective. Population-wide laws had the most reach, but in the 
case of school-entry laws, there was no adequate cost and cost-effectiveness data. Additionally, 
the authors noted that, from an economic perspective, HPV vaccine strategies were among the 
least studied (Jacob et al., 2016).  
States’ police powers, vaccine mandates, and public health.  
The 10th amendment of the US Constitution prescribes that the powers that are not part of 
the federal government nor prohibited by the Constitution are reserved to the states, these are 
known as the police powers (Cole & Swendiman, 2014; Gostin, 2008). Due to the police powers, 
the states have the authority to enact laws for the protection of the health and general welfare of 
their citizens (Cole & Swendiman, 2014; Gostin, 2008). Thus, each state in the US has its power 
to decide vaccination policies. From a public health perspective, policy powers “include all laws 
and regulations directly or indirectly intended to reduce morbidity and premature mortality in the 
population” (Gostin, 2008, p. 135). Examples of these regulations include isolation, quarantine, 
and vaccination laws (Gostin, 2008).  
The theory of herd immunity has historically been used as a justification to enact vaccine 
mandates in the US. This theory poses that a chain of infection is interrupted when large 
numbers of individuals in the population are immune to the disease (Javitt et al., 2008). The US 
Supreme Court established a legal precedent in the case of Jacobsen v. Massachusetts 
(1905.197U.S.11) when it decided to uphold a smallpox vaccine mandate in favor of herd 
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immunity over the principle of autonomy (Colgrove & Bayer, 2005; Field & Caplan, 2008). 
With this decision, the US Supreme Court acknowledged the state of Massachusetts’ police 
powers to create reasonable regulations for the protection of the public’s health (Cole & 
Swendiman, 2014). Additionally, public health practitioners tend to favor vaccine mandates 
based on a utilitarian perspective, where society’s well-being overrides individual autonomy 
(Field & Caplan, 2008). A result of making vaccinations a requirement via vaccine mandates, 
access increases for underserved populations; thus, justice is another principle considered by 
Field & Caplan (2008) in the ethical framework. Furthermore, other perspectives also justify the 
need to enact laws requiring vaccination. Brennan (2016) argues that mandatory vaccination 
under a libertarian political framework is achievable because people advocating against vaccines 
are imposing unfair harm on others.  
School-entry requirements.  
Vaccination mandates for school entrance are a highly effective strategy commonly used 
in the US to increase adolescent uptake of vaccines (Averhoff et al., 2004; Field & Caplan, 2008; 
Hinman et al., 2002). Additionally, vaccine mandates for school entry are recommended by the 
CPSTF (2016) to increase vaccination uptake among children and adolescents. Moreover, these 
types of mandates have been found to be effective in reducing racial/ethnic disparities in vaccine 
uptake; such as in the case of requiring the hepatitis B vaccine for 5th grade in Illinois (Morita, 
Ramirez, & Trick, 2008). Currently, all of the US states and Washington DC have some kind of 
school-entry laws that require documentation of immunization (Cole & Swendiman, 2014). 
However, most of these policies provide opt-out options or exemptions based on medical 
reasons, religious objections or philosophical concerns (Bradford & Mandich, 2015; Field & 
Caplan, 2008).  
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According to Bugenske, Stokley, Kennedy, and Dorell (2012), while education-only 
requirements do not increase meningococcal conjugate and HPV vaccine coverage; middle-
school requirements are associated with higher coverage of vaccines such as tetanus/diphtheria 
(Td) or tetanus/diphtheria/pertussis (TdaP). Thus, one way to increase HPV vaccination rates 
would be to make the vaccine mandatory for school entrance. For instance, mandating the polio 
vaccine has proven effective in the eradication of the virus in the US (Osazuwa-Peters, 2013). 
However, in the case of the HPV vaccine policies, controversy has surrounded the matter due to 
“the intersection of two highly charged policy areas: immunization safety and adolescent 
sexuality” (Colgrove et al., 2010, p. 785).  
HPV vaccine mandates.  
As mentioned before, legislation related to the HPV vaccine vary. Some states have 
created legislation  in favor of educational campaigns, while others require health insurance to 
cover the HPV vaccine, or require the HPV vaccine for middle-school entrance (Abiola et al., 
2013; Colgrove et al., 2010; Laugesen et al., 2014). Currently, only Virginia, Rhode Island, and 
Washington, DC require the HPV vaccine for school-entry. As of September 2017, eight states 
(Georgia, Hawaii, Illinois, Minnesota, New Mexico, New York, Texas, and Rhode Island) have 
proposed different bills related to HPV vaccination for the 2017-2018 sessions. From those, only 
two from New York proposed for the HPV vaccine to be required for all children born after 
January 1, 1996/8 (National Conference of State Legislatures, 2017). 
One of the first efforts to require the HPV vaccine occurred in 2007, when the Texas 
Governor at the time, Rick Perry, issued an executive order to require the vaccine for sixth-grade 
girls (Colgrove et al., 2010). A strong backlash followed when donations from Merck to his 
campaign were made public (Mello et al., 2012). The order was overridden by the Legislature, 
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which thought the governor was ‘overreaching’ his constitutional powers (Abiola et al., 2013; 
Colgrove et al., 2010).  
In the US, Virginia’s mandate was the first one to be enacted in 2007 and was put into 
effect on 2009 (Pitts & Tufts, 2013). Virginia’s school entry law requires the first dose for 
females entering sixth grade. However, it is up to parental/guardian discretion to elect not to get 
the vaccine, since broad opt-out options are available (Virginia Department of Health, 2014). 
Consequently, such policy has not improved HPV vaccine uptake rates in Virginia five years 
after its enactment (Cuff et al., 2016). The Washington DC mandate that was initially passed in 
2007 and implemented in 2009 applied only to girls. Later in 2014, it was amended to include 
boys (Barraza et al., 2016). It currently requires the three-dose completion for all students 
entering sixth to twelve grade and allows for all the types of opt-out options (i.e., medical 
reasons, religious objections or philosophical concerns) (Government of the District of Columbia 
Department of Health, 2015). Rhode Island’s school-entry HPV vaccine mandate (passed in July 
2015 – through public regulation by Rhode Island Department of Health) only allows exceptions 
based on medical or religious reasons and requires boys and girls to be vaccinated (State of 
Rhode Island Department of Health, 2015; Washburn et al., 2016).  
In June 2017, the PR’s Department of Health (DOH) announced the HPV vaccine was 
going to be required for children 11-to-12 years old starting on the 2018-2019 academic year. 
The Secretary of Health indicated in a press release that the HPV vaccine series should be 
initiated at 11 years old along with the Tdap and the meningococcal vaccine. On June 2018, the 
official announcement of the DOH was published indicating that the HPV vaccine was going to 
be required for children 11-to-12 years old starting in fall 2018.  
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Arguments in favor of and against the HPV vaccine school-entry requirement.  
Support from different types of stakeholders and the public’s involvement is necessary 
for policy creation and adoption (Walt et al., 2008). Thus, exploring and understanding 
stakeholders’ reasons and identifying factors in support of or against the HPV vaccine school-
entry requirement is important for these policy processes to be successful. Based on a systematic 
search of the literature (last updated on September 12, 2017), 25 studies were identified as 
research involving any stakeholder reasons and factors in support or against the HPV vaccine 
school-entry requirement (Tables 2 and 3). The purpose of the following sections is to present a 
summary of the current state of the literature. 
Overall studies’ characteristics.  
Although 25 studies were identified, three pairs of studies used the same 
dataset/participants (Table 2). Publication years ranged from 2007 to 2016. A total of eight 
studies used qualitative methods, 13 studies used quantitative methods, two used mixed methods, 
and two studies used an experimental design (Table 2).  
Data collection years ranged from 2005 to January 2015 (two studies did not report this 
information) (Table 2). Only four studies reported collecting their data after October 2011 when 
the HPV vaccine was recommended for routine vaccination for boys by ACIP (Centers for 
Disease Control Prevention, 2011). Nan and Madden (2014) did not report year for data 
collection, but it was estimated to be during 2012). Furthermore, from these studies, just three 
asked if the HPV vaccine school-requirement should be created for boys and girls (Califano, 
Calo, Weinberger, Gilkey, & Brewer, 2016; Calo, Gilkey, Shah, Moss, & Brewer, 2016; 
Vercruysse et al., 2016). Two studies (although using the same database/participants) were about 
an existing mandate (the Virginia school-entry requirement) (Pitts & Tufts, 2013; St John, Pitts, 
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& Tufts, 2010), and one study addressed perceptions of school-entry compared to school-based 
programs among parents of girls and physicians (Vercruysse et al., 2016).  
In terms of theoretical frameworks used; nine studies did not mention any theory, and six 
studies used a theoretical approach to guide their study (Table 2). The theories used included 
Theory of Planned Behavior, the Awareness-to-adherence Model and the Diffusion Model (Kahn 
et al., 2009), the Cultural Cognition/Risk Theory (Kahan, Braman, Cohen, Gastil, & Slovic, 
2010), Journalistic Framing (St John et al., 2010), Multiple Streams Theory (Abiola et al., 2013), 
the Health Belief Model (HBM) (Perkins et al., 2013) , and the Cultural Theory of Risk with 
Message Framing Theory (Nan & Madden, 2014). One study did not mention a theory, but it was 
based on the same database/participants from the Abiola et al., 2013 study; thus, it was probably 
guided by Multiple Streams Theory (Colgrove et al., 2010).  
Finally, seven studies used theories for data collection purposes (e.g., items/scales), such 
as the Health Belief Model (HBM) (Pierre-Joseph, Belizaire, et al., 2014; Pierre-Joseph, Clark, et 
al., 2014), and Transtheoretical model (Vercruysse et al., 2016).  For their data analysis, Tissot et 
al. (2007) used framework analysis, Perkins, Pierre-Joseph, Marquez, Iloka, and Clark (2010) 
used Grounded Theory and content analysis, and Pitts and Tufts (2013) used thematic analytic 
procedures. Sanderson et al. (2009) integrated their findings to the HBM in the discussion 
section.   
Stakeholders/participants.  
In terms of the stakeholders involved in these studies; about half of the studies (n = 12) 
included parents/guardians. From those, seven studies were with parents of girls only, four were 
with parents of boys and girls, and one study included parents of only boys (Table 2).  Three 
studies involved physicians; one included pediatricians (Tissot et al., 2007), another one was 
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with primary care physicians (Kahn et al., 2009), and one study included both, pediatricians and 
family physicians (Califano et al., 2016).  
Three studies included multiple types of stakeholders. Abiola et al. (2013) and Colgrove 
et al. (2010) (same dataset/participants) had mostly policymakers, but also included 
representatives from the industry, medical professional organizations, and advocacy groups. 
Vercruysse et al. (2016) recruited both parents of 11 to 17-year-old girls and health care 
providers.  
Finally, seven studies included other types of stakeholders such as, emergency 
department patients (Millen, Ginde, Anderson, Fang, & Camargo, 2009), a national sample of 
American adults (mean age 47, study did not indicate if the participants were parents) (Kahan et 
al., 2010), minority men 18 to 22 years old (Pierre-Joseph, Belizaire, et al., 2014), minority 
women 18 to 22 years old (Pierre-Joseph, Clark, et al., 2014), 18 to 22 years old college students 
(Smith, Wilson, Pulczinski, & Ory, 2014), undergraduate students (18 to 29 years old) (Nan & 
Madden, 2014), and 18 to 26 year old female college students (Wilson, Smith, Rosen, Pulczinski, 
& Ory, 2016). 
Reasons and Factors in Support of or Against an HPV vaccine school-entry 
requirement among Parents/Guardians, Physicians, and Policymakers. 
Parents/guardians. (see Table 3) 
Reasons and factors in support of an HPV vaccine school-entry requirement. There are 
some characteristics of the parents that make them more likely to support the HPV vaccine 
school-entry requirement. These include if the mother - in this case, Latina - has been diagnosed 
HPV+ (Sanderson et al., 2009), had a Pap test during the previous year (Yeganeh, Curtis, & Kuo, 
2010),  and parents having a low socioeconomic status and a history of HPV-related disease  
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(Ferris, Horn, & Waller, 2010). Another factor associated with support is the reported ethnicity 
of the parent. Ethnic minorities, including immigrants, compared to Caucasians (Perkins et al., 
2010), Latinos compared to another ethnicity (Yeganeh et al., 2010), and Hispanics responding 
to a survey in Spanish compared to African Americans and Hispanics answering in English were 
more likely to support the HPV vaccine school-entry requirement (Robitz et al., 2011).  
 When parents discussed reasons to support the HPV vaccine school-entry requirement, 
characteristics specific to the HPV vaccine were mentioned. An overall positive attitude towards 
the benefits of the vaccine (St John et al., 2010), its function in the prevention of cervical cancer 
(Perkins et al., 2010) and STIs (Vercruysse et al., 2016) were some of the reasons mentioned. 
Moreover, factors associated with support included thinking that the vaccine works well (Robitz 
et al., 2011), the benefits of the vaccine (Carlos et al., 2011), vaccine safety (Yeganeh et al., 
2010), being interested in the vaccine (Ferris et al., 2010), knowledge about the reduction of the 
risk and effectiveness of the vaccine against cervical cancer (Ferris et al., 2010; Smith et al., 
2011), and genital warts (Ferris et al., 2010). Furthermore, the perceived severity of the virus was 
also a reason to support the HPV vaccine school-entry requirement among parents of adolescent 
boys (Perkins et al., 2013).  
 There were also factors related to the child that parents associated with the support of an 
HPV vaccine school-entry requirement. For instance, parents of children between the ages of 12 
and 14 compared to parents of younger (9-11) and older children (15-17) were more likely to 
support it (Ferris et al., 2010). Similarly, Smith et al. (2011) found parents were more likely to 
agree if they thought there were more benefits of providing the vaccine at a younger age.  Other 
factors associated with supporting the requirement was if their daughters were already vaccinated 
(Yeganeh et al., 2010) or if the parents intended to get the HPV vaccine for their daughters 
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(Robitz et al., 2011; Smith et al., 2011). Some factors were about their children’s’ sexual 
behavior.  Parents thinking that their children are susceptible to contract the HPV (Ferris et al., 
2010) were more likely to support the requirement. Similarly, parents considering protecting 
sexually active adolescents expressed their support (Perkins et al., 2010).  
 Another reason mentioned among parents that support the HPV vaccine school-entry 
requirement was the idea that it is a public health intervention that would be beneficial for all 
(Perkins et al., 2010; Perkins et al., 2013; Vercruysse et al., 2016). Moreover, one study found 
that irrespective of parents supporting or not the mandate; they all thought it should be required 
for both, boys and girls (Perkins et al., 2013). In the Smith et al. (2011) study, parents who 
thought all children should get the vaccine were also more likely to support the requirement.  
 Lastly, there were factors related to the characteristics of the HPV vaccine school-entry 
requirement. Back in 2008, parents thought the opt-out option of the Virginia HPV vaccine 
school-entry requirement was a ‘ploy’ to get parents to agree to it (St John et al., 2010), and once 
the vaccine is normalized the government would remove the option to opt -out. However, 
subsequent studies have found that parental agreement increases when opt-out options are 
provided in the requirement. For example, agreement to the HPV vaccine school-entry 
requirement increased from 59% to 92% (Robitz et al., 2011), from 47% to 84%, and from 21% 
to 57% (Calo et al., 2016) when opt-out options were included as part of the mandate. Moreover, 
in a recent study by Calo et al., 2016, factors associated with supporting an HPV vaccine school-
entry requirement were evaluated by looking at the HPV vaccine school-entry requirement with 
and without the opt-out option. Without the opt-out option, Hispanic parents compared to non-
Hispanic Whites were more likely to support the HPV vaccine school-entry requirement; as well 
as parents who thought the HPV vaccine was as important as other vaccines and was effective at 
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preventing cervical cancer. Similarly, parents who thought it would be difficult to find a clinic or 
provider to get the vaccine were more likely to support the HPV vaccine school-entry 
requirement without any opt-out option provided (Calo et al., 2016). When the opt-out option 
was considered, parents who thought that the HPV vaccine is effective at preventing cervical 
cancer, and is as or more important than other vaccines, were more likely to support the 
requirement (Calo et al., 2016).  
Reasons and factors against the HPV vaccine school-entry requirement. The 
infringement on parental rights and autonomy was the most common reason cited and associated 
with being against the HPV vaccine school-entry requirement (Ferris et al., 2010; Horn, Howard, 
Waller, & Ferris, 2010; Pitts & Tufts, 2013). Moreover, they expressed it is the parents’ rights or 
personal choice to decide to vaccinate their children, thus; a mandate would be a limitation to 
parental autonomy (Perkins et al., 2013; Pitts & Tufts, 2013; Smith et al., 2011; St John et al., 
2010; Vercruysse et al., 2016).  
There were characteristics of the parents or parental factors associated with not 
supporting an HPV vaccine school-entry requirement presented in the literature. These factors 
included ethnicity, such as African American (Robitz et al., 2011), and Caucasian (Perkins et al., 
2010), their beliefs that the vaccine will not work, and not having vaccinated or not having the 
intention to vaccinate their daughters (Robitz et al., 2011). Lastly, parents residing in the 
Midwest states compared to the Northeast states were less likely to support the HPV vaccine 
school-entry requirement when on opt-out option was provided (Calo et al., 2016).  
There were also reasons related to the HPV vaccine and the HPV. Parents who thought 
that the vaccine was new and who had safety concerns about it and its side effects were more 
likely to be against the HPV vaccine school-entry requirement (Carlos et al., 2011; Horn et al., 
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2010; Perkins et al., 2010; Robitz et al., 2011; Smith et al., 2011). The newness of the vaccine 
was also mentioned as a reason not to support the HPV vaccine school-entry requirement, even 
though the data for this study were collected during 2012 to 2013, almost a decade after the HPV 
vaccine approval by the FDA (Vercruysse et al., 2016). Also, parents discussed that there is not 
enough research on the vaccine and that its long-term efficacy it’s not known (Pitts & Tufts, 
2013). The mode of HPV transmission was also discussed as a reason to be against the HPV 
vaccine school-entry requirement among parents. Some noted the lack of casual transmission 
(Perkins et al., 2013; Vercruysse et al., 2016), while others emphasized the sexual transmission 
of the virus (Pitts & Tufts, 2013).  
Related to sexual activity/behavior of their children, parents who thought that their 
daughters would initiate sexual activity were less likely to support the HPV vaccine school-entry 
requirement (Smith et al., 2011). Additionally, parents also discussed that adolescents were not 
sexually active; thus, there was no need for the requirement (Vercruysse et al., 2016). 
Additionally, mothers who thought their daughters were too young for vaccination were less 
likely to support the HPV vaccine requirement for school entrance (Carlos et al., 2011).  
Parents who thought that drug companies or ‘pharma’ were behind the push for the HPV 
vaccine school-entry requirement were less likely to support it (Calo et al., 2016; Smith et al., 
2011). This was also a concern among parents when discussing their thoughts about the existing 
mandate in Virginia (Pitts & Tufts, 2013). These parents also mentioned a lack of information 
about the mandate and the safety and efficacy of the vaccine as concerns for them (Pitts & Tufts, 
2013; St John et al., 2010), which were also commented among parents of boys (Perkins et al., 
2013).   
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Physicians. (see Table 3)  
Among physicians reasons mentioned in support of the HPV school-entry requirement 
included the effectiveness of this strategy to increase immunization and its public health impact 
(Kahn et al., 2007; Tissot et al., 2007; Vercruysse et al., 2016). Similar to parents, agreement to 
an HPV school-entry requirement increased when opt-out provisions were provided (Califano et 
al., 2016). In this study 74% of physicians supported an HPV vaccine school-entry requirement 
with or without opt-out options; but when opt-out options were not specified only 47% agreed. 
Moreover, being in practice longer than 20 years, providing a good quality HPV vaccine 
recommendation (which was a self-reported measure the authors based on the following 
characteristics: as being gender and age appropriate, consistent, urgent and with a strong 
endorsement), and considering the HPV vaccine as important as Tdap and meningococcal 
vaccines were physicians’ characteristics associated with support when no opt-out options were 
included (Califano et al., 2016).  
The most common reason mentioned against the HPV vaccine school-entry requirement 
among physicians was the lack of HPV transmission through casual contact (Kahn et al., 2009; 
Tissot et al., 2007; Vercruysse et al., 2016). Physicians also expressed concerns about the long-
term efficacy and safety (Kahn et al., 2009; Tissot et al., 2007) and newness of the HPV vaccine 
(Vercruysse et al., 2016). Other reasons such as limitations to parental autonomy (Kahn et al., 
2009), costs, and challenges of the implementation (Vercruysse et al., 2016), worries that some 
patients not covered by Medicaid or VFC may not be able to get vaccine, society’s poor 
understanding of HPV and the vaccine, and the limited clinicians’ experience with the HPV 
vaccine (Kahn et al., 2009) were also discussed.  
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Policymakers.  
Colgrove, Abiola, and Mello (2010) found policymakers have indicated factors such as 
newness of the vaccine, the sexually transmitted nature of the HPV, cost of the vaccine, 
governmental coercion, and the policy process as reasons against the adoption of school 
mandates. Policy entrepreneurship was reported as in important factor in support of this type of 
vaccine mandates (Colgrove et al., 2010). 
The case of Puerto Rico 
Background.  
For July 2016, the US Census Bureau estimated a population of 3,411,307 in the Commonwealth 
of Puerto Rico. Moreover, 20.4% of the estimated population was under 18 years of age, and 
52.4% of the population was estimated to be female (United States Census Bureau, n.d.). PR is 
among the states/territories with the highest rates of estimated HPV-associated cancer (including 
anal, cervical, oropharyngeal, and rectal cancers), with a rate of 13.10 cases per 100,000 people 
who develop cancer (Centers for Disease and Control Prevention, 2016a). Furthermore, PR has 
the highest rate of HPV-associated cervical cancer in the nation with rates of 11.70 cases per 
100,000 women; followed by West Virginia with a rate of 9.9 per 100,000 women (Viens et al., 
2016).  Overall initiation and completion rates in Puerto Rico were estimated to be 75.8% and 
52.8% respectively. Among females, the initiation rate was 80.8% and among males was 71.1%. 
Completion rates were 61.9% and 44.1%, for females and males respectively (Walker et al., 
2017). 
Current immunization policy.  
PR’s current immunization law is Act 25 of 1983, which repealed Act 235 from 1974. 
Act 25 of 1983 was enacted to cover mandatory immunization for private and public schools at 
all levels, day care centers and social treatment centers ("Ley de Inmunizacion," 1983). As part 
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of the instructions of the law, students need to provide the completed DOH’s certificate of 
immunization at the beginning of the academic year, to be accepted at school. It is the duty of the 
school’s director and staff to ask for this certificate and notify the parents/caregivers if any of the 
required vaccinations is missing and where to get them (“Ley de Inmunizacion,” 1983). The opt-
out option mechanisms provided by this law include either a sworn declaration indicating 
religious reasons or a certification indicating medical reasons. School administrators must also 
prepare a report to the DOH indicating the number of students accepted, those accepted 
provisionally, and those who submitted any type of exception (“Ley de Inmunizacion,” 1983). 
The immunization record should be revised every 60 days until all immunizations have been 
completed. Those who do not comply after the determined timeframe will be excluded from 
school (“Ley de Inmunizacion,” 1983).  
By the law guidelines, the Secretary of Health must announce the required vaccinations 
every year three months before the beginning of classes (“Ley de Inmunizacion,” 1983). The 
only vaccines listed in the law are the ones against polio, diphtheria, tetanus, measles, and 
mumps (“Ley de Inmunizacion,” 1983). Additionally, under Act 25 of 1983, PR’s government 
authorized the Secretary of Health to decide which vaccines will be required for school entrance. 
Under this regulatory authority, the Secretary of Health officially announced in the summer of 
2018 that the HPV vaccine was going to be required for children 11-to-12 years old starting in 
the fall of 2018.  
Summary 
Persistent infections with Human Papillomavirus (HPV), the most common STI in the 
US, can lead to genital warts and cancers such as cervical, vaginal, penile, anal, and 
oropharyngeal. The HPV vaccine provides the opportunity to prevent cancer; yet, vaccination 
rates in the US remain low. Vaccine mandates such as school-entry requirements are 
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recommended evidence-based population strategies use to increase vaccination. In the case of the 
HPV vaccine, only Virginia, Rhode Island, Washington DC, and more recently Puerto Rico, 
have adopted an HPV vaccine for school entrance. PR adopted the HPV vaccine school-entry 
requirement in the summer of 2018 providing a timely scenario to explore the limited use of this 
type of policy.  Thus, the purpose of this study is to understand the macro-level factors that 
influenced the adoption of the HPV vaccine school-entry requirement in PR.   
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Chapter 3: Theoretical Framework 
 
Introduction  
Theories are useful in research to explain and predict phenomena, such as human 
behaviors. According to Glanz, Rimer, and Viswanath (2008), a theory is “a set of interrelated 
concepts, definitions, and propositions that present a systematic view of events or situations by 
specifying relations among variables, in order to explain and predict the events or situations” 
(p.26). Theories can help investigators frame their research questions, the study design, the 
process for data analysis, and the writing/reporting of their findings. Also, theories are useful in 
the development and evaluation of public health interventions (Glanz et al., 2008). The purpose 
of this study is to understand the macro level factors that influenced the adoption of the HPV 
vaccine school-entry requirement in PR. Multiple Streams Approach/Framework (MSA) 
considers macro-level factors, as well as the process by which a policy is adopted. In the 
literature, Multiple Streams has been labeled as a theory, a framework and as an approach. The 
following sections describe the theoretical framework used for this study.  
Theoretical Framework: Multiple Streams Theory 
  
Overview of the Theoretical Framework.  
In 1984 John W. Kingdon published his seminal work Agendas, Alternatives, and Public 
Policies in which he led the underpinnings for MSA (Kingdon, 1995; Zahariadis, 2007, 2014). 
His primary goal was to understand “why some subjects become prominent on the policy 
agenda, and others do not, and why some alternatives for choice are seriously considered while 
other are neglected” (Kingdon, 1995, p. 3). Kingdon was curious about the agenda-setting 
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process in the US, rather than about the implementation of policies. Therefore, MSA explains 
how the coupling of the three streams – problems, politics, and policy – by the policy 
entrepreneurs during policy windows increases the chance of policy adoption (Kingdon, 1995; 
Zahariadis, 2007, 2014).  
MSA considers choice as a collective output of the system in which policymaking occurs 
under ambiguity (Zahariadis, 2014). More recently, Zahariadis has defined MSA as “a lens or 
framework […] that explains how policies are made by the government under conditions of 
ambiguity” (Zahariadis, 2014, p. 25). Additionally, he argues that manipulation is an important 
aspect of the dynamics of the policy process since it is a way to deal with ambiguity (Zahariadis, 
2003, 2014). Ambiguity is manipulated by the policy entrepreneurs to serve different aims in the 
policy process (Zahariadis, 2014). 
Zahariadis (2014) describes the following assumptions in which MSA is based. First; 
“Individual attention or processing is serial, systematic attention or processing is parallel” (p. 
28). MSA operates under the assumption that, in political systems, many issues can be seen at 
the same time – parallel processing – and that MSA includes the broader social aspects and the 
individual level, thus; goes from the macro to the micro level. Second; “Policymakers operate 
under significant time constraints” (p. 29), which refers to the lack of time policymakers have to 
attend the different problems and potential solutions. Third, “The streams flowing through the 
system are independent” (p. 29), which describes how the three streams – problems, policy, and 
politics – run separate and in parallel one to another. These assumptions of MSA are useful in the 
understanding of how the system works, and for setting the context for the policy decision 
making process. 
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Key Structural Elements of MSA. 
The problem stream, policy stream, politics stream, policy window, and the policy 
entrepreneurs are the five key structural elements part of the MSA (Zahariadis, 2007, 2014). For 
a diagram that shows the relationship of these key elements see Zahariadis, 2007.  
The problem stream is composed of the concerns and conditions that people, such as 
policymakers and citizens, believe need to be resolved. For example, increasing HPV vaccine 
uptake and completion or reducing cervical cancer disparities. Policymakers become aware of 
these concerns through the following factors: indicators or the data that describe the problem 
(e.g., HPV vaccine uptake data from the National Immunization Survey-Teen), the focusing 
events – which are events that call attention to the problems these are usually pointed out by the 
media or the policy entrepreneurs (e.g., Merck “One Less” campaign), feedback from previous 
experiences that worked or did not work, and the load or the amount of problems the 
policymaker needs to attend to (Zahariadis, 2007, 2014).    
The policy stream includes the “primeval soup” of ideas or all the options for solutions 
coming from the experts. It is important to note that not all ideas will receive consideration by 
the policymakers (Kingdon, 1995; Zahariadis, 2014). Thus, MSA posits that there are criteria 
that guide and are part of the policymakers’ selection process (Zahariadis, 2007, 2014). These 
criteria include; technical feasibility, value acceptability, and level of integration. If a solution 
seems challenging to implement, does not align with the values of the policymaker, or seems too 
costly, it has a lesser chance of approval (Zahariadis, 2007, 2014).  
The politics stream refers to the broader political context and is composed of three 
features: “the national mood, pressure-group campaigns, and the administrative or legislative 
turnover” (Zahariadis, 2007, p. 73). The way groups of people think, the changes in members, 
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positions and political parties in power, and the influence some groups have over policymakers, 
all impact the chance that an idea is set on the agenda (Zahariadis, 2007, 2014). Moreover, when 
the national mood and changes in the government combine, these have powerful effects on the 
agenda (Zahariadis, 2014).  
The policy windows are particular moments in time when the three streams align, 
intersect or couple. These moments tend to be short in duration, and MSA assumes that the 
policy windows open one at a time (Zahariadis, 2007, 2014). As Kingdon (1995) defines it, a 
policy window “is an opportunity for advocates of proposals to push their pet solutions, or to 
push attention to their special problems” (p. 165). These windows are critical because they 
provide context to the policy-making process. For example, this alignment (policy window) 
occurred in 2009 when the state of Virginia was able to pass the first HPV vaccine school-entry 
requirement in the US (Pitts & Tufts, 2013).  
Finally, the policy entrepreneurs are the people or institutions who work on the coupling 
or joining the three streams together when the policy window opens (Kingdon, 1995). This group 
includes individuals and organizations, such as think tanks. They are, as Zahariadis (2007, 2014) 
describes, the manipulators of the policymakers, and those with the strategies, time, and 
resources to invest in their problem of interest.  
MSA includes three processes in order for these elements to combine and produce a 
choice. These processes are 1) attention, 2) search, and 3) selection (Zahariadis, 2014). 
Attention, the first of these processes, tends to be limited or scarce among policymakers. MSA 
posits that this is resolved by “institutional structure, the type of policy window that opens, and 
the symbols used to attract attention” (p. 36). The search process of solutions in governments is 
constant and influenced by the policy communities. Both public and private sectors can generate 
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ideas, and depending on the integration of these communities, different approaches will be 
conceived (Zahariadis, 2014). Lastly, the selection process is directed by the policy 
entrepreneurs using their skills and manipulation tactics. These strategies include framing or how 
the options are presented; affect priming or using emotions to drive social processes; salami 
tactics (slicing solutions into distinct phases presented to the policymakers who perceive them in 
this way as less risky); and the use of symbols which provide messages and evoke emotions 
(Zahariadis, 2014).  
Critiques.  
Several critiques have been raised regarding MSA. One critique questions if the 
conclusions of MSA are either empirical or assumption driven. To this, Zahariadis (2014) 
explains, that although MSA is based on the garbage can model in which decisions are the result 
of unplanned energy fluctuations, and in MSA the policy entrepreneurs couple the streams on 
purpose. These fluctuations are based on, what MSA assumes is the ambiguity of the decision-
making process by the policymakers. Zahariadis (2016) notes this “does not reject but rather 
supplements rational choice” (p. 4) 
Furthermore, a meta-review concluded that, even though MSA has been very prolific, has 
been used in many studies to analyze public policy, and has also been used in a variety of 
political contexts; most studies only use the five main or core elements but lack consistency in 
using all the subcomponents of the theory (Jones et al., 2016). This presents a problem since all 
the components were proposed to work together when the theory was developed (Jones et al., 
2016; Kingdon, 1995). Others point to MSA’s easy usability or low ‘barrier to entry’, due to its 
flexibility and apparent lack of need for a thorough codebook or hypotheses testing; and call for 
further empirical theoretical development (Cairney & Jones, 2016).  
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Other research applications of MSA.  
MSA has been used as an approach to evaluate different areas of health policy. This 
approach has been commonly used in tobacco policy research. For instance, a systematic review 
of qualitative studies looked at the application of frameworks used in tobacco policy studies and 
found that most of the studies used MSA (Arabloo, Tourani, & Ravaghi, 2018). One study 
included in the systematic review, used MSA to assess the enactment of a smoke-free law in 
Kentucky despite strong opposition from the hospitality industry. Findings noted the importance 
of collaborations between health care providers and a legal group with knowledge in tobacco 
control (Greathouse, Hahn, Okoli, Warnick, & Riker, 2005). MSA also guided another study that 
used interviews and archival documents to evaluate a non-smoker protection act brought to the 
agenda by the Governor of Tennessee (Mamudu et al., 2014). The authors noted the convergence 
of the streams occurred, but the contextual factors did not support the policy change; thus, 
resulting in the use of a weaker bill (Mamudu et al., 2014).   
Blackman (2005) utilized MSA to describe the literature regarding tobacco control policy 
process in the state of California and highlights a couple of limitations of the theory. These 
limitations relate to the power differential between the stakeholders (i.e., the tobacco industry 
and public health advocates), and the lack of focus on implementation (Blackman, 2005). In a 
case study included in the systemic review, MSA was used to understand the factors of tobacco 
control in Turkey and included data from interviews, documents, and surveys (Hoe, Rodriguez, 
Uzumcuoglu, & Hyder, 2016). Based on the findings, these researchers added the global stream 
to include the influence that had global prioritization of the issue of tobacco control (Hoe et al., 
2016). Lastly, in a recent case study, MSA was also used to appraise the adoption of Bill C-32 
banning flavored tobacco products in Canada (Lencucha, Ruckert, Labonte, & Drope, 2018). 
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Other studies have used MSA to guide the analysis of interview data on health care 
administration practices in Canada (Smith et al., 2015), to explore, via interviews with 
policymakers and researchers, the agenda-setting process of HIV/AIDS control in Iran 
(Khodayari-Zarnaq, Ravaghi, Mohammad Mosaddeghrad, Sedaghat, & Mohraz, 2016), and to 
look at non-communicable diseases policy development in Barbados and identify policy 
entrepreneurs (Unwin, Samuels, Hassell, Brownson, & Guell, 2016). Also, a recent study by 
Kumar, Gleeson, and Barraclough (2018), used MSA to analyze interviews with consumer 
advocates, and food industry and government employees on the development of nutrition 
labeling standards in Australia.  
Current related research.  
Research using MSA includes a literature review of the issues of redefining HPV-related 
anal neoplasia as a problem of all sexually active individuals and not only an issue of people 
living with HIV (Walhart, 2013). In this review, policy solutions to increase anal cancer 
screening are examined via a theoretical application of MSA (Walhart, 2013). The author uses 
the elements of problem, policy and political streams, policy window, and policy options in her 
application of MSA. There are also two publications using qualitative methods, one explored the 
factors that influenced states’ action regarding the HPV vaccine mandates (Colgrove et al., 
2010), and another one explored the HPV vaccine policy formation process in the US (Abiola et 
al., 2013). These studies used the same dataset consisting of 73 key informant interviews 
collected from six states (i.e., California, Indiana, New Hampshire, New York, Texas, and 
Virginia). These interviews were conducted following an interview guide based on the elements 
of MSA. Abiola et al. (2013), provides a comprehensive description and discussion of MSA in 
its application to understanding the political dimensions of HPV vaccine policy formation in 
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those six states. The authors found the importance of effective policy entrepreneurs in the 
influencing of the policy process. For Colgrove et al. (2010) it is important to note that there is 
no mention of MSA in their publication, but the study is included here because the data used 
were collected using MSA as the guiding framework.  
Lastly, a recent study by Shapiro, Guichon, Prue, Perez, and Rosberger (2017) utilized 
MSA to explore the reasons why some Canadian jurisdictions decided to fund the HPV vaccine 
school-based program for boys by reviewing the literature. The authors conclude that MSA was 
useful to identify factors that influenced the decision under each of the streams, particularly how 
cost-effectiveness and stakeholder advocacy guided the policy-making process (Shapiro et al., 
2017).  
Summary  
This chapter presented the theoretical framework used for this study selected based on the 
purpose of this study, which is to understand the macro-level factors that influenced the adoption 
of the HPV vaccine school-entry requirement in PR. The key elements of Multiple Streams 
Theory were discussed, as well as critiques, other research applications of MSA, and current 
research related to the topic at hand.   
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Chapter 4: Methods 
 
Introduction  
The methodology used to conduct this study is presented in this chapter. The purpose and 
research questions guiding this study are provided to guide the reader. Also, an overall 
description of the setting is presented to contextualize the study. An overview of the study design 
is followed by the details of the methodology used for each Phase. The chapter ends with a 
description of the strategies used to maximize data trustworthiness.   
Purpose and Research Questions.  
Guided by the Multiple Streams Theory, the purpose of this study is to understand the macro 
level factors that influenced the adoption of the HPV vaccine school-entry requirement in PR 
during the summer of 2018. This was achieved via the following research questions:  
1. How did the problems, politics, and policy streams intersect to inform the HPV vaccine 
school-entry requirement in Puerto Rico? 
2. Who were the policy entrepreneurs involved in the adoption process and what were their 
roles? 
3. What were the arguments in favor of and against the HPV vaccine school-entry 
requirement? 
Research Setting: Puerto Rico  
 Puerto Rico is an island on the Caribbean with an estimated population of around 
3,411,307 million residents (United States Census Bureau, n.d.). In 2015, the Puerto Rican 
median house income was $18,626 with 58% of children living in poverty (Krogstad, Starr, & 
Sandstrom, 2017), and the unemployment rate was estimated to be at 13% (Government 
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Development Bank for Puerto Rico, 2016). In a 2014 Pew Research Center survey describing 
religion in Latin America found that 56% of Puerto Ricans identified as Catholic, 33% as 
Protestant, 8% as unaffiliated, and 2% as other. Spanish is the main language spoken on the 
island.  
A Spanish colony since 1493, PR became a US territory in 1898, after Spain lost the 
Spanish-American war and conceded the island. In 1900, the Foraker Act established a civil 
government, after two years of military rule (Trías Monge, 1997). The Jones Act awarded Puerto 
Ricans US citizenship in 1917 (Trías Monge, 1997). The Commonwealth of PR was established 
in 1952 when the US government approved the island’s constitution, and a three-branch 
government (i.e., executive, legislative and judiciary) was created  (Government Development 
Bank for Puerto Rico, n.d.).  
Every four years, local elections take place, and Puerto Ricans elect their Governor and 
the members of the Legislative Assembly (Senate and House of Representatives). Puerto Ricans 
living on the island have representation in the US Congress via a Resident Commissioner, but 
cannot vote for members on the Congress or the President (Government Development Bank for 
Puerto Rico, n.d.). The current Governor, elected in 2017, is from the PNP party (Partido Nuevo 
Progresista). This political party advocates for statehood status for the island.  
As a territory of the US, PR has a Medicaid Program that receives funds from the federal 
government since January 1st, 1966 under the Social Security Act (Departamento de Salud, n.d.-
b). This program is managed directly by the PR’s DOH and provides healthcare services access 
to the medically indigent population. The Administration of Health Insurances of Puerto Rico or 
ASES (Administración de Seguros de Salud de Puerto Rico – in Spanish) plays the role of  
administrating the PR’s government health plan or “Plan de Salud Vital del Gobierno” which is 
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responsible for providing coverage for physical and mental health services through networks of 
preferred providers (Administracion de Servicios de Salud [ASES], n.d.). 
In terms of preventative health services, a division in the DOH administer the 
immunization funds available from the VFC to vaccinate low-income population from 0 thru 18 
years old (Departamento de Salud, n.d.-a).  Also, the ‘Centros de Salud Primaria 330’ provide 
immunization services to uninsured or underinsured groups. Funds for these primary care clinics 
come from the Bureau of Primary Health Care part of HRSA (VOCES, 2015). In the private 
sector, there are health insurance carriers available on the market. For immunization coverage, 
there are available vaccination centers in private hospitals that accept private health insurances 
with the corresponding copayments. Also, but less common, there are some providers, such as 
pediatricians, who provide these services (VOCES, 2015). 
Aftermath of hurricane Maria. 
 This section is described here to provide contextual information about the period during 
which this study took place. On September 20th, 2017 Maria hit PR as a category four hurricane 
with winds of 155 mph spreading all over the island and rain producing catastrophic flooding 
(National Weather Service, 2017).  Due to this atmospheric event, the island lost 
power/electricity causing significant damages to the healthcare system, including the private and 
the public sectors. 
Overview of study design  
This study employed an exploratory sequential mixed-methods research design (Clark & 
Creswell, 2011). The study consisted of two phases (Figure 1). First, a qualitative phase 
consisting of in-depth interviews, followed by a content analysis of newspaper articles. This 
second phase of the study was conceptualized to address the need for information on the 
arguments against the HPV vaccine school-entry requirement.   
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Figure 1. Overview study design 
Phase 1 consisted of in-depth interviews. Participants included stakeholders in the PR’s 
HPV vaccine school-entry approval process. Purposive sampling was used to recruit stakeholders 
identified from online sources, by consulting local experts, and utilizing snowball sampling. 
Interviews were audio-recorded and transcribed. Data were analyzed using applied thematic 
analysis (Guest, MacQueen, & Namey, 2012a). Phase 2 consisted of a content analysis guided 
by Bernard and Ryan (2010) steps and Neuendorf (2016) recommendations, that looked at 
articles published about the HPV vaccine school-entry requirement in two PR’s newspapers from 
January 1st, 2015 to July 31st, 2018. Data were described quantitatively and qualitatively. More 
details describing each of these phases are provided below. All study materials and procedures 
were approved by the University of South Florida Institutional Review Board (Appendix A). 
Phase 1: In-depth Interviews 
Recruitment.  
Participants were recruited using a non-random sampling strategy or purposive 
recruitment which is appropriate for qualitative studies (Hennink, Hutter, & Bailey, 2011). 
Purposive sampling techniques were used to recruit stakeholders identified from online sources 
with publicly available contact information (e.g., PR’s Department of Health website), by 
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consulting local experts, and utilizing the snowballing technique (Hennink et al., 2011). If 
participants were identified through an online source, they were contacted via email using the 
information available online. Email recruitment scripts provided information about the study. 
Key informants shared study information with potential participants and provided them with the 
researcher’s information (i.e., phone and email) if they were interested in further details about 
the study.  
Inclusion Criteria.  
Inclusion criteria included being 21 years old and older and involved in the PR’s HPV 
vaccine school-entry adoption process (in favor or against), such as staff from the department of 
health, physicians and organizations that played a role in the policy process. Participants 
categories included members from non-profit organizations, leaders from professional medical 
organizations, government employees, professors, researchers, and physicians, among others 
(See Phase 1: Interviews, Sample Description in the Results section). Exclusion criterion 
included being younger than 21 years old.  
Data collection.  
All interested participants meeting the inclusion criteria were scheduled for an in-depth 
interview. In-depth interviews were conducted either by phone or in-person depending on the 
participant’s preference and were audio-recorded.  
Sample size. 
In qualitative research, there is no mathematical formula to determine the sample size. 
Guest, Bunce, and Johnson (2006) call to “operationalize the concept as the point in data 
collection and analysis when new information produces little or no change to the codebook” (p. 
65). In other words, when the “information you collect begins to repeat itself” (Hennick et al. 
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2011, p. 88). For in-depth interviews, Guest et al. (2006) have suggested that data saturation can 
be achieved with 12 interviews. Thus, interviews were conducted until saturation was reached, 
measured by following guidelines provided by Guest et al., 2006 and the when during the 
snowballing process participants recommended stakeholders who had already been interviewed 
or were scheduled for an interview. A total of 21 interviews were conducted. Twenty participants 
described themselves as in favor of, and one was against the HPV vaccine school-entry 
requirement. From the 21 interviews, eight were conducted in person, and 13 were conducted 
over the phone. Interviews lasted an average of 45 minutes (ranging in minutes from 20:30 to 
72:30) and were completed between May and August 2018.  
Instrumentation.  
The interview guide consisted of open-ended questions adapted from an instrument used 
by Abiola et al. (2013). This guide was composed of open-ended questions to evoke 
conversations with the participants (Hennink et al., 2011). The format followed Hennick et al., 
2011 recommendations. Thus, a funnel design with an introduction, opening, introductory, 
transition, key, and closing questions was considered in the adaption of the interview guide. The 
main topic areas of the interview guide included background information about the participant, 
previous work (e.g., strategies or policies) related to the HPV vaccine, motivation, barriers and 
facilitators for the adoption, and arguments in favor of and against the adoption of the HPV 
vaccine school-entry requirement.   
This interview guide was translated into Spanish by the researcher and shared with two 
local experts for feedback. Additionally, the interview guide was pilot tested with two key 
informants, and suggested changes were made. The suggested changes mainly consisted in the 
variation of some words to reflect everyday language, and the flow/order of the questions. A 
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journal was kept to collect notes and thoughts during and after the interview was conducted. 
Probing was another technique used to gather information during discussions (Hennick et al., 
2011).  
Data analysis.  
Data were analyzed using applied thematic analysis (Guest et al., 2012a) and techniques 
recommended by Hennink et al. (2011). The following analytic steps were followed and are 
expanded below: the creation of a codebook, training of a second coder, assessment of intercoder 
agreement, application of data reduction and summarization techniques, and the selection of 
exemplary quotes. All the data were analyzed in Spanish.  
First, the audio-recorded material for all interviews was transcribed. A codebook with a 
priori codes, based on the interview guide was prepared. Additionally, the researcher was 
cognizant of emerging themes that arose from the data; thus, inductive codes were included in 
the codebook as suggested by Hennink et al. (2011). The codebook included the name and short 
name of the code, a description of the code, and an example of a quote from the data as 
recommended by Hennink et al. (2011). The notes taken during the interviews (noted in the 
journal) helped during the codebook development process by providing the ID number of the 
participant who provided a good quote or was eloquent in their narration when answering the 
questions. 
A second coder who is proficient (reading and speaking) in Spanish was trained using the 
codebook. Before all the data were coded, the researcher and the second coder independently 
coded one interview. Then they met to clarify issues about the codebook, and discuss the coding 
of the interview to achieve agreement (Morrison-Beedy, Côté-Arsenault, & Feinstein, 2001). 
After the meeting, the researcher made the agreed changes to the codebook and listed the set of 
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coding rules that were also agreed with the second coder. The journal also helped to keep track 
of the agreements and discussions that occurred during the training process.  
All interview data were imported to MaxQDA (VERBI Software, 2017). After the 
training process discussed above, the second coder and the primary investigator independently 
and consecutively coded three interviews (n = 3). An inter-coder agreement score of Kappa equal 
to 0.80 or more is a standard recommended to establish the reliability of the coded data (Guest, 
MacQueen, & Namey, 2012b). Using MaxQDA a Kappa score was calculated using those three 
interviews. After meeting and clarification of the coding, a final Kappa score of 0.89 was 
achieved. The remainder of the interview data were coded by the researcher (n = 18). During the 
process of coding, the researcher created memos that were later used for the creation of the data 
summaries.  
During the data reduction phase, qualitative matrixes were created by code. This step 
enabled the researcher to use a cross-case comparison technique to identify patterns by 
comparing a code across all interviews (Hennink et al., 2011). Additionally, categorization of the 
data was done to create summaries. These summaries or themes were linked back to the 
theoretical framework, by conceptualizing the data at an abstract level (Hennink et al., 2011). 
Exemplary quotes were chosen by the researcher to represent the themes. In Chapter 5: Results, 
the themes are presented following the key elements of MSA.  
Protection of Human Subjects. 
As part of the steps set in place to ensure the protection of human subjects, this study was 
submitted to the University of South Florida Institutional Review Board (USF IRB) for review 
and approval. All recruitment materials (i.e., emails) were prepared following the USF IRB 
guidelines.  
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All participants in Phase 1 were asked to sign an informed consent form (Appendix B) 
approved by the USF IRB and were given adequate time to read and ask questions about the 
study. A copy of the consent form was provided to each participant, which contained the contact 
information for the USF IRB and the researcher. Participants who took part in the phone 
interviews were asked to provide verbal consent. The researcher explained the purpose of the 
study to all participants. Participants were informed that they could stop participation at their 
discretion. Interviews were audio recorded after obtaining informed consent from the 
participants. Participants received a $20 gift card in appreciation for their time. Participants who 
preferred to complete the interview over the phone received the gift cards via email.  
All data collected were stored on a password-protected computer. Data were only shared 
with members of the research team (doctoral candidate, Committee Members, and second coder). 
Data analyses were conducted with de-identified data. Lastly, exemplary quotes taken from the 
participant's interview data were de-identified for the dissemination activities (i.e., posters, 
dissertation, and oral presentations). 
Phase 2: Content Analysis of PR’s newspaper articles  
During Phase 1 of this study only one person who identified as been against the HPV 
vaccine school-entry requirement was interviewed. Thus, this second phase of the study was 
conceptualized to address the need to include more information on the arguments against the 
HPV vaccine school-entry requirement. Overall, the methodology of this phase was guided by 
the seven steps of content analysis as summarized and recommended by Bernard and Ryan 
(2010, p. 289) and listed here: 
“1. Formulate research question or a hypothesis, based on existing theory or prior 
research. 
2. Select a set of texts to test the question or hypothesis. 
3. Create a set of codes (variables, themes) based on the research questions or hypothesis. 
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4. Pretest the variables on a few of the selected texts. Fix any problems that turn up with 
regards to the codes and the coding so that the coders become consistent with the coding. 
5. Apply the codes to the rest of the texts. Keep checking for coder reliability.   
6. Create a case-by-variable matrix from the texts and codes. 
7. Analyze the matrix using whatever level of analysis is appropriate.” (Bernard and 
Ryan, 2010, p. 289) 
 
Additionally, guidelines from Neuendorf (2016) on the design of descriptive quantitative 
content analysis as well as previously published content analysis guided the development of 
Phase 2. Guidelines by Neuendorf (2016) used in this study included the addition of a second 
coder, the recommendation for coder training, and the calculation of Kappa for the assessment of 
inter-rater reliability. Previously published content analyses related to the HPV vaccine (Dodd, 
Marlow, Forster, & Waller, 2016; Penţa & Băban, 2014; Quintero Johnson, Sionean, & Scott, 
2011) and the HPV vaccine school-entry requirement newspapers’ coverage (Casciotti et al., 
2014), were used to guide the selection and development of potential variables to abstract.  
 Protocol.  
A protocol delineating the steps for this phase was developed. This document was shared 
with members of the committee for their feedback. The information included in the protocol that 
guided the content analysis is described below.  
Newspapers and unit of analysis.  
Two of the most circulated Puerto Rican newspapers and their respective websites were 
reviewed (El Nuevo Dia, n.d.; elVocero.com, 2013). These are El Nuevo Día and El Vocero. 
Both newspapers are available online. Each article was considered the unit of analysis.  
Key terms.  
The words ‘VPH’ and ‘virus del papilloma humano’ (Spanish), (‘HPV’ and ‘Human 
Papillomavirus’), were the key terms used to search the articles on each of the newspapers search 
engine.  
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Inclusion and Exclusion criteria.  
Articles published from January 1st, 2015 to July 31st, 2018 were included. The year 
2015 was chosen as the starting date because on May 2015 the VOCES HPV Panel Report was 
published by VOCES (PR’s vaccine coalition). This report summarizes HPV and HPV-related 
cancers epidemiological data, HPV vaccination uptake and completion rates, and population 
sexual behaviors all in the context of PR. It also included the HPV vaccine school-entry 
requirement as one of the strategies to help achieve the Healthy People 2020 goal (80% of males 
and females with the recommended doses of the HPV vaccine). Additionally, the report was 
mentioned by the stakeholders who participated in the interviews as an important document that 
guided the process of adoption of the HPV vaccine school-entry requirement. The unrelated 
advertisement was excluded from the content analysis. The process of selection is described in 
Figure 2.   
Instrumentation.  
A set of variables was created based on the previous studies listed, and from the findings 
of Phase 1. A data collection sheet (i.e., a codebook) was prepared and tested with a sample of 
10% of the articles by two coders. This step allowed for latent themes, if any, to be captured, and 
for revisions to the data collection sheet. The final version of the data collection sheet was 
transformed into a case-by-variable matrix in Excel. Each article was listed in the first column by 
their identification number. The other variables were listed in a column each.  
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Figure 2. Article selection process for content analysis (based on PRISMA guidelines by Moher, 
Liberati, Tetzlaff, & Altman, 2009) 
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Data collection. 
Scanning steps.  
The researcher searched for the keywords on each of the newspapers’ online database 
search engines. The titles of articles were reviewed to eliminate articles that were not relevant or 
could be excluded based on the date. Repeated articles were also excluded. The remaining 
articles were accessed in full and were reviewed using the inclusion and exclusion criteria 
described above (Figure 2).  
Data abstraction.  
Data were abstracted from the articles and entered into the case-by-variable matrix. The 
researcher and a second coder independently coded a random sample of 10% of the articles and 
an inter-coder agreement was calculated. Kappa of ≥ 0.80 was used as a reference to establish 
reliability (Bernard & Ryan, 2010). Coding of the rest of the articles was completed by the 
researcher on the main variables that summarized the articles. As additional assurance of 
reliability, intra-coder reliability or stability reliability (Neuendorf, 2016) was assessed when the 
researcher reached the coding of the first 100 articles. A randomly selected sample of 10% of the 
articles was coded a second time by the researcher and intra-coder Kappa was calculated. SPSS 
version 24 was used to calculate Kappa scores. 
Data analysis.  
Data were summarized using descriptive statistics (i.e., frequencies and percentages) in 
Excel and SPSS version 25. The articles were also analyzed qualitatively to identify the 
arguments against the HPV vaccine school-entry requirement. This analysis was also conducted 
following techniques of applied thematic analysis (Guest et al., 2012a), such as coding, 
categorization, summarization, and the selection of exemplary quotes. These steps were 
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conducted using Excel and a word document, due to the small simple size of the articles 
analyzed qualitatively.  
Trustworthiness 
The concept of trustworthiness was introduced in the 1980s in order to address the 
criteria needed to evaluate the quality of qualitative research (Morse, 2015; Ulin, Robinson, & 
Tolley, 2005). These criteria or standards include credibility, transferability, dependability, and 
confirmability (Guba, 1981; Lincoln & Guba, 1985), and are equivalent to what in quantitative 
research is called internal validity, external validity, reliability, and objectivity (Guba, 1981; 
Morse, 2015). Not without criticism, these criteria have been used with little change over time 
(Morse, 2015). The following descriptions of trustworthiness apply to both phases of the study.  
Credibility (i.e., validity), refers to “the confidence in the truth of the findings, including 
an accurate understanding of the context” (Ulin et al., 2005, p. 25). To maximize credibility for 
the findings of this study, the researcher engaged in prolonged engagement with the data, had 
debriefing meetings with the co-major advisors, and triangulated the findings from the phases 
when writing the Results and Discussion Chapters (more details in the Triangulation section), as 
recommended by Guba (1981). Moreover, interviews were conducted until saturation was 
reached, measured by following guidelines provided by Guest et al., 2006 and the moment 
during the snowballing process when participants recommended stakeholders who 
had already been interviewed or were scheduled for an interview. Additionally, the findings are 
based on the narrative data, as exemplified by the included quotes, to show credibility (Ulin et 
al., 2005).  
Transferability (external validity, generalizability), refers to the ability to be able to apply 
findings to other contexts, however, in qualitative research “data are conceptually, not 
statistically, representative of people in a specific context” (Ulin et al., 2005, p. 27). To be able 
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to achieve this, it was important to select a sample representative of the experiences crucial for 
answering the research questions noted for the study (Ulin et al., 2005). As recommended by 
Guba (1981), purposive sampling was utilized for both phases of this study. Additionally, the use 
of a theoretical framework and an interview guide adapted from a previous study, help with the 
transferability when comparing and contrasting the findings to other contexts.  
Dependability (reliability), refers to “whether the results are dependable, whether the 
research process is consistent and carried out with careful attention to the rules and conventions 
of qualitative methodology” (Ulin et al., 2005, p. 26). For this study, a journal that includes all 
the decisions made regarding data collection and analysis during the investigation was kept as a 
way to address dependability by creating an audit trail (Guba, 1981). Having a second coder for 
both of the phases to discuss coding also helped with this criterion (Morrison-Beedy et al., 2001). 
Additionally, for Phase 1 inter-coder agreement, i.e., Kappa statistic, and for Phase 2 inter-coder 
and intra-coder agreement were calculated and considered. These steps contributed to creating a 
methodically sound study that can be replicated, even though its findings will be context specific 
due to the nature of qualitative research (Ulin et al., 2005). 
Confirmability (objectivity) means that the researcher makes an effort to separate her 
personal values from those of the participants (Ulin et al., 2005, p. 26). For the current study, the 
researcher kept a journal in which she wrote her thoughts, assumptions, and biases during the 
data collection and analysis steps of both phases of the study (see Reflexivity section) (Guba, 
1981). Additionally, during the data analysis process memos were written to track any thoughts 
that might bias the interpretation and/or the findings, and were considered during the data 
summarization (Guest et al., 2012a). The limitations of the study are also recognized as 
suggested by Shenton (2004) (see Chapter 6: Discussion).  
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Reflexivity.  
As the researcher of this study, my perspectives may have influenced the data collection 
and analysis processes (Hennink et al., 2011). Reflexivity requires the researcher to keep track of 
his/her thoughts, biases and assumptions along the research process to be able to identify 
situations in which those could influence the data collection and analysis (Ulin et al., 2005). 
Thus, in my reflection described below, I tried to put forward my background, position, and 
biases, as a way to acknowledge their potential effect during the overall research process of this 
study.  
I am from Puerto Rico. I was born and raised in San Juan, the capital of Puerto Rico. 
Both of my parents are physicians. Although in mainland US, I am categorized as 
“Latina/Hispanic,” in the sociocultural context of PR I am a white woman from a highly 
educated family. Before entering the world of public health research, I studied law and became 
an attorney. I worked in PR as an attorney in a non-profit corporation that provided legal aid for 
underserved populations. This job exposed me to the detrimental effects of social inequality, 
poverty, addiction, violence, and abuse daily. As a mother, witnessing other mothers lose 
custody of their children was almost unbearable. I could not prevent myself from empathizing. 
The difficult situations experienced by my clients under extremely aggravating circumstances 
produced a profound feeling of sadness and a sense of powerlessness. I was able to momentarily 
aid my clients, but I knew that once they got out of the door, they would again face the same 
social circumstances that in the first place got them in trouble. This made me realize that social 
problems require a change at the collective level, and not at the individual level. Larger societal 
changes take place through policy change.  
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During and after my MPH program, I had the opportunity of working with cancer 
survivors. Interviewing cancer survivors and talking about personal experiences was saddening 
and draining. Following that, I did research with various USF faculty on oropharyngeal cancer 
prevention, Hispanic cancer survivors, and barriers to HPV vaccine uptake in Hispanic 
populations. After identifying and understanding some of the barriers for cancer prevention at the 
individual and societal levels, my interest continued to be on policy. I was interested in 
documenting, analyzing, and understanding the process of adoption of the HPV vaccine school-
entry requirement. This was taking place in Puerto Rico and was perfect timing for my 
dissertation research.  
As a native Puerto Rican with well-developed interpersonal-professional skills, it was 
easy to navigate the institutional culture in Puerto Rico. I have a good understanding of unwritten 
rules, social expectations, and subtleties during social interactions that can only be learned by 
living many years as a Puerto Rican in the island. This allowed me to gain access to informants 
and promote openness during interviews, by being assertive. 
This project involved studying a population of Puerto Ricans, not as the other, but as a 
member of it; with the capacity to “zoom out” and observe as an outsider. This has provided me 
with multiple angles and varied ranges of magnification for analysis. My perspectives have one 
foot on the emic side and one foot on the etic side. On the emic side, I share some of the 
experiences, views, and identities of the Puerto Rican participants. On the etic side, I bring the 
outsider’s perspective of a researcher who has been academically trained in the mainland US. 
Making sense of what lies behind the events that led to the process of adoption, requires an 
understanding of the historical and cultural particularities of Puerto Rico. This is where being 
Puerto Rican is an asset.  
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Triangulation  
By using different sources of data and methods, or triangulation, a better understanding 
of phenomena can be achieved (Carter, Bryant-Lukosius, DiCenso, Blythe, & Neville, 2014; 
Patton, 1999). In qualitative research, triangulation can also be used to “test validity through the 
convergence of the information from different sources” (Carter et al., 2014, p. 545). Four types 
of triangulation have been described: 1) method, 2) investigator, 3) theory, and 4) data source 
triangulation (Denzin, 1978; Patton, 1999). This study used method and data source triangulation 
to better understand the process of adoption of the HPV vaccine school-entry requirement. The 
details of the data triangulation for this study are provided in Chapter 5: Results.  
Summary  
This chapter presented the design of the current study as well as the detailed information 
about the methodology conducted for both phases. Phase 1 consisted of a qualitative study in PR 
using in-depth interviews. Participants included stakeholders in the PR HPV vaccine school-
entry approval process (in favor/against). Purposive sampling was used to recruit stakeholders 
identified from online sources, by consulting local experts, and utilizing snowball sampling. 
Interviews were audio-recorded and transcribed. Data were analyzed using applied thematic 
analysis. Phase 2 consisted of a content analysis of PR’s newspapers from 2015 to July 2018 to 
further explore the arguments against the HPV vaccine school-entry requirement. Data were 
summarized and described quantitatively and qualitatively.  The findings from both phases are 
presented in the next chapter.  
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Chapter 5: Results 
 
Introduction  
The following chapter presents the findings from this study. For each phase, an overall 
description of the sample is provided, followed by a summary of the results. For Phase 1 of the 
study, findings are framed following the key elements of the theoretical framework. Phase 2 
results are presented following the stages of the content analysis. A final section includes 
triangulation of the results obtained from each phase.  
Phase 1: Interviews 
Sample Description.  
A total of 21 stakeholders were interviewed. These participants spoke about their current 
or past experience with the adoption process of the HPV vaccine school-entry requirement. In 
the sample, there was only one person who expressed views against the HPV vaccine school-
entry requirement. For the purpose of an overall description participants were categorized into 
five groups: 1) “Non-profit” included leaders and members of non-profit organizations or from a 
public corporation (n = 5), 2) “Professional Organization” included leaders of professional 
medical organizations (n = 3), 3) members of the “Government” (e.g., DOH employees and 
policymakers) (n = 5), 4) “Researchers” included members of the academia such as professors 
and researchers (n = 4), and 5) “Other” category (i.e., physicians, attorney, pharma 
representative) (n = 3). Note that participants could fit under two of the previous categories based 
on their different roles. For this sample description, participants were grouped under the category 
they identified their role was during the interview. For example, two OBGYN physicians 
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expressed their thoughts from their experiences as researchers, thus, were grouped under the 
Researchers group.  
Themes. 
Based on the interview data, and presented guided by the MSA elements, the following 
themes were found to be salient in the process of adoption of the HPV vaccine school-entry 
requirement in PR. The stakeholders highlighted indicators such as the high incidence of HPV 
and HPV-related cancers in PR (e.g., cervical/oropharyngeal) indicators of problems to be 
resolved. Also, social factors such as the case of Rhaiza López Plumey, a young mother, who 
died of cervical cancer in 2015, and the VOCES HPV Advisory Panel Report served as focusing 
events during the process. Stakeholders discussed other policy initiatives, such as changes to the 
current immunization law as concurrently being worked on.  
Additionally, the political turn-over in key government positions influenced the adoption 
process. During the summer of 2017, a policy window opened, and the HPV vaccine school-entry 
requirement was adopted in the summer of 2018. All the work needed for the HPV vaccine 
school-entry requirement to be adopted was conducted through collaborations among different 
sectors composed of the policy entrepreneurs. Below is a summary of each of the themes 
including exemplary quotes to illustrate the findings. Additional exemplary quotes are listed in 
Table 4. 
Problem Stream. 
Stakeholders talked about problems or factors they perceived served as catalysts to the 
process of adoption of the HPV vaccine school-entry requirement. These conditions can be 
organized into two categories, either health-related (indicators) or social conditions (focusing 
events).  
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Indicators. 
Among the health-related problems, one of the most frequently mentioned condition by 
the participants was the high HPV-related cancers incidence and prevalence in the island’s 
population. Particularly, stakeholders mentioned the current high rates of cervical cancer and the 
increasing rates of oropharyngeal cancer. Another health-related problem that served to initiate 
the process of adoption was the concern of how common HPV is in PR, as evidenced by studies 
conducted in the island. For example, stakeholders from a medical professional organization and 
from the government noted about HPV and cervical cancer; 
 
Participants noted that PR already had a relatively high HPV vaccine uptake (first dose). 
However, participants mentioned the need to increase HPV vaccine completion rates. This need 
to increase HPV vaccination completion rates was another health-related problem that needed to 
be solved. The following quotes from a researcher and a member of a medical professional 
organization convey these notions; 
“Bueno, yo creo que el hecho de que los 
cánceres cervicales hayan estado 
aumentando dramáticamente y se presentaron 
de hecho en la conferencia de prensa que se 
hizo las estadísticas del aumento en cáncer de 
cervicales y de que no hemos podido bajar el 
cáncer de boca y de las áreas asociadas, no 
porque no estemos bajando la incidencia de 
fumar sino porque nos está aumentando los 
asociados a VPH.” –003  
 
“Well, I think that the fact that cervical 
cancers have been increasing dramatically, 
and as a matter of fact the statistics of the 
increase in cervical cancer were shown in the 
press conference that was done, and that we 
have not been able to decrease oral cancer 
and related areas, not because we are not 
decreasing smoking incidence, but because 
we have an increase of HPV related 
[cancers]”—3, Professional Organization 
 
 
“Con VPH por la consecuencia tan terrible 
que es el desarrollo de cáncer y por las tasas 
elevadas de prevalencia de la infección, no 
del cáncer sino de la infección, sobre todo en 
las mujeres jóvenes de Puerto Rico, ciertos 
grupos entienden que esto se debe hacer.”—
007  
 
“With HPV, due to the terrible consequences 
of developing cancer and the high incidence 
of infection rates, not cancer but the infection, 
especially in young women in Puerto Rico, 
some groups understand that this needs to be 
done.” –007, Government 
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Focusing events. 
Among the social conditions affecting the adoption of the HPV school entry requirement 
policy, stakeholders mentioned two main factors 1) VOCES HPV Advisory Panel Report 
(Report), and 2) the case of Rhaiza López Plumey, a young Puerto Rican mother, who died of 
cervical cancer in 2015. 
VOCES HPV Advisory Panel Report (Report): Participants highlighted the importance of 
the Report made possible by VOCES and publicly available in 2015. VOCES took the initiative 
to make this report by creating a panel of experts. This report documented the need for 
increasing HPV vaccination on the island due to the high prevalence of HPV and HPV-related 
cancers and provided recommendations for action. One of the main recommendations suggested 
by the Report’s panel was to make the HPV vaccine a requirement for school entrance.  
 
 
 
 
 
 
“El hecho de que muchos teníamos una 
primera dosis bien alta en los 60 y pico 
porciento, pero entonces no se ponían la 
segunda ni la tercera.”—006 
 
“The fact that we had a high percentage, 60 
something, of first dose [of the vaccine], but 
then they would not get the second or 
third.”—006, Researcher 
“Puerto Rico siempre ha tenido una buena 
cobertura de la primera dosis, se habla de un 
85%. Ahora, donde ha decaído es la segunda 
y la tercera dosis que está por debajo del 50 y 
ahora al hacerse requisito supongo que ese 
porcentaje estimamos que suba también.”    
—013 
“Puerto Rico has always had good coverage 
of the first dose; it is said to be 85%. Now, 
where it has declined it is for the second and 
third doses which fall under the 50, and now 
with it becoming a requirement I suppose that 
percentage...we estimate it will go up too.”—
013, Professional Organization 
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The following quote illustrates how stakeholders described the Report; 
 
Among other recommendations, the Report noted the need for comprehensive HPV-
related education not only for the parents but also for providers, religious leaders, and the press. 
The following quote from a stakeholder part of the government shows how education was an 
important area for improvement; 
 
 
 
 
“No es algo que se logró de hoy para 
mañana, o que fue un capricho, sino esto fue 
un plan de trabajo establecido que yo te 
puedo compartir el documento, este es un 
documento de casi 70 y pico de páginas. De 
hecho, lo puedes encontrar en el Internet, 
puedes poner "Informe del panel asesor", de 
hecho, se llama "Informe y recomendaciones 
del Panel Asesor de VPH al Departamento de 
Salud.” –002 
 
“It [HPV vaccine school-entry requirement] 
is not something that was accomplished 
overnight, or that it was a whim, instead this 
was an established work plan for which I can 
share with you the document, this is an almost 
70-something page document. In fact, you can 
find it on the Internet, you can enter “Informe 
del panel asesor” [Advising Panel’s Report], 
in fact, it is called “Informe y 
recomendaciones del Panel Asesor de VPH al 
Departamento de Salud” [HPV Advising 
Panel’s report and recommendations for the 
Department of Health].” –002, Non-profit 
  
“Una de las cosas que se ha identificó es que, 
en ese momento, tanto la comunidad, como 
hasta los mismos profesionales de la salud, 
no habían recibido suficiente educación sobre 
la vacuna, indicaciones, sus efectos, el 
propósito, efectos secundarios, que la gente, 
particularmente la comunidad, pero también 
había desconocimiento en las profesionales 
de la salud.” – 015 
 
“One of the things that was identified was 
that, at that moment, the community, and even 
the healthcare professionals, had not received 
adequate education regarding the vaccine, 
indications, its effects, purpose, side effects, 
that the people, in particular, the community, 
but there was also a lack of knowledge in the 
healthcare professionals.” –015, Government 
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Here is a quote from a member of the ‘Other’ category that illustrates how the Report 
promoted the HPV vaccine school-entry requirement as a recommendation from the expert 
panel;  
 
The case of Rhaiza López Plumey: Another social condition mentioned was the case of 
Rhaiza López Plumey. Stakeholders described the case of Rhaiza as the story of a young Puerto 
Rican mother of three boys who died of cervical cancer in 2015. Rhaiza took part in an interview 
that narrated her cancer journey/story and made a call to all women to get screened for cervical 
cancer. This interview was part of a video that was posted and shared on social media. From the 
participants’ perspectives, Rhaiza’s story, and later her death, impacted the PR population and 
seemed to have brought awareness to the issue of cervical cancer. The following quotes illustrate 
Rhaiza’s case as a significant factor in the adoption;  
“Una de las cosas que surtió un efecto, que 
fue como bien emotivo fue un video que 
preparó Rhaiza Vélez Plumey, una joven 
madre de 32 años que murió a consecuencia 
de un cáncer de cérvix, donde ella hacía un 
llamado a las mujeres a hacerse los exámenes 
de rutina, de prevención de cáncer de cérvix y 
un llamado a vacunar a los jóvenes para 
evitar el cáncer de cérvix.”— 015 
 
“One of the things that had an effect, that was 
like very moving was a video prepared by 
Rhaiza Vélez Plumey, a 32-year-old young 
mother that died as consequence of cervical 
cancer, in which she made a plea to women to 
get their routine tests of cervical cancer 
prevention and a plea to get vaccinated to 
young people to avoid cervical cancer.” –
015, Government 
 
 
“A nosotros nos ayudó mucho también, por 
último, la historia de Rhaíza. La historia de 
Rhaíza para mí fue  
un turning point total […]”—002 
“Rhaíza’s story helped us a lot too. For me, 
Rhaíza’s story was a complete  
turning point [...]” –002, Non-profit 
 
“Hubo un consenso, uniforme de todos los 
participantes, de que en Puerto Rico se debía 
promover el uso de la vacuna y que, 
eventualmente, si queríamos bajar nuestras 
tasas de incidencia del virus, debíamos 
promocionar también que fuese uno de los 
requisitos de admisión escolar […]”—005 
 
“There was a unanimous consensus of all 
participants, that in Puerto Rico the use of the 
vaccine should be promoted and that, 
eventually, if we wanted to lower our virus 
incidence rates, we should also promote that 
it be one of the requirements for school 
admission […]” –005, Other 
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Feedback.  
Stakeholders described the work that was accomplished before the HPV vaccine school-
entry requirement could be adopted in 2018. These efforts to increase HPV vaccination rates date 
back to the years when the vaccine was first recommended by ACIP. The PR’s DOH listed the 
HPV vaccine as a recommend vaccination for girls and women, and then for boys and men 
following the ACIP guidelines and approvals for each group. For example, this quote illustrates 
DOH’s actions to stay on par with ACIP guidelines changes on age recommendations for girls; 
“Aquella vez, para el año 2006, el ACIP 
decía, "Vamos a vacunar a las niñas a los 11 
años, ese es el mejor momento" te dan toda la 
data científica y se estableció esa política 
pública. después entendimos, un año más 
tarde, entendimos que no había que limitarlo 
solamente a los 11 años, sino que aquella que 
no se hubiese vacunado a los 11 y ahora 
tuviera 13 o 15 podía beneficiarse porque 
calificaba para el programa, así que 
emitíamos (DOH) la recomendación.” –007  
“That time, for 2006, the ACIP was saying, 
“We are going to vaccinate girls at age 11, 
that is the best moment” they give you all the 
scientific data and it was established as a 
public policy. Afterwards we understood, a 
year later, we understood that it should not be 
only limited to 11-year-olds, but that for those 
[talking about girls] that had not been 
vaccinated at 11 and now had 13 or 15 could 
benefit because [she/they] still qualified for 
the program, hence we (DOH) issued the 
recommendation.” –007, Government  
 
 
Following the changes in the ACIP guidelines related to the inclusion of boys, the DOH 
also recommended the HPV vaccine for boys. As illustrated by this quote, a pediatrician noted; 
“Sí, la vacuna del VPH una vez salió se 
integró como parte de las recomendaciones 
del Departamento de Salud y se dieron 
charlas […] luego salió que se aprobó para 
los niños y cuando se aprobó hubo una 
campaña para que se vacunara a los varones 
también.” –001 
“Yes, once the HPV vaccine came out it was 
integrated as part of the Department of 
Health’s recommendations and talks were 
given [...] after, it came out that it was 
approved for boys and when it was approved 
there was a campaign for the vaccination of 
boys too.” –001, Other 
 
 
Having limited access to the HPV vaccine in terms of availability and cost was also 
commonly mentioned as a barrier to the adoption. The HPV vaccine is expensive, and the 
stakeholders considered that it needed to be covered by the health insurances. Therefore, 
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previous work described also included the support of policies that made it mandatory for private 
insurance companies to cover the HPV vaccine for girls (2010) and then for boys (2012). As 
indicated by the stakeholders, Vaccines for Children and Salud Vital (insurance provided by the 
PR’s government) cover the vaccines for the public sector. Thus, access to the public and the 
private sectors was ensured. As noted by the following participants;  
“Antes de eso, también apoyamos lo que fue 
la primera legislación, que tenía que ver con 
lograr que todos los planes médicos que hay 
en Puerto Rico ofrecieran la vacuna de 
manera gratuita, que la tuvieran en su 
cubierta para las niñas primero, y después en 
la política pública se incluyó varones. 
Nosotros tuvimos la oportunidad de revisar 
esos proyectos de ley, y apoyar que se 
dieran.” – 014 
 
“Before that [HPV vaccine school-entry 
requirement], we also supported what was the 
first legislation, that had to do with 
accomplishing that all health insurance plans 
in Puerto Rico offered the vaccine free of 
charge, that they would have in their 
coverage for girls first, and then in the public 
policy boys were included. We had the 
opportunity to revise those bills, and 
supported they were achieved.” –014, 
Researcher 
 
“En Puerto Rico la legislatura de los años 
2009 y posteriormente en el 2014 se legisló 
para que todos los seguros-- O sea, además 
de las-- Del código de seguros que te 
mencioné y la ley federal, hay unas leyes 
locales específicas sobre el VPH sobre de que 
las aseguradoras deben cubrir el costo de la 
vacuna.” – 007 
 
“In Puerto Rico the legislature of the years 
2009 and later in 2014 legislated that for all 
insurance [plans]-- that is, in addition to the-- 
insurance code that I mentioned and the 
federal law, there are some HPV specific 
local laws on how insurance companies 
should cover the cost of the vaccine.”—007, 
Government 
 
 
Also, stakeholders noted the importance of different strategies to increase education and 
awareness about cervical cancer (2016) and the HPV vaccine. As it is illustrated in the following 
quote, a member of a non-profit organization provided an example of a bill to increase HPV-
related cancer awareness; 
“El otro proyecto de ley que se trabajó, … fue 
crear un mes de awareness para los cánceres 
asociados a VPH y crear un mes de 
awareness para lo que es el mes del cáncer 
cervical que es el por ciento mayor de 
canceres asociados que estamos viendo, así 
“The other proposed bill that was worked on, 
was to create an HPV-related cancers 
awareness month, and to create a cervical 
cancer awareness month which is the highest 
percentage of related cancers that we are 
seeing, so a proposed bill was created in PR 
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que se creó un proyecto de ley en Puerto Rico 
que fue aprobado en el 2016 donde se declara 
enero como el mes del cáncer cervical y todos 
los cáncer ginecológicos asociados a VPH y 
eso está por ley y se creó lo que es el mes 
TEAL que significa, es un acrónimo que dice 
Take Early Action and Live, así que 
empezamos esta campaña, llevamos  
tres años haciéndola donde los hombres y 
mujeres se ponen un accesorio TEAL y se 
educa sobre cuáles son los cánceres 
asociados a VPH.” – 002 
that was approved [enacted] in 2016, in 
which January is declared as cervical cancer 
month and all gynecological cancers related 
to HPV and this by law and the TEAL month 
was created which means, it is an acronym 
that says Take Early Action and Live, so we 
started this campaign that we have been 
doing for three years, in which men and 
women wear a TEAL accessory and education 
is given on which are the HPV-related 
cancers.” –002, Non-profit 
 
 
Table 5 shows a timeline of the specific policies and strategies that were mentioned by 
the participants and identified by the researcher.  
Stakeholders noted these previous efforts that happened before the HPV vaccine school-
entry requirement, seemed to have helped increase HPV vaccine rates in PR. The following 
quote illustrates this remark by a member of the government; 
“En los últimos años, a pesar de que todavía 
no era efectivo el que fuera mandatorio la 
vacuna, sí la campaña promoviendo la 
vacuna, educando a la gente y a todos los 
profesionales lograron aumentar 
significativamente el nivel de vacunación 
contra VPH en PR.” – 015 
 
“In recent years, despite that the vaccine 
mandate was still not realized, yes the 
campaign promoting the vaccine, educating 
people and all professionals achieved 
significant increases in the vaccination rates 
against HPV in PR.” –015, Government 
In fact, stakeholders indicated that the CDC awarded recognition to the PR’s DOH in the 
summer of 2018 due to high adolescent overall and HPV specific vaccination rates. For example, 
a member from a non-profit organization noted;  
“Para que tengas una idea, Puerto Rico en el 
2016 ganó el territorio de mayor a nivel de 
vacunación de HPV en toda la nación. Lleva 
dos años consecutivos ganando este premio a 
nivel del Departamento de Salud, y realmente 
“nosotros si tú miras dentro de esta nacional 
del Gobierno Federal, pues la primera dosis 
ya nosotros estamos al 80%, la segunda dosis 
“So you can have an idea, Puerto Rico in 
2016 won the territory in all of the nation 
with the highest rates of HPV vaccination. It 
has won this award consecutively for two 
years at the Department of Health level, and 
“we really if you look inside of that national 
from the Federal Government, well we 
already have the first dosage at 80%, for the 
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estamos como un 60 y pico. Ahora, como 
ellos se enfocan entre las edades de la 
encuesta de 11 a 14 años, pues no hablamos 
de la tercera dosis sino que se mantiene en 
esa población, y los varones tienen un 
incremento de un 13% a un 44%,  
en dos años.” – 002 
second one we are at a 60%-something.  Now, 
as they focus between the ages of the 
poll/survey from 11 to 14 years, well we do 
not really talk about the third shot in that 
population, and the boys had an increment 
from 13% to a 44%, in two years.” –002, 
Non-profit 
 
 
The DOH Secretary announced during the summer of 2017 that the HPV vaccine school-
entry requirement was going to start during the 2018 academic year. The purpose of this 
announcement was to have an entire year for additional education and promotion of the HPV 
vaccine, and for parents to begin the HPV vaccine series for their children. This notion is 
illustrated by the following quote by a member of the government;  
“En ese año el Departamento de Salud y 
otros grupos han hecho campañas de 
educación, de divulgación, se han hecho 
actividades educativas para enfermeras, para 
médicos, para personal escolar, inclusive 
hasta para periodistas, comunicaciones en 
periódicos y otros medios, para educar al 
pueblo sobre este mandato.” –015 
“During that year the DOH and other groups 
have done educational campaigns, promotion, 
educational activities for nurses, for 
physicians, for school personnel, even for 
journalists, and other media, to educate the 
country about the requirement” –015, 
Government 
 
Policy Stream. 
After the 2017 DOH’s announcement during the summer, other policies started to be 
considered by policymakers. Some stakeholders mentioned the House of Representatives (HR) 
Bill 537 and HR Resolution 537, HR Bill 1303, and HR Bill 1576 (Table 4).  
Stakeholders described the purpose of the HR Bill 537 to investigate the safety and 
efficacy of the HPV vaccine as a reaction by policymakers after anti-vaccination groups raised 
concerns. Public hearings were conducted in early 2018, and HR Resolution 537 was published 
in June 2018. The investigation concluded that the DOH’s determination to include the HPV 
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vaccine to the school required vaccine schedule aligns with the medical community position, as 
it is illustrated in the following quote; 
“Un proyecto de ley [Proyecto 537] donde 
supuestamente la cámara de representantes, 
la Comisión de Salud de la Cámara de 
Representantes investiga cuán segura es la 
vacuna de HPV. […] Pero por lo menos se 
vio. Se vio y se habló ahí, todo mundo tuvo 
tiempo de exponer cuán segura era la vacuna, 
fueron todos los expertos, etcétera.” –009  
 
“A bill [referring to HR 537] where 
supposedly the chamber of representatives, 
the HR representatives’ Health committee, 
researches how safe the HPV vaccine is. […] 
But at least it was looked upon. It was looked 
upon and talked about there; everybody had 
time to state how safe the vaccine was, all the 
experts were there [attended] etcetera.”         
–009, Non-profit 
 
Some stakeholders also talked about HR Bill 1303 as a project that was petitioned by 
VOCES and supported by the DOH. This bill had the goal of changing the current immunization 
law (Act 25 of 1983). The bill included making the use of the PR Immunization Registry (PRIR) 
as mandatory and continue to require health insurance companies to pay for vaccinations.  
The following quote by a member of a medical professional organization describes some 
of the changes proposed to the current immunization law by Bill 1303; 
“El cambio que se está haciendo ahora es 
poniendo en ley, es que aquí nosotros 
tenemos en Puerto Rico el Puerto Rico 
Inmunization Registry [PRIR], se está 
incluyendo ahí, como para que todo, 
cualquier proveedor y cualquier escuela que 
acepte niños, tenga necesidad y la obligación 
de entrar toda la data al sistema. […] 
Lo otro era obligar a las aseguradoras a 
crear conciencia en cuanto a la prevención, 
para que cubrieran sus vacunas y todas las 
vacunas, que salen no solo en el esquema de 
vacunación, si no las que están requisitos,  
las paguen.” –013 
“The change that has been done right now is 
including in the law, is that here in Puerto 
Rico we have the Puerto Rico Immunization 
Registry [PRIR], it is being included there, so 
that everything, any provider and school that 
takes in children, have the necessity and 
obligation to enter all the data into the system 
[...] The other change was to make the health 
insurers to raise awareness regarding 
prevention, for them to cover the vaccines and 
all the vaccines, that are not only on the 
scheduled vaccines but the ones that a 
requirements, to be covered [paid for].” –
013, Professional Organization 
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During the summer of 2018, again as a reaction to the HPV vaccine school-entry 
requirement announcement by the DOH Secretary, the anti-vaccination groups promoted the 
presentation of Bill 1576. A few participants mentioned Bill 1576 which proposed an 
amendment to Law 25 of 1983. The amendment consisted in the addition of the philosophical 
vaccination exception that would allow parents to not vaccinate their children due to their 
beliefs. The amendment proposed on Bill 1576 was described by a Researcher as follows;  
“La 1576 [Proyecto] todavía no ha entrado a 
floor no ha sido discutida, pero para mí el 
elemento más importante que tiene esa ley, es 
que se abre otra oportunidad para que el 
padre puede decir que no quiere vacunar a su 
hijo por conciencia, por conceptos 
filosóficos.” –019 
 
“The 1576 [Bill] has not yet been brought to 
floor, it has not been discussed, but for me the 
most important element that this law has, is 
that it opens another opportunity for the 
parent to say that he/she does not want to 
vaccinate his/her child due to beliefs, due to 
philosophical beliefs.”—019, Researcher 
 
Technical feasibility. 
The fact that the current PR immunization law authorizes the DOH Secretary, not the 
Legislature, to decide the addition of the HPV vaccine to the list required vaccinations for school 
entrance was also mentioned by the stakeholders as a facilitator. As the following participant 
described; 
“Por ejemplo, en los 50 estados de los 
Estados Unidos quien decide si se pone una 
vacuna mandatoria o no, son los legisladores 
y los senadores, en Puerto Rico no. En Puerto 
Rico la Ley 25, que es la ley de Inmunización 
que si quieres también te la puedo compartir, 
establece que quien tiene la responsabilidad 
de velar por la salud pública en términos de 
enfermedades prevenibles es el secretario de 
salud. La ley 25 le da esa potestad al 
secretario, obviamente, el secretario tiene que 
hacerlo todo con evidencia, no es porque a él 
le dio la gana, poner la vacuna, entiendes. 
Así ha sido históricamente, y él tiene un 
“For example, in the 50 states of the United 
States the ones that decide if a vaccine 
becomes mandatory or not, are the legislators 
and senators, not in Puerto Rico. Law 25 in 
Puerto Rico, which is the Immunization law 
that if you want, I can share it with you too, 
established the secretary of health is the one 
that has the responsibility to look out for 
public health in terms of preventable 
diseases. Law 25 gives that authority to the 
secretary. Obviously, the secretary has to do 
everything with evidence, not because it is 
his/her caprice to include the vaccine, you 
understand. That is historically the way it has 
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equipo de expertos que es el que sienta con él 
a hacerle las recomendaciones.” —002 
 
been, and he has a team of experts that give 
him the recommendations.” –002, Non-profit 
 
 
Additionally, stakeholders considered that announcing the requirement during the 
summer of 2017 eased the adoption process of the HPV vaccine school-entry requirement. The 
stakeholders described that the DOH Secretary made this announcement a year early in order to 
provide education and orientation for parents before making it officially mandatory for 2018. 
The following quotes illustrate this decision;  
“El año pasado para mayo del 2017 ya el 
secretario de salud anunció que durante el 
año escolar 2018-2019 la vacuna del VPH 
comenzaba como un requisito en ese grupo de 
edad de 11 y 12 años. Eso es un paso muy 
sabio de parte del departamento de salud que 
dio a la población un año completo para 
educarse en el tema, para buscar información 
con sus proveedores de salud, fuese médico, 
farmacéutico, enfermeras, centro de 
vacunación. Y tienes un año completo de esa 
preparación y esa educación.” –005 
 
“Last year around May 2017, the secretary of 
health had already announced that for the 
2018-2019 school year the HPV vaccine will 
be a requirement for that group [between] 
ages 11 and 12. That is a very wise step from 
the department of health that gave the 
population a whole year for them to educate 
themselves, to seek information from their 
health providers, be it medical, 
pharmaceutical, nurses, vaccination centers. 
And you have a whole year of that 
preparation and that education.” –005, Other 
 
 
“El secretario firmó el comunicado que él 
hace todos los años promulgando la política 
pública de salud dando un año para que 
hubiese un proceso de educación, de 
divulgación, esto lo firman el 17, para que 
entonces en vez de ser efectivo en el 17, fuera 
efectivo en el curso escolar que comienza en 
agosto de 2018.” –015  
“The secretary signed the announcement that 
he does every year promoting the public 
health policy giving a year so that there was 
an education, dissemination process, this was 
signed the 17, so that instead of being official 
in the 17, it would be official during the 
school year that starts in August 2018.” –015, 
Government 
 
 
Another aspect that participants mentioned made the HPV vaccine school-entry 
requirement feasible, was that it targeted 11 and 12-year-old adolescents. This was an important 
factor for the stakeholders due to two reasons 1) the economic savings of only having to provide 
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two doses, and 2) the better immune response to the HPV vaccine at these ages. These two 
reasons are illustrated in the following quotes;  
“11, 12 años es la edad que se ha escogido 
por el Departamento de Salud actualmente 
para que sea el requisito preadmisión 
escolar. Sabemos que el CDC extiende la 
edad hasta los 26 años, pero mientras más 
joven la persona, científicamente se ha 
descubierto que más resistencia o mejor 
apego a su sistema inmunológico va a  
tener esa persona.”—005 
 
“The current chosen age requirement for 
school entry by the Department of Health is 
11, 12 years of age. We know that the CDC 
extends it until 26 years, but it has been 
proven scientifically that the younger the 
person is the higher the response or the better 
the adherence to his/her immunological 
system that person will have.”—005, Other 
“En este caso lo que va a decir la orden 
administrativa es el corte, se le llama el corte, 
de 11 a 12, y cada año se va a ir añadiendo 
un grupo adicional. Pues nosotros vamos 
asegurando que esas niñas y esos niños 
reciban solamente dos dosis, lo que va a 
representar una economía inmediata en dosis 
de vacuna, porque si esperas a los 14, 
entonces le tocan tres.”—002 
 
“In this case what the administrative order is 
going to say is the cohort, it is called the 
cohort, from 11 to 12, and an additional 
group will be added each year. Well, we are 
going to ensure that those girls and boys 
receive just the two dosages, which will 
represent an immediate economization in 
vaccine doses, because if you wait till 14, then 
[he/she] will need three.”—002, Non-profit 
 
Value acceptability.  
The HPV vaccine school-entry requirement also aligned with the stakeholders’ idea of 
providing protection and overall public health wellness to the population of the island. From 
their perspective the creation of this requirement would address HPV-related cancer health 
disparities in the population. A researcher noted; 
“Sigue siendo un problema de salud pública, 
porque si tú miras históricamente tú miras la 
data, el cáncer cervical y muchos de los 
cánceres asociados al virus del VPH tienden 
a ocurrir en las pacientes que son 
socioeconómicamente nivel más bajo.”—017  
 
 
“It is still a public health issue because if you 
look historically if you look at the data, 
cervical cancer and many of the HPV-related 
cancers tend to occur on low socioeconomic 
level patients.”—017, Researcher  
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Moreover, stakeholders described the HPV-related cancer prevalence as a public health 
issue that needed to be solved. For example, as illustrated with the quotes below;  
“Así que dentro de los primeros 10 cánceres, 
vamos a poner tanto en hombres como en 
mujeres, cánceres asociados a VPH son las 
primeras razones de muerte. Por ende, esto es 
un asunto de salud pública que hay que 
atender.” —002 
 
“So in the first 10 cancers, including in men 
as in women, HPV-related cancers are the 
first [number one] causes of death. Hence, 
this is a public health matter that needs to be 
addressed.”—002, Non-profit 
 
In addition to the public health implications of this requirement, some stakeholders 
mentioned it was important for them to make sure the HPV vaccine continues to be covered by 
the health insurances, and that its cost is reimbursed to medical providers. As conveyed by a 
member of a professional organization;  
“Importante es el asunto de Salud pública, 
que la vacuna sea requisito, cómo se va a 
cubrir, y estamos bregando con ese asunto en 
el proyecto de la cobertura y de ese tipo de 
cosas, y de la intención de las aseguradoras 
de bajar lo que pagan por la vacuna del VPH, 
porque va a aumentar la cantidad de gente 
vacunándose, lo cual es una barbaridad que 
hicieron Triple S y MCS. Estamos 
básicamente tratando de resolver el asunto 
económico, pero lo más importante es el 
asunto de Salud Pública, y entonces ahora 
estamos bregando con lo otro”. –003  
 
“The public health issue is important, that the 
vaccine becomes a requirement, how will it be 
covered, we are dealing with this issue in the 
coverage project, and that type of things, and 
the intention of the insurers to lower what 
they pay for the HPV vaccine, because the 
people getting vaccinated will increase, which 
what Triple S and MCS did was an atrocity. 
We are basically trying to resolve the 
economic issue, but the public health issue is 
the most important, and then now we are 
dealing with the other [thing].” –003, 
Professional Organization 
 
Stakeholders also mentioned the economic savings in the long-term due to the prevention 
of HPV-related cancers, as another important factor that was considered for the adoption of the 
HPV vaccine school-entry requirement. For instance, a member of a non-profit organization 
talked about the data showing the monetary savings;  
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“Demostramos con un estudio que hizo el 
Centro Comprensivo de Cáncer, de que si 
Puerto Rico para el 2020 logra vacunar el 
80% de las niñas y el 67% de los niños, 
vamos a ahorrar casi $88 millones en 
diagnósticos y tratamientos posteriores en 
cáncer cervical. Así que se le presentó al 
Departamento de Salud una data 
contundente, una data basada en evidencia, 
una data acumulativa, unas estadísticas.”—
002 
“With a study done by the Comprehensive 
Cancer Center we showed that if Puerto Rico 
achieves to vaccinate 80% of the girls and 
67% of the boys by 2020 we will have saved 
almost $88 million in diagnosis and 
subsequent cervical cancer treatments. So 
compelling data were presented to the 
Department of Health, a data based on 
evidence, cumulative data, statistics.” –002, 
Non-profit 
 
Level of integration. 
Stakeholders agreed that the adoption process of the HPV vaccine school-entry 
requirement was successful because different sectors, such as the government, academia and 
non-profit organizations, collaborated to create a consistent message and had a defined purpose. 
This aspect is illustrated by the following quote;  
“Nosotros teníamos un objetivo claro y ahora 
mismo es reducir los cánceres asociados al 
VPH a través de inmunización aumentando 
un 80% la taza de inmunización en los 
adolescentes para la vacuna de VPH, ese es 
nuestro objetivo y nuestro norte, y todo lo que 
trabajamos, lo trabajamos en esa dirección. 
Si tú le preguntas a cualquiera que está 
partnership te va decir que ese es su 
objetivo.” —008  
 
“We had a clear objective and right now that 
is to reduce HPV related cancers through an 
80% rate increase of immunization among 
adolescents for the HPV vaccine, this is our 
objective, our north, and everything we work 
on, we work in that direction. If you ask 
anyone who is partnership they will tell you 
that this is their objective.”—008, Other 
 
Politics Stream. 
Pressure-group campaigns. 
When the HPV vaccine school-entry requirement was announced by the Secretary of 
Health on the summer of 2017, the anti-vaccination groups reacted and created resistance. From 
the stakeholders’ perspective, the composition of these groups varied based on their views, but 
all shared concerns towards the HPV vaccine and making it mandatory. These views included 
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worries related to the safety and side effects of the vaccine, not wanting to do something against 
their will, religious concerns, and lifestyle choices. The following quotes present these 
arguments; 
“Ellos hablan de la seguridad mayormente, 
problemas de seguridad, los cuentos de que 
tuvo de que si en España murieron yo no sé 
qué cuántas niñas que han quedado, que han 
tenido problemas neuromusculares, que han 
quedado paralítico, etcétera, y la evidencia 
científica no prueba eso, no es lo que nos dice 
los estudio que se han hecho.”—009  
 
“They mainly spoke about safety problems [of 
the vaccine], stories that in Spain girls died, 
others have neuromuscular problems, or are 
paralyzed, etc., and the scientific evidence 
does not support this, this is not what the 
studies say [about the vaccine]”—009, Non-
profit 
“El hecho de hacerlo obligatorio ha creado 
que aquel que no quería vacunarse le estás 
reforzando de que alguna razón, que le están 
haciendo algo en contra de su voluntad y se 
aferra más en no oír las explicaciones.”—001  
 
“The fact of making it mandatory resulted in, 
for those that did not want to get vaccinated, 
you are reinforcing that for some reason, you 
are doing something against his/her will and 
they will not pay attention to the 
explanation.” –001, Other 
 
“Porque la iglesia aquí en Puerto Rico es 
bastante poderosa, y en los estados que la 
vacunación es mandatoria, esos son los 
grupos que más se han opuesto, porque va un 
poco de acuerdo a la filosofía de las iglesias, 
que ellos lo que promueven es la abstinencia, 
y nosotros lo que estamos promoviendo es 
una vacunación.—002 
 
“Because here in Puerto Rico the Church is 
quite powerful, in the states where the 
vaccination is mandatory these are the groups 
that have opposed it the most, because they 
promote abstinence in accordance to the 
churches’ philosophy, and what we are 
promoting is a vaccination.” –002, Non-profit 
“Hay un sector bastante amplio de la 
sociedad que considera que sus vidas deben 
estar guiadas más por lo que dicte la 
naturaleza y no por lo que dicte la ciencia, 
como con medicamentos, como con químico, 
como con producto procesados, como con 
productos biológicos, como son las 
vacunas.”—005  
 
“There is a quite large sector of society that 
considers that their lives should be guided 
more by what nature dictates and not by what 
science says, like with medicine, like with 
chemicals, like with processed products, like 
with biological products, what vaccines are.” 
–005, Other 
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Stakeholders attributed this resistance to the level of misinformation related to the HPV 
vaccine and vaccinations in general. A stakeholder noted; 
“La dificultad mayor obviamente siempre es 
el movimiento antivacunas que reacciona, y 
empieza a hacer política pública por ahí por 
los pasillos y a hacer ruido en la prensa y en 
la televisión, y a dar información errónea a 
los padres en cuanto a los supuestos daños.” 
–009  
“Obviously, the main barrier is always the 
anti-vaccine movement which reacts and 
starts doing public policy around there by the 
hallways and making noise in the press and in 
television and provide parents with incorrect 
information regarding the supposed harms.” 
–009, Non-profit 
 
 
Also, the misinformation included concerns from parents and religious groups regarding 
the (incorrect) relationship of the HPV vaccine with sexual activity in children. For instance, a 
pediatrician mentioned;  
“Que no querían obligarles a poner, ellos 
decían que eso le daba libertad a los niños 
para tener relaciones sexuales ya que no van 
a tener que pensar, por alguna enfermedad 
venérea.” –001 
 
“That they did not want to make them [anti-
vaccination groups (religious)] get it, they 
said that it would give kids the freedom to 
have sexual relationships since they would 
not have to think of some venereal 
disease.”—001, Other 
 
A few participants attributed this misinformation to the incorrect information available in 
social media. As a researcher noted;  
“Porque todo el mundo asume que todo lo 
que escriben en el Internet es correcto. 
Entonces es como, ¿cómo tú contrarrestas 
esto?” –017 
“Because everyone assumes that everything 
that is available on the Internet is correct. 
Then, how do you challenge that?” –017, 
Researcher 
 
 Stakeholders also mentioned specific anti-vaccination groups representing some of these 
views against the HPV vaccine and the requirement. These anti-vaccination groups included a 
Catholic priest who was very vocal, an online religious group, a feminist organization, an autism 
organization, and parents who said they did not want the vaccine to be mandated.   
 
 
 
90 
 
Administrative or legislative turnover. 
Stakeholders mentioned changes in government positions as a factor that impacted the 
adoption process. The current Secretary of Health was named by the current Governor of PR, 
and both started in their positions on 2017. For instance, stakeholders noted about the changes in 
political parties and in the position of Secretary of Health; 
“VOCES hace informe de un panel asesor 
que llega a la conclusión de que si la vacuna 
no es mandatoria no se hace, porque han 
habido proyectos de ley para la vacunación 
que se estancan cuando van a crear su 
proyecto de ley, por los detractores, porque 
viene una vista pública o viene un cambio de 
política, un cambio de partido, etcétera. Bajo 
la gobernación de Fortuño se firmaron las 
leyes de que será cubierta en varones. Viene 
luego el mandato de García Padilla, ahí se 
presenta un proyecto de ley si  
no me equivoco no se hace nada.  
Luego cambia el partido y ahí se le presenta 
el resultado del panel, el informe del comité 
asesor que viene secundario al informe de 
vacunación o al panel que hizo Obama, que 
hace algo local y ahí se le presenta al 
secretario cuando cambia al secretario de 
salud. [Previous Secretary of Health] nunca 
quiso firmar, no fue una de sus prioridades y 
el secretario toma esto como una prioridad y 
ahí es que lo firma.” –012  
 
“VOCES creates a report with an expert 
panel that concluded that if the vaccine is not 
mandatory it [the vaccine] will not be done, 
because there have been vaccination bills 
previously proposed that get stalled when 
they [introduce] the bill, due to detractors, 
because there is a public hearing or there is 
an upcoming political change, a party 
change, etcetera. The laws that covered boys 
were signed during Fortuño’s 
[governor]administration. Then came Garcia 
Padilla’s [governor] administration, in which 
a bill is proposed but, if I am not mistaken, 
nothing was done. Then the political party 
changes and the panel’s results are 
presented, the advisory committee’s report is 
ancillary to Obama’s vaccination report, [the 
VOCES expert panel] does something local 
and that is when it is presented to the 
secretary, when the secretary of health is 
replaced. [The previous Secretary of Health] 
never wanted to sign, it was not one of his/her 
priorities and the [new] secretary makes this 
a priority and then he signs it [HPV school-
entry requirement].” –012, Non-profit 
 
 
Moreover, this assignment of key government positions facilitating the adoption of the 
HPV vaccine school-entry requirement also included the changes in the person occupying the 
position of Sub-secretary of Health. A member of a medical professional organization described 
this factor noting that;  
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“El hecho de que la Subsecretaria de Salud 
sea ahora pediatra, ella fue subsecretaria 
cuando Luis Fortuño era gobernador, y 
ahora es de nuevo Subsecretaria de Salud, no 
se logró cuando Luis Fortuño era 
gobernador, pero ciertamente se ha 
impulsado grandemente. […] entonces eso 
ayudó que la doctora fuera subsecretaria, de 
convencer al secretario de que era importante 
que esta vacuna fuera requisito.” –003  
 
“The fact that the current subsecretary of 
health is a pediatrician, she was subsecretary 
when Luis Fortuño was governor, and now 
she is health subsecretary again, it was not 
achieved when Luis Fortuño was governor, 
but admittedly it [the HPV vaccine school-
entry requierement] has been pushed very 
much [...] hence it helped that the 
subsecretary was a physician, to convince the 
secretary that it was important for the vaccine 
to become a requirement.” –003, 
Professional Organization 
 
 
However, it was also noted that if the current Secretary of Health is changed, the HPV 
vaccine does not need to be kept in the list of required vaccination for school entrance by a new 
Secretary of Health. For instance, this was expressed by a member of a professional organization 
by stating;  
“El legislativo es más difícil, obviamente, 
porque tienes todos estos grupos religiosos y 
naturistas en contra que cabildean fuerte, 
entonces se hacía más lento. Se pudo hacer, 
que no es tan permanente, no tiene tanta 
sostenibilidad, pero por lo menos nos resolvía 
en el momento el problema y nos ayudaba un 
poco con el awareness que el Departamento 
de Salud lo adoptara. El problema es que si 
cambian el secretario de salud, el otro 
secretario de salud no tiene que honrar eso. 
Nosotros tenemos que convertir eso en un 
proyecto de ley, y eso es parte de lo que 
tenemos que hacer.” –004  
“The legislative [process] is the most 
difficult, obviously, because you have all 
these religious and naturist groups that are 
against that lobby strongly, and that made it 
[the process] slower. It was done, it’s not 
permanent, it does not have a lot of 
sustainability, but at least it solved us the 
problem, for now, and it helps a bit that the 
DOH adopted it with creating awareness. The 
problem is that if the secretary of health is 
changed, the next secretary does not need to 
do it. We have to make this into a bill, and 
that is part of what we have to do.” –004, 
Professional Organization 
 
Policy Windows.  
Stakeholders noted that in the summer of 2018 was the moment during which the HPV 
vaccine was officially announced by the Secretary of Health to be a requirement for school 
entrance, but a previous announcement was done in 2017. This timeframe is described below by 
a stakeholder;  
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Stakeholders also noted the disposition and pro-vaccination views of the current 
Secretary of Health. These also contributed to the adoption of the HPV vaccine school-entry 
requirement during this moment in history. The Secretary of Health was receptive to the 
information and committed to decreasing cervical cancer rates in PR. As a stakeholder noted 
about the current Secretary of Health;  
“Yo entiendo que nos dimos en un momento 
histórico donde se ha hecho mucha campaña, 
la reacción negativa no ha sido muy severa 
como lo ha sido en los Estados Unidos, y nos 
vimos con un secretario de salud que es muy 
provacuna.”—009 
 
“I think that we had a historical moment 
where a lot of campaign was done, the 
negative resistance was not as strong as it has 
been in the United States, and we have a 
secretary of health that is very pro-vaccines.” 
–009, Non-profit 
 
Policy entrepreneurs. 
Stakeholders listed and described different organizations or sectors of the society that 
contributed to the process of adoption of the HPV vaccine school-entry requirement. In general, 
stakeholders commented about the composition of these sectors; 
“esto es un ejército de organizaciones sin 
fines de lucro, de entidades privadas, de 
personas individuales, de científicos 
salubristas y por supuesto sin el apoyo del 
estado no puedes, sin el apoyo del gobierno 
no puedes. Porque ellos son los que crean, los 
que definen la política pública, uno en el 
sector privado, ya sea sin fines de lucro o con 
fines de lucro, uno puede sugerir y uno puede 
tener estrategias para poder hacer unas 
“This is an army of nonprofit organizations, 
of private entities, individual people, of health 
scientists and of course without the 
government's support you cannot do it. 
Because they are who create and define 
public policy, one in the private sector, that is 
to say, nonprofit, or for profit, one can make 
suggestions, and one can have strategies for 
making recommendations, but one cannot 
create public policy, nor define it, that is up 
“El año pasado [2017]se tomó la 
determinación de hacerla obligatoria para 
este año [2018], para dar un año de 
orientación para los que no querían 
vacunarse. […] al Secretario de Salud se le 
presentó […] y el Secretario lo firmó  
ahora [2018].” –001  
 
“In the past year [2017] a determination was 
made to make it [HPV vaccine] mandatory 
for this year [2018], in order to give a year of 
orientation to those that did not want to get 
vaccinated. […] it was presented to the 
Secretary of Health and the Secretary signed 
it now [2018].” –001, Other 
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recomendaciones, pero uno no puede crear la 
política pública, ni definirla, eso le 
corresponde al Gobernador junto a sus 
secretarios y directores de agencias.”—005    
 
to the governor alongside his secretaries and 
agency directors.” –005, Other 
 
Another stakeholder mentioned a variety of organizations such as;  
“Sí, la Coalición para la Prevención del 
Cáncer de Puerto Rico que tiene, obviamente 
entre tantos sakeholders, está el 
Departamento de Salud, está el Centro 
Compresivo de Cáncer, está la Coalición de 
Vacunación de Puerto Rico, etcétera.” –010  
“Yes, the Coalition for Cancer Prevention of 
Puerto Rico that has, obviously among many 
stakeholders the Department of Health, the 
Comprehensive Cancer Center, the 
Vaccination Coalition of Puerto Rico, 
etcetera.” –010, Government 
 
These groups or organizations mentioned by the stakeholders can be categorized in the 
following groups: the non-profit organizations, the academia, the medical professional 
organizations, government staff, and the private sector. Each sector had an important and 
distinctive role based on each of their expertise and/or area of interest. These sectors as well as 
their roles are described below.  
Non-profit organizations: VOCES, a pro-vaccinations coalition, is a non-profit 
organization that was fundamental in the HPV vaccine school-entry requirement adoption 
process. It is important to note the VOCES includes many medical professional organizations, 
other cancer prevention coalitions, and members of the private sector. As a researcher noted; 
“Lo que pasa es que VOCES reúne todos los 
pediatras, la asociación de pediatras, la 
obstetra ginecólogo. En realidad, VOCES lo 
que hizo fue unir a las distintas instituciones, 
que abogan por el departamento de salud, 
educación. En un foro hay gente de 
farmacéuticas, gente de farmacias, 
farmacéuticas como tal de farmacias. No de 
farmacéuticas, sino farmacéuticos.”—006  
 
“What happens is that VOCES gathers all the 
pediatricians, the pediatrician association, 
the OB-GYN. What actually VOCES did was 
to unite different institutions, that advocate, 
the Department of Health, Education. In a 
forum, there are people from pharmacies, 
pharmaceuticals such as pharmacies. Not 
from pharmaceuticals, but pharmacists.” –
006, Researcher 
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VOCES served multiple functions within its role. This coalition created awareness and 
provided education about the HPV and HPV-related cancers. They organized the experts that 
created the Report and supported its publication.  
“El grupo VOCES fue instrumental en 
colaboración con ellos, que también diera la 
última política pública del secretario de 
Salud de lo de la vacuna mandatoria en las 
escuelas. Y nosotros como científicos les 
proveemos a ellos los datos para justificar 
que hace falta ese tipo de política pública en 
Puerto Rico, porque los virus asociados a 
VPH son un problema en nuestra población.” 
–014  
 
“Collaborating with the VOCES group was 
instrumental, that the secretary of health gave 
the public policy making the vaccine 
mandatory for school. And we as scientists 
provided them with the data to justify that in 
Puerto Rico there is a need for that type of 
public policy because the HPV associated 
viruses are a problem in our population.”—
014, Researcher  
 
Additionally, they were active actors in undertaking advocacy, by promoting the HPV 
vaccine and the HPV vaccine school-entry requirement. As illustrated by this quote; 
“Yo tengo que reconocer que en términos de 
liderato y de mayor exposición, ha sido 
VOCES. Uno por las estrategias que ellos 
han delineado y establecido y dos, por los 
esfuerzos de Advocacy a nivel de política 
pública y a nivel de legislación.” –019  
 
“I have to recognize that in terms of 
leadership and major exposition, it has been 
VOCES. One because of the strategies they 
have delineated and established and two, 
because of their advocacy efforts on the 
public policy and legislation levels.” –019, 
Researcher 
 
Other non-profit organizations mentioned by the stakeholders included the ACS, which 
mainly supported education and vaccination, the Head and Neck coalition, and the PR Cancer 
coalition.  
Academia: Stakeholders listed members of the academia that included researchers from 
the University of Puerto Rico (UPR), the UPR Medical School, and UPR Public Health School, 
and the Comprehensive Cancer Center. Their role was to provide scientific information to the 
overall community including the DOH and Legislature. Their role was important because they 
provided evidence from studies conducted in PR. These studies provided relevant evidence about 
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the issues affecting the Puerto Rican population, such as the data on the incidence and prevalence 
of HPV and related diseases.  
“Nosotros hicimos los primeros estudios 
donde documentamos, por ejemplo, la 
prevalencia del virus del papiloma humano 
en mujeres residentes del área metropolitana 
de San Juan, infecciones cérvix y en ano.” –
014 
 
“We did the first studies in which we 
documented, for example, the prevalence of 
the human papillomavirus in women residing 
in San Juan’s metropolitan area, cervix and 
anal infections.” –014, Researcher 
 
Medical professional organizations: Many medical professional organizations supported 
HPV vaccine school-entry requirement adoption process by providing education and advocacy 
using their respective expertise. These medical professional organizations included the PR’s 
Pediatricians Society, the PR Pediatricians Academy, PR’s ACOG chapter, and PR’s Dentists 
Society.  
“Como te digo, los diferentes grupos que hoy 
vienen nuestro programa de inmunización, la 
academia, pero también con los pediatras, 
pediatras como que son los pilares aquí para 
hacer una recomendación clara y 
contundente sobre la importancia de 
inmunizar. Los pediatras tienen un rol bien 
importante, y también con ellos se ha ido 
trabajando a través de los años.” –008  
 
“As I say, the different groups coming here 
today, our immunization program, the 
academy, but also the pediatricians, 
pediatricians are like the pillars here to make 
a clear and compelling recommendation on 
the importance of immunization. The 
pediatricians have a very important role, and 
also we have worked with them throughout 
the years.” –008, Other 
“A favor de los requisitos de esta vacuna y de 
todas las vacunas siempre vamos a encontrar 
el sector de los profesionales de ciencia, de la 
salud, de la medicina, educadores en salud, y 
por supuesto guiados por el departamento de 
salud local.” –005 
“In support of this vaccine requirement, and 
all the vaccines we will always the sector of 
the science professionals, of health, medicine, 
health educators, and of course always being 
guided by the DOH.”—005,  
 
Government: The government category consists of employees of the DOH, such as the 
DOH vaccination program, that were mentioned as key actors of the adoption process. From the 
stakeholder’s perspective, the DOH’s vaccination program position was always on par with the 
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current scientific guidelines. The DOH had included the HPV vaccine as a recommended vaccine 
for adolescents following the ACIP guidelines since the HPV vaccine was approved.  
“Es como te dije los oficiales del 
departamento de salud actuales de este 
gobierno han sido sumamente clave para que 
esto se dé, porque no todos  
son provacuna” –009 
 
“It is like I said the current Department of 
Health officers [officials] of this 
administration had been a key [factor] for 
this to be [achieved] because not everyone is 
pro-vaccine.” –009, Non-profit 
“Sí, como te digo, ha habido el programa de 
vacunación del departamento de salud, 
definitivamente ha estado bien a la 
vanguardia de esto […]”—018 
 
“Yes, as I said, the vaccination program of 
the DOH, they have been at the forefront of 
this for sure […]” –018, Non-profit 
 
 
Stakeholders also noted the key role of the current Sub-Secretary of Health. The Sub-
Secretary of Health was described by the stakeholders as a strong supporter of the requirement 
and the HPV vaccine. The following quote by a member of a medical professional organization 
describes the role of the Sub-Secretary of Health as helping in the process;  
“entonces eso ayudó que la doctora fuera 
subsecretaria, de convencer al secretario de 
que era importante que esta vacuna fuera 
requisito.”—003 
 
“hence it helped the sub-secretary was a 
physician, of convincing the secretary that it 
was important for the vaccine to become a 
requirement.” –003, Professional 
Organization 
 
 
It is important to note that the Sub-Secretary of Health was also part of VOCES at some 
point, as noted by this member of a non-profit organization; 
“La subsecretaria de salud, [nombre] es 
inclusive parte de la junta de directores de 
VOCES de la coalición de vacunación, ella es 
pediatra y también es una persona que está 
muy envuelta y muy al tanto de esta 
problemática.”—009  
“The sub-secretary of health [name] actually 
she is part of the board of directors of 
VOCES the vaccine coalition, she is a 
pediatrician y she is very involved and up-to-
date in this problem.” –009, Non-profit 
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Private sector: The private sector included organizations such as hospitals, pharmacies, 
physicians from private practice, a private group of gynecologists, and Merck which is the HPV 
vaccine manufacturer. Overall, this sector collaborated by providing information, funding for 
research, promotion related to the HPV vaccine, and support indicating their agreement to the 
HPV vaccine school-entry requirement. For instance, stakeholders stated about the private sector 
including Merck and physicians in the private practice;  
“Obviamente Merk que son los que lo hacen, 
ellos han dado mucha ayuda financiera para 
campañas publicitarias, foros y ese tipo de 
cosas, ellos han ayudado mucho 
económicamente.”—009  
 
“Obviously Merck who are the ones that 
make it, they have provided a lot of financial 
help for promotional campaigns, forums, and 
that type of things, they have helped a lot 
economically.” –009, Non-profit 
“Muchos pediatras, profesionales de la salud 
están a favor de este requisito, médicos, 
ginecólogos. Muchos médicos están a favor 
de este requisito.”—020  
 
“A lot of pediatricians, health professionals 
are in favor of the requirement, physicians, 
gynecologists. A lot of physicians are in favor 
of this requirement.” –020, Non-profit 
 
Another active role undertaken by the stakeholders was to take part in public policy 
advocacy. Members of nonprofit organizations such as VOCES, professional medical 
associations, and the academia talked about their support for not only the HPV vaccine as a 
public health prevention mechanism, but also for policy changes that were needed to increase 
education and access to the HPV vaccine. The following quotes illustrate this advocacy role; 
“El departamento [university] en pleno 
hemos sido unos grandes advocates del uso 
de la vacuna para prevención, desde el 
primer día.” –017  
 
“The department [university] in general, 
since the first day we have been big advocates 
of use of the vaccine for prevention.” –017, 
Researcher 
“Desde entonces ha habido una lucha y un 
trabajo que se ha realizado, ya no solo por 
vacunación en el departamento de salud sino 
por diferentes sectores de la comunidad 
médica y de la comunidad en general, las 
sociedades que agrupan los pediatras, la 
“Since then there has been a struggle and 
work that has been undertaken, no longer just 
by vaccination [program] in the department 
of health but by different sectors of the 
healthcare community and the community in 
general, the societies that group 
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Sociedad Americana del Cáncer, Centro 
Compresivo del Cáncer de la Universidad de 
Puerto Rico, por mencionarte algunos.” – 
014 
pediatricians, the American Cancer Society, 
the University of Puerto Rico’s 
Comprehensive Cancer Center, just to 
mention some.” –014, Researcher 
 
Lastly, stakeholders noted that with the pass of the years the narrative surrounding the 
HPV vaccine changed. When the HPV vaccine came out the narrative used was related to a 
vaccine-preventable STI.  The current narrative is about the opportunity to prevent cancer, 
specifically, cervical cancer. A participant noted; 
“El tema de VPH es un tema que ha venido a 
través de muchos años trabajándose con la 
prensa, yo creo que en este año es que vamos 
a ver más cobertura en los medios a raíz de 
eso, porque el tema de VPH y de cáncer 
cervical y de los canceres asociados al virus 
se ha venido trabajando por mucho tiempo y 
ha ido evolucionando. Al principio se veía 
como una infección de transmisión sexual y 
tenía unas connotaciones fuertes” –008  
“The HPV topic has been a topic that has 
been worked on with the press throughout 
many years, I think that this year we will see 
more media coverage because the topic of 
HPV and cervical cancer and the virus-
related cancers has been worked on for a 
long time and it has been evolving. At the 
beginning, it was seen as a sexually 
transmitted infection and had strong 
connotations.”—008, Other 
 
Aftermath of hurricane Maria 
Participants were asked if they thought that the passing of hurricane Maria could affect 
the implementation of the HPV vaccine school-entry requirement that was announced to start on 
August 2018. All stakeholders agreed that hurricane Maria affected the vaccine availability and 
the operation of the vaccination clinics and private medical offices. However, most stakeholders 
did not anticipate any major barriers to HPV vaccine availability. They noted that, for the most 
part, public clinics were going to be open and were going to have enough vaccinations, and that 
private providers should be prepared.  
“Los proveedores de vacunas, todavía no 
están al 100% que estaban pero, estamos 
cerca, estamos como a un 90%. O sea que en 
cuanto a accesibilidad de vacunas no debe 
ser el problema”. –010  
“The vaccine providers are not 100% yet, but 
we are close, we are about 90%. So, in terms 
of vaccine accessibility, that should not be the 
problem.”—010, Government  
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“María trastocó pero, lo que es el programa 
de vacunación y el sistema de vacunación, ha 
vuelto a la normalidad en un gran porciento, 
no 100% pero un gran porciento”. –015  
“Maria affected but, the vaccination program 
and the vaccination system, has returned to 
normal by a large percentage, not 100%, but 
a large percentage.”—015, Government 
 
A few stakeholders seemed unsure about the current situation of the 
healthcare/vaccination system but sounded optimistic about the implementation process. For 
example, a Researcher said; 
“yo pensaría que ya a estas alturas esto se ha 
restablecido. Pero sinceramente cómo esa 
infraestructura se afectó y cómo está 
corriendo en estos momentos, tampoco tengo 
esa información, discúlpame”. –014  
“I would think that by now this has been 
restored. But sincerely how that 
infrastructure was affected and how is it 
running right now, I do not have that 
information either, excuse me.”—014, 
Researcher 
 
Phase 2: Content analysis of newspaper articles  
Reliability  
An inter-coder Kappa score of 0.80 was achieved with the second coder after 
independently coding a random sample of 10 % of the articles. An intra-coder Kappa score of 
0.95 was achieved after the researcher coded a randomly selected sample of 10% of the articles a 
second time.  
Overall sample description.  
After removing the repeated news articles, there was a total of 286 news articles that 
included the key terms (Figure 2). As stated in the methods, these key terms included “HPV” and 
“HPV vaccine” (in Spanish). Most articles were published in 2016 (Table 6). Figure 3 shows the 
average number of articles per month because data for 2018 only covers the first seven months 
of the year.  
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Figure 3. Average number of articles per month 
 
For this study, primary focus means the main message the article was providing. Each 
article could have more than one message, but the main one was captured during data 
abstraction. To make this decision the researcher was guided by the title and the first paragraph 
of the article. A list of the overall sample of articles, based on their primary focus, can be found 
in Table 7. The most common primary focus category included educational articles with 
information about the HPV and the HPV vaccine (23.8%), followed by the advertainment 
category (16.8%). This category included adds promoting the HPV vaccine (e.g., by VOCES and 
others by Merck), announcement of health fairs providing the HPV vaccine, and adds about 
professional and health conferences. The third most common focus was articles providing 
general information about vaccines (11.2%), such as types available, their benefits and 
appropriate ages for inoculation. Articles focusing mainly on providing information about 
cervical cancer and the importance of cervical cancer screening compromised about 11% of the 
sample. The HPV vaccine school-entry requirement was the primary focus of discussion in a 
total of 19 articles (6.6%).  Other areas of focus included general health information (5.9%), 
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cancer information or information on other types of HPV-related cancers such as oropharyngeal, 
penile and anal (4.2%). 
The distribution of the categories of primary focus was also evaluated by the year of 
publication. Most of the articles about HPV and the HPV vaccine, advertisement, cervical cancer 
and cervical cancer screening, as well as those providing information about cancer in general 
were published in 2016. Most of the news articles with the HPV vaccine school-entry 
requirement as their primary focus were published in 2017 (Table 8). Figure 4 shows the average 
number of articles per month of each of the top eight focus categories by year because data for 
2018 only covers the first seven months of the year.  
 
 
Figure 4. Average number of articles per month by the top eight primary focus categories 
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Further investigation of the news articles that mentioned the HPV vaccine school-entry 
requirement in PR. 
To further investigate the sample, all the articles that mentioned the HPV vaccine school 
entry requirement were evaluated. Of the 286 news articles, 34 articles (12.2%) mentioned the 
HPV vaccine school-entry requirement. Note that ‘mentioned’ is broader than the primary focus 
category. The highest number of publications that mentioned the HPV vaccine school-entry 
requirement in PR occurred in 2017, and during the first seven months of 2018. The distribution 
of those articles by year and newspaper source is presented in Table 9. Furthermore, when 
explored by the month of publication, most of the news articles that mentioned the HPV vaccine 
school-entry requirement were published during June (n = 13) and July (n = 8).   
From the 34 articles, 20 (58.8%) presented arguments in favor of the HPV vaccine 
school-entry requirement, five articles (14.7%) presented arguments against, and five articles 
(14.7%) showed both sides of the arguments. Four (11.8%) of the articles only mentioned the 
HPV vaccine school-entry requirement (n = 2) or were the DOH’s HPV vaccine school-entry 
requirement announcement (n = 2). These four articles were grouped in an ‘other’ category. 
Table 9 shows the distribution of these categories based on the argument presented in the article 
by year of publication. Three out of the five articles citing arguments against the HPV vaccine 
school-entry requirement were published in 2017. A similar pattern was observed in the articles 
about been in favor of the requirement, where most of the articles were published in 2017 
(Figure 5). Lastly, an area to note is that no articles with the HPV vaccine school-entry 
requirement as the primary focus or mentioning it were published during 2016. This finding 
should be considered within the limitations of the content analysis phase that are discussed in the 
next chapter.  
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Arguments against the HPV vaccine school-entry requirement articles.  
During Phase 1 of this study, only one person who identified as been against the HPV 
vaccine school-entry requirement was interviewed. Thus, in this section, a further analysis of the 
articles that presented arguments against the requirement is presented.  
The people who were cited providing arguments against the HPV vaccine school-entry 
requirement in the articles reviewed included: a concerned mother, a couple of pediatricians, a 
policymaker member of the legislature, members of a feminist non-profit organization, a 
university professor, a member of an autism organization, and a representative of a religious 
group.  
The arguments listed in the articles included concerns related to the side effects of the 
HPV vaccine (40%), the sexual nature of the transmission of the virus (40%), and that it should 
be the parents’ right to choose to vaccinate their children (40%). Other areas such as the HPV 
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clears by itself (20%) and that the is no consensus regarding the HPV vaccine (20%), were 
mentioned less frequently. Below are some quotes that represent these types of arguments.   
For instance, a member from an autism organization mentioned the sexual nature of the 
transmission of the virus as one of the concerns;  
“¿Qué necesidad tiene un niño o niña en 
edad escolar que no se ha iniciado 
sexualmente de ser protegido contra una 
enfermedad que se adquiere por contacto 
sexual? […] “Esta no es una enfermedad que 
el nene va a estornudar y se le va a pegar a 
otro”, indicó [nombre], quien dijo que otra 
preocupación son las muertes que, en algunos 
países, se le han atribuido a esta vacuna. 
Entre estos, mencionó a Japón.” –246  
 
“What is the reason for a boy or a girl in 
school-age that has not initiated sexual 
activity, to be protected against a disease that 
is acquired by sexual contact? […]” “This is 
not a disease that a boy sneezing will transmit 
it to the other one”, indicated [name], who 
said that another concern are the deaths, that 
in some countries, have been attributed to this 
vaccine. Among these, she mentioned Japan.” 
– 246, endi.com, 2018 
 
In an article published in 2017, a member of a feminist non-profit organization noted that 
parents should decide, after reviewing the information, if they want to vaccinate their children.  
“Las vacunas contra el VPH son una 
herramienta de prevención del cáncer 
cervical. Sin embargo, la vacuna no debe ser 
obligatoria" "Cada familia, luego de haber 
sido debidamente informada sobre ventajas y 
riesgos de la vacuna, debe decidir libremente 
cuáles de estas estrategias desean asumir 
para su salud y la de su familia" –243  
 
“The vaccines against HPV are a tool for 
cervical cancer prevention. However, the 
vaccine should not be mandated.” “each 
family, after being rightly informed about the 
advantages and risks of the vaccine, should 
freely decide which of the strategies they 
would like to use to protect their health and 
their family’s health” –243, endi.com, 2017  
 
In 2018 a policymaker was cited in one news article saying; 
“(si se aprueba la medida [Proyecto 
1303]), no aplicaría (el requisito escolar de 
la vacuna contra el VPH) para entrar en 
vigor en agosto”, dijo [name of 
policymaker]” –203  
 
“(if the Bill is passed [Bill 1303]), it would 
not be required (the HPV vaccine school-
entry requirement) to start on August”, said 
[name of policymaker]”—203, El Nuevo Dia, 
2018  
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The feminist group was emphatic that sex education and access to screening services 
should be provided by the Government, a factor that was also a concern for the interviewee 
against the HPV vaccine school-entry requirement. For example, in the article, the member of 
the feminist group was cited as discussing that; 
 
“[…] es responsabilidad del Estado 
garantizar acceso a información completa y 
objetiva sobre los beneficios, riesgos, y 
limitaciones de cada una de las alternativas 
de prevención disponibles.” –243  
 
“[…] it is the Government responsibility to 
guarantee access to complete and objective 
information about the benefits, risks, and 
limitations of every preventive option 
available.” –243, endi.com, 2017  
 
Some of these reasons or concerns were also mentioned by the participant who self-
identified as being against the HPV vaccine school-entry requirement. For instance, this quote 
describes the concern related to the lack of education regarding the HPV vaccine, despite it been 
mandated.   
“Primero porque no viene acompañado de 
una adecuada educación realmente, la 
vacuna está siendo mandatoria, el pediatra lo 
está también fomentando, pero voy a ponerlo 
a nivel de escuela, en escuela te obligan 
hacerlo.” 
“First of all, it does not come with adequate 
education, really, the vaccine is being 
required, the pediatrician is also encouraging 
it, it's going to be at the school level, at the 
school you are required to do.” 
 
This participant also noted during the interview that this lack of education would later 
have effects on the girl’s future sexual decision making. This is illustrated in the following quote;  
“La niña es la que tiene que decidir que 
quiere, porque es la vida de ella y va a ser el 
futuro de su vida sexual, pero como no 
educan, cómo van a tomar una decisión 
responsable si no los educo, no pueden, 
nunca la tomaran, nunca.” 
 
“The girl is the one who should decide what 
she wants, because it is her life, and it’s going 
to be the future of her sexual life, but since 
there is no education, how are they going to 
make a responsible decision if I don’t educate 
them, they can’t, they will never make it, 
never.” 
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Lastly, an argument that was present in the news articles and was echoed by the 
participant who identified as being against the HPV vaccine school-entry requirement, was the 
belief that the HPV vaccine was a sort of business or marketing strategy to make money based 
on fear. In a news article published in 2018 a university professor noted;  
“Esto se ha convertido en algo que no es, y se 
vende la vacuna bajo el factor del miedo,” 
señaló.” –246 
“This has become something that it’s not, and 
the vaccine it's being sold under the fear 
factor”, indicated.” –246, endi.com, 2018 
 
The participant against the HPV vaccine school-entry requirement said during the 
interview; 
“Dinero, millones que cuando dicen dar, 
desde apoyar campañas políticas, desde 
favores políticos, pero sobre todo y más que 
todo, dinero que igual pueden estar 
distribuyendo a nivel de gobierno y estoy 
hablando a nivel ya de Estados Unidos, 
porque acuérdate que por nuestra situación 
política, lo que pasa allá repercute acá y 
algún acuerdo que se haya dado que a partir 
de ahí se hace mandatorio y quizás es la 
colaboración que existen entre todas las 
agencias porque es mandato como quien dice 
presidencial o gubernamental, 
independientemente de.”  
“Money, millions they say will give, from 
support to political campaigns, from political 
favors, but above all and beyond all, money 
that they may be distributed to the 
government, and I am speaking at the United 
States level, because remember our political 
situation, what happens there affects us here, 
and any agreement making it mandatory, and 
maybe is a collaboration that exists between 
all agencies because its mandatory, like they 
say presidential or governmental, 
regardless.”  
 
Data triangulation  
 There are some areas of similarity between the results of these two phases. The top area 
of primary focus identified in the content analysis during the years before the adoption of the 
HPV vaccine school-entry requirement (i.e., 2015, 2016, and 2017), included educational and 
informative articles related to HPV and the HPV vaccine (Table 8).  This type of information 
could be important in terms of better understanding the process of education and awareness that 
took place in PR and that stakeholders mentioned during the interviews. The second primary 
focus, advertisement, including HPV vaccine ads from Merck and VOCES, also seems to 
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support the findings from the interviews in which the stakeholders mentioned how the private 
sector, which included Merck, provided education and support towards the vaccine and the 
requirement. 
It is interesting to note that the number of articles mentioning HPV as an STI or with 
other STIs as the primary focus, declined from four in 2015 to zero in the first seven months of 
2018 (Table 8). This would seem to align with what the stakeholders said about framing the HPV 
vaccine and the HPV vaccine school-entry requirement as cancer prevention. Also, the number 
of articles with cervical cancer as their primary focus increased in 2016 and 2017, which also 
seem to support this idea.  
One important finding of the interviews was the identification of the 2017 announcement 
of the HPV vaccine school-entry requirement as the starting point or opening of the window of 
opportunity. Findings from the content analysis show that the greatest number of publications 
with the HPV vaccine school-entry requirement as the primary focus occurred in 2017 (Table 8), 
followed by the year when the official announcement of the requirement was published and 
noted by the stakeholders. This trend is similar when looking at the articles that mentioned the 
HPV vaccine school-entry requirement (Table 9); most were published in 2017 and 2018.  
During the interviews, stakeholders explained how the current immunization law 
facilitated the process of adoption of the requirement. Per the current immunization law, the 
DOH must publish every year the list of required vaccinations for school at least three months 
before classes start. In PR classes start in August, the increase in number of articles that 
mentioned the HPV vaccine school-entry requirement occurred during the months of June and 
July, soon after the DOH announcements were published (Table 5).  
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Another area of overlap between the findings of the two phases relates to the Report and 
the case of Rhaiza, both mentioned by the stakeholders as important events that occurred in 2015 
in the overall process of adoption of the HPV vaccine school-entry requirement. The two news 
articles published in 2015 in favor of the requirement were about the presentation of the Report 
during which tribute was paid to Rhaiza, and in which a variety of stakeholders, including 
Rhaiza’s widower, advocated for making the HPV vaccine required for school entrance.  It is 
also important to note that articles with Rhaiza as the primary focus were scarce (n = 2, Table 8). 
However, there were articles in the advertisement category that did mention Rhaiza and or used 
pictures of her to promote the HPV vaccine.  
From the stakeholders’ viewpoint, the composition of the anti-vaccination groups varied. 
Some of the groups mentioned by the stakeholders, as well as the arguments against the HPV 
vaccine and the requirement, were also found in the articles. In both datasets a feminist non-
profit organization, an autism organization, and a representative of a religious group were 
present. Also, the arguments against the HPV vaccine school-entry requirement that the 
stakeholders listed were also listed in the articles. The similar arguments included the concerns 
about the HPV vaccine safety and side effects, the religious concerns related to the sexual nature 
of the transmission of the virus, and that it should be the parents’ right to choose to vaccinate 
their children. However, an argument that was only present in the articles was the concern the 
member from a feminist group and the participant who identified as being against the HPV 
vaccine school-entry requirement mentioned regarding the lack of human sexuality education in 
PR.  
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Summary  
This chapter presented the findings for both phases of the study. It included the themes 
based on the interview data, framed using the theoretical framework. Quotes were provided to 
show examples of the conversations that took place during the interviews and in support of the 
results. Additionally, this chapter presented the findings from the content analysis with a focus 
on the arguments against the HPV vaccine school-entry requirement. The chapter ended with the 
triangulation of the results from the interviews ant the content analysis. The following chapter 
includes a discussion of the overarching findings of the study interweaving the results of the two 
phases in the context of the theory and the literature.  
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Chapter 6: Discussion 
  
Introduction  
Despite cancer-preventive properties of HPV vaccination and the effectiveness of prior 
vaccine mandates, HPV vaccine school-entry requirements have not been widely adopted in the 
US. There remains a public health need to understand the low adoption rates of the HPV vaccine 
school-entry requirement. Thus, the purpose of this study was to understand the macro-level 
factors that influenced the adoption of the HPV vaccine school-entry requirement in PR during 
the summer of 2018. To accomplish this purpose a macro-level theory, the MSA was used to 
guide the three research questions of this study. The following section includes a discussion of 
the findings in the context of the theory and the literature, a recognition of the limitations and 
strengths of this study, a description of the implications for research, policy, and practice, and 
areas for future research.  
Intersection of Problems, Policy, and Politics 
The MSA posits that when policy entrepreneurs purposely intervene with different 
tactics, the problems, policy, and politics streams will converge to create a window of 
opportunity that results in a policy output (Kingdon, 1995; Zahariadis, 2007, 2014). Briefly, the 
problems stream represents the issues that need to be solved. The policy stream includes the 
soups of ideas that compete for the policymaker’s attention. The politics stream refers to the 
political factors and pressure groups that influence adoption (Kingdon, 1995; Zahariadis, 2007, 
2014). In the case of PR, findings from this study indicate that this window of opportunity 
opened during the summer of 2017; ultimately, the final output was produced in the summer of 
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2018 when the DOH, via the Secretary of Health, officially announced the requirement of the 
HPV vaccine for school entrance. To be able to understand how this intersection occurred, each 
of the streams will be discussed (Figure 6).  
 
Stakeholders agreed that specific health factors, or indicators, as the MSA labels them, 
contributed to the process of adoption of the HPV vaccine school-entry requirement. As 
indicated, PR is among the US states/territories with the highest rate of estimated HPV-
associated cancer (including anal, cervical, oropharyngeal, and rectal cancers), with a rate of 
13.10 cases per 100,000 people who develop cancer. Moreover, PR has the highest rate of HPV-
associated cervical cancer in the nation with rates of 11.70 cases per 100,000 women (Viens et 
al., 2016). The stakeholders in this study were concerned about the high incidence of HPV and 
HPV-related cancers, in particular, cervical cancer and the increasing rates of oropharyngeal 
cancer. These high rates of HPV and related cancers were among the main problems that 
Figure 6. Application of MSA to study findings 
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stakeholders thought needed to be resolved by the HPV vaccine school-entry requirement. This 
finding is similar to the case of Virginia’s HPV vaccine school-entry requirement, where 
concerns regarding cervical cancer were noted as a health issue by the proposed legislation that 
passed in 2009 (Abiola et al., 2013). Additionally, stakeholders described the relatively high 
uptake HPV vaccination rates in PR as a facilitator; however, the low completion rates were an 
indicator that was considered for the adoption process of the requirement.  
In addition to the health indicators, there were two focusing events that contributed to the 
initiation of the adoption process of the HPV vaccine school entry requirement in PR: 1) Rhaiza 
López Plumey died of cervical cancer [January 2015] and 2) the VOCES HPV Advisory Panel 
Report (Report) was published [May 2015]. The video posted on social media, and later the 
announcement of Rhaiza’s death, contributed to bringing awareness among the Puerto Rican 
population about the cervical cancer issue. The Report was meaningful because it included the 
epidemiological and cost-effectiveness data based on studies conducted in PR. Having available 
the local epidemiological data about the incidence of HPV and HPV-related cancers, and HPV 
vaccine uptake rates, as well as data on cost-effectiveness, facilitated the process of adoption. 
The results from the interviews show that stakeholders were guided by this Report, published 
after the passing of Rhaiza, and that included objectives recommending education efforts and the 
HPV vaccine school-entry requirement.  
Before the window of opportunity opened, policy entrepreneurs worked on other areas 
and issues that needed to be addressed to clear the way for the adoption of the HPV vaccine 
school-entry requirement. The results of this study narrate the background of efforts undertaken 
to address these areas. For instance, policies to make it mandatory for health insurance 
companies to cover the HPV vaccine were supported by the policy entrepreneurs and created at 
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the Legislature level. These policies allocated money and resources to pay for the HPV vaccine, 
making it available for the population in the private sector.  
Another facilitator of adoption process was the education campaigns that took place in 
PR years before the adoption of the requirement and during the year between the DOH 
announcement in 2017 and the official requirement in 2018. This process of education created 
awareness of HPV, HPV-associated cancers, and the HPV vaccine. Findings indicate that, from 
the stakeholders’ perspectives, this education process was essential to reduce the likelihood of 
resistance from the anti-vaccination groups. The educational efforts also focused on the adoption 
of the HPV vaccine requirement as a form of cancer prevention, rather than prevention of an STI. 
This finding is similar to previous research in which the idea of preventing cancer is the primary 
driver of the decision to adopt such a policy (Abiola et al., 2013; Colgrove et al., 2010). 
Additionally, based on the content analysis data, most of the articles mentioning the HPV 
vaccine school-entry requirement were published during the years of 2017 and 2018. Thus, the 
process of adoption did get media attention, in particular during the months of June and July, 
which are close to the dates of the DOH announcements. A previous content analysis of print 
news from three states (i.e., Texas, Virginia, and DC), also found increased media attention in 
response to governments’ discussions about HPV vaccine mandates (Casciotti et al., 2014).  
In response to the DOH’s announcement of 2017, both the anti- and pro-vaccination 
groups presented policies to members of the Legislature. These other policy options were in the 
soup of ideas competing for the policymaker’s attention (Kingdon, 1995; Zahariadis, 2014). The 
policies that the stakeholders discussed included, HR Bill 537, Bill 1303, and Bill 1579. 
Policymakers gave attention to HR Bill 537 in 2017, and an investigation on the safety and 
efficacy of the HPV vaccine was conducted through public hearings in 2018 (Table 4). This 
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investigation resulted in a positive overview of the HPV vaccine, published in June 2018, after 
the Secretary of Health had already announced the official HPV vaccine school-entry 
requirement. Due to the positive results regarding the safety and efficacy of the HPV vaccine 
published in the Bill 537 resolution, the legislators let the HPV vaccine school-entry requirement 
continue its course. Despite that, at some point, policymakers were asking the secretary of health 
to retract it. It is important to note that, during the summer of 2018, HR Bill 1576, petitioned by 
members of the anti-vaccination groups, was presented but not discussed in plenary; neither was 
Bill 1303, petitioned by the pro-vaccination group. Thus, the adoption of the HPV vaccine 
school-entry requirement occurred despite the concurrent proposition of other policies.  
An important finding from this study is that stakeholders thought that PR’s current 
immunization law made it technically feasible to adopt the HPV vaccine school-entry 
requirement. This regulatory approach may have facilitated the HPV vaccine school-entry 
requirement adoption because convincing the members of the legislature, whose decisions are 
highly influenced by the voters, can be difficult. Instead, policy entrepreneurs talked to and 
shared scientific evidence with the current Secretary of Health. This approach is similar to the 
case of the state of Rhode Island, where the Department of Health also established the 
requirement via its rulemaking powers (Barraza et al., 2016; Washburn et al., 2016). On the other 
hand, both Virginia’s and DC’ mandates were created through the legislature (Barraza et al., 
2016). 
Another way in which the HPV vaccine school-entry requirement was described as 
technically feasible by the stakeholders was because it only includes the 11 to 12 years old 
cohort of children. This was important for the stakeholders because it meant that the government 
and public health system would only spend money on the cost of two doses, which is the number 
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of shots required for the targeted cohort. This is an in alignment with the current HPV vaccine 
ACIP recommendations (Centers for Disease and Control Prevention, 2016b).  
Related to the technical feasibility aspects of the HPV vaccine school-entry requirement, 
findings support that there were considerations regarding the value of this policy approach. 
Mainly, participants noted concerns about the public health and economic implications of the 
HPV vaccine school-entry requirement. These were essential values captured by the HPV 
vaccine school-entry requirement, which included the protection and the overall wellness of the 
island population by preventing the physical, emotional, and economic implications of HPV-
related cancers in the long term.  
From a political perspective, the stakeholders frequently mentioned the anti-vaccination 
sector as active members of the society exercising pressure on the policymakers. These pressure 
groups varied in composition and posed a direct resistance to the adoption of the HPV vaccine 
school-entry requirement in PR. In an attempt to weaken the reach of the HPV vaccine school-
entry requirement, one of the anti-vaccination groups petitioned Bill 1576. The purpose of this 
bill was to amend PR’s immunization law to include an opt-out option based on personal beliefs. 
However, during the summer of 2018, the bill was not discussed. In other scenarios, such as in 
the case of Virginia, the passing of an HPV mandate encountered less resistance. Here, a quick 
passing of a bi-partisan bill did not provide enough time for an anti-bill campaign to form and be 
a barrier for the passing (Abiola et al., 2013). Members for the RI’s DOH also noted minimal 
opposition to the addition of the HPV vaccine to the school entrance requirements in 2014 
(Washburn et al., 2016). However, there have been actions taken through the legislature to limit 
RI’s DOH powers relating to its authority to establish vaccine requirements, particularly to 
requirements related to diseases not contagious in the school setting (Barraza et al., 2016).   
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Additionally, the political turn-over in key government positions seems to have 
facilitated the HPV vaccine school-entry requirement adoption process in PR. With a change in 
political party in the government of PR for 2017, new individuals were named to occupy 
positions in the governor’s cabinet, including the secretary of health. Results from the interviews 
indicate the policy entrepreneurs perceived the secretary of health as someone supportive of 
vaccinations and open to making the reduction of cervical cancer one of his priorities. This 
political turn-over in government positions was also considered a concern. Changes in 
administrations due to changes in political parties could mean that whoever is named to occupy 
the position of secretary of health may decide to remove HPV from the list of required 
vaccinations. This is a limitation of how the HPV vaccine school-entry requirement was created 
in PR, through an announcement of the secretary of health and not via the legislature.  
Policy Entrepreneurs  
The work needed for the problems, politics, and policies to intersect was conducted 
through collaborations efforts among different sectors composed of the policy entrepreneurs. 
Similar to the findings from Abiola et al. (2013), policy entrepreneurs were instrumental in the 
adoption process of the HPV vaccine school-entry requirement in PR. As the MSA describes 
(Kingdon, 1995; Zahariadis, 2014), and noted in the findings from this study, the role policy 
entrepreneurs played, and their participation in the adoption process indicates how they made the 
three streams intersect/converge. For instance, policy entrepreneurs worked in changing 
narrative related to the HPV vaccine; thus, creating awareness in the population. This change in 
narrative was a result of the education and campaigns and efforts discussed by the stakeholders. 
They were all giving the same message to the community, as noted before, that the HPV vaccine 
school-entry requirement is about cancer prevention.  
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In the case of the Virginia mandate, Senator Janet Howell and Delegate Hamilton were 
the policy entrepreneurs who achieved consensus in the legislature and support from stakeholder 
organizations (Abiola et al., 2013). In contrast, policy entrepreneurs in PR were from a variety of 
sectors of the population. For example, VOCES, PR’s pro-vaccinations coalition, played an 
important role unifying all the sectors to advocate for the HPV vaccine school-entry requirement 
with the scientific evidence needed to convince the secretary of health. Also, other sectors, some 
of which are part of VOCES, had additional roles based on each of their expertise and area of 
interest. In the case of DC’s mandate, the ACS provided a statement in support of the legislation 
(Barraza et al., 2016). 
Comparison of PR’s HPV vaccine school-entry requirement to Virginia, 
Washington DC and Rhode Island’s HPV vaccine school-entry requirements. 
 Barraza et al. (2016) identified some areas of similarities and differences between the 
Virginia, Washington DC, and Rhode Island’s HPV vaccine school-entry requirements. These 
areas include when the requirement was adopted, mode or process of adoption, who the 
requirement applies to and the timing of the HPV vaccine doses, and the opt-out mechanisms 
available to the population. In this section, these areas will be compared to the PR’s HPV 
vaccine school-entry requirement.  
Back in 2009, when the state of Virginia adopted its HPV vaccine school-entry 
requirement, it was done through the legislature (Barraza et al., 2016; Colgrove et al., 2010; 
Virginia Department of Health, 2014). This approach is similar to the Washington DC 
requirement, which was enacted in 2009 via the legislature (Barraza et al., 2016; Government of 
the District of Columbia Department of Health, 2015). In contrast, RI’s 2015 and PR’s 2018 
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requirements were adopted using the DOH regulatory and administrative powers (Barraza et al., 
2016; Washburn et al., 2016). 
The present HPV vaccine school-entry requirements vary with respect to who should get 
the vaccine and the timing of the HPV vaccine doses. Washington DC, RI and PR’s 
requirements, all currently indicate that girls and boys should get the HPV vaccine for school 
entrance (Barraza et al., 2016; Government of the District of Columbia Department of Health, 
2015; "Ley de Inmunizacion," 1983; State of Rhode Island Department of Health, 2015). In the 
state of Virginia, the requirement only applies to girls. Virginia requires three doses to be 
completed before entering the sixth grade (Barraza et al., 2016; Virginia Department of Health, 
2014). In Washington DC, three doses are needed upon starting sixth grade at 11 years old. The 
state of RI took a different approach and requires the first dose of the HPV vaccine before 
starting seventh grade and finishing the series before starting ninth grade  (Barraza et al., 2016). 
In PR, the DOH requests the HPV vaccine for all 11 and 12 years old.  
Lastly, in terms of opt-out options, there is a range of variation. Virginia has the most 
lenient process of exception. Basically, by just reviewing some educational materials and signing 
a documented waiver, parents can get the exception approved, without the need to provide any 
documentation at the school (Barraza et al., 2016; Virginia Department of Health, 2014). In the 
case of the Washington DC requirement, the three exceptions allowed are the religious, the 
medical and the philosophical (Government of the District of Columbia Department of Health, 
2015). Both RI and PR only allow for medical and religious exceptions (Barraza et al., 2016; 
Puerto Rico Department of Health, 2013; State of Rhode Island Department of Health, 2015).  
Arguments in favor of and against the HPV vaccine school-entry requirement in PR  
Arguments influencing support for HPV vaccine mandates have been framed under the 
umbrella of women’s health and children’s welfare (Colgrove, 2006). Vamos et al. (2008)  
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summarized the arguments literature in favor of a school vaccine mandates describing them as 
those about the appropriate age for vaccination, those related the cost-effectiveness of requiring 
the HPV vaccine, those highlighting the need for the prevention and reduction of cervical cancer, 
and the parent’s participation in the health decisions concerning their children. In PR, the 
framing strategy used was to describe the HPV vaccine school-entry requirement as a tool for 
cancer prevention. Notably, based on the need to reduce the high rates of cervical cancer among 
Puerto Rican women. Additionally, the cost-effectiveness and the alignment with the ages of 
inoculation, 11 and 12 years old, were important for the policy entrepreneurs, as was the public 
health impact on the wellness of the population due to the reduction of HPV-related cancers. 
Studies among physicians have reported similar reasons in support of the HPV school-entry 
requirement such as its effectiveness in increasing immunization and its public health impact on 
immunization (Kahn et al., 2007; Tissot et al., 2007; Vercruysse et al., 2016). 
Conversely, arguments against the need for HPV vaccine school-entry requirements are 
based on lack of transmission of the virus through casual contact, intrusion into parental 
autonomy, public distrust due to pharmaceutical lobbying during the policy development 
process, and the potential economic burden on the government, and health care system including 
the health departments and private physicians’ offices (Gostin & DeAngelis, 2007; Javitt et al., 
2008; Mello et al., 2012). Some of these reasons were echoed in the findings from this study as 
described by the stakeholders and in the news articles reviewed.  
Arguments against the HPV vaccine school-entry requirement seem to be intrinsically 
related to the HPV vaccine and the virus. For instance, concerns related to the side effects and 
safety of the HPV vaccine were mentioned by the stakeholders and present in the articles, as 
reasons to be against the HPV vaccine school-entry requirement. This reason has also been 
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discussed among parents in previous research who thought that the vaccine was new and had 
concerns about its safety and side effects and were more likely to be against the HPV vaccine 
school-entry requirement (Carlos et al., 2011; Horn et al., 2010; Perkins et al., 2010; Robitz et 
al., 2011; Smith et al., 2011). 
Another argument mentioned by the stakeholders, and that also was presented in the 
reviewed articles, was the mode of transmission of the virus and its association with sexual 
activity. Previous studies among parents discussed the way of HPV transmission as a reason to 
be against the HPV vaccine school-entry requirement, while other studies have reported the lack 
of casual transmission (Perkins et al., 2013; Vercruysse et al., 2016), or emphasized the sexual 
transmission of the virus (Pitts & Tufts, 2013) as arguments against the HPV vaccine school-
entry requirement. Similarly, Casciotti et al. (2014) found that in the print media that 
encouragement of sexual activity was an argument against the HPV vaccine school-entry 
requirement. Moreover, Vercruysse et al. (2016) found that parents discussed that adolescents 
were not sexually active; thus, there was no need for the requirement. A similar reason was 
presented in the news articles by one of the anti-vaccination groups.  
Finally, parental rights to decide what is best for their children was another argument 
discussed during the interviews and published in the Puerto Rican news articles. Previous 
research with parents has also reported the parents’ choice or decision to vaccinate their children 
(Perkins et al., 2013; Pitts & Tufts, 2013; Smith et al., 2011; St John et al., 2010; Vercruysse et 
al., 2016) as an argument against the HPV vaccine school-entry requirement. The government 
imposition of the HPV vaccine to parental autonomy was the most common theme that was 
reported by Casciotti et al. (2014) in print news media from Texas, Virginia, and DC between 
2005 and 2009. 
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Strengths and Limitations  
As with any research study, some strengths and limitations should be noted. There are 
different types of biases that could have affected this study. For instance, researcher bias could 
be considered a limitation to this study. Based on my education and life experiences, I am a 
supporter of HPV vaccination and school-entry requirements. Therefore, I took steps to maintain 
a neutral position while conducting the interviews, and while analyzing both the qualitative and 
quantitative data. To address this issue, I was aware of and documented my biases, which are 
presented in the Reflexivity section of this dissertation. Recall bias from the participants may also 
be impacting the findings, more so in the narratives related to the work done before the summer 
of 2018, when data were collected.  
Overall, purposive sampling limits the generalizability of the results. Additionally, there 
are problematic aspects of conducting interviews with stakeholders such as participant 
recruitment and participation. In terms of recruitment, the strategies that worked best in this 
study to access participants in favor of the HPV vaccine school-entry requirement were key 
informant introduction and snowballing. Nonetheless these strategies, the researcher had only 
one person who identified as been against the HPV vaccine school-entry requirement. Not 
having a key informant who could introduce the researcher to the community of stakeholders that 
were against the HPV vaccine school-entry requirement may have hindered the recruitment 
process.  
This posits limitations to the findings of this study, which are mostly informed by the 
participants who identified as been in favor of the requirement. To address this limitation, the 
content analysis was conducted and emphasis was given to explore the argument against the 
HPV vaccine school-entry requirement.  
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It is important to note that this study lacks an in-depth exploration of the HPV vaccine 
school-entry requirement adoption process from the perspective of the stakeholders who were 
opposed to the mandate. Some participants from this study mentioned that the anti-vaccination 
groups mainly communicate and obtain their information via social media. Future research could 
look at the anti-vaccination groups utilizing social media as a means for recruitment or engaging 
with this type of stakeholder.  
Regarding participation, the type of participant chosen for this study tends to have limited 
time to engage in activities not related to their primary duties, such as research studies. This 
limitation was addressed by using two different strategies to conduct the interviews, in-person or 
via phone. Providing the participant these options enabled them to choose the most convenient 
method for them. Thus, facilitating their participation.  
Moreover, there could be issues related to saturation. Saturation is an iterative process in 
which the researcher is the one who notes if saturation has been achieved (Hennink et al., 2011) 
and has become the ‘gold standard by which purposive sample sizes are determined in health 
science research” (Guest et al., 2006, p. 60). The researcher noted saturation in the themes. 
However, saturation may not have been achieved for some sub-codes or sub-themes (e.g., 
misinformation available in the social media). Not achieving data saturation in these themes 
hinders their validity (Fusch & Ness, 2015); thus; careful consideration of these themes should 
be noted.   
In terms of the content analysis, a limitation was that the search process for each 
newspaper’s database differed. These search engines are created for everyday use and leisure 
reading. They are not designed with rigorous algorithms needed for research (Lacy, Watson, 
Riffe, & Lovejoy, 2015). Thus, there may be a possibility that not all the news articles that were 
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published were captured in the searches executed. To address this limitation, the researcher used 
two newspaper search engines and online databases. The missing of the last five months of the 
2018 year is another limitation related to the content analysis. Additionally, the articles were 
sampled purposively (a non-probabilistic sample), and the data are not truly dichotomous, thus; 
inferential analysis is not recommended  (Guest et al., 2012a).  
Besides these methodological limitations, there were also theoretical limitations. MSA 
assumes that each of the streams runs independent from each other and only converge at short 
times called the windows of opportunity (Kingdon, 1995; Zahariadis, 2007). Nonetheless, in the 
case of the HPV vaccine school-entry requirement adoption process in PR, it was difficult to 
evaluate the streams in isolation. From the data, it seems that the streams are always in contact 
with one another. They were influenced by the policy entrepreneurs who were in constant 
interaction with the streams at many points in time (Figure 6). Additionally, time was an 
important factor in the findings of this study. MSA posits that the window of opportunity is short 
in duration (Kingdon, 1995; Zahariadis, 2007). However, based on the findings of this study, the 
window of opportunity opened when the Secretary of Health made the announcement during the 
summer of 2017 and stayed opened for about a year until the official announcement was 
published in the summer of 2018. Moreover, the previous work conducted by the policy 
entrepreneurs dated years before the window of opportunity opened. This is noted by the blue 
arrows in Figure 6.  
Also, this theory is ‘adoption biased.’ This means that not only it favors evaluation of the 
creation of policies, but it also falls short in looking at the implantation phase. This limitation 
about lacking a focus on the implementation of policies, was also discussed by Blackman (2005) 
her literature review of tobacco control policy development in California. To somewhat address 
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this limitation, the researcher asked about the potential effects that the hurricane Maria could 
posit to the implementation of the requirement. To this question, participants noted that for the 
most part it, the vaccine was supposed to be available. Nonetheless, the use of theory can also be 
a strength, since it did serve to guide the research questions, analyze, and summarize the data.  
Several other strengths exist in this study. The data collection process of this study was 
opportune. This study took place amid the HPV vaccine school-entry requirement adoption 
process in PR and helps with reducing the chances of recall bias. Also, the addition of the 
content analysis served to gather more data on the reasons expressed against the HPV vaccine 
school-entry requirement. It was used to triangulate the data from the interviews that primarily 
had the perspective of people in favor of the HPV vaccine school-entry requirement.   
Research, Practice, and Policy Implications  
This study has the potential to contribute to research because it adds to the existing 
literature trying to understand the controversies surrounding the HPV vaccine school-entry 
requirements. Additionally, it helps to inform the application of a macro-level theory to data 
from a current policy issue. Similar interviews with stakeholder from other states, and even from 
other Spanish-speaking countries, can be conducted to explore additional contextual issues 
surrounding the potential creation of HPV vaccine-related policies. Furthermore, this study’s 
methodology could be applied to the exploration of the creation of other immunization or health 
policies. Thus, contributing to the development of health policy research.  
Further research is still needed regarding the HPV vaccine school-entry requirement. For 
example, there is a need to study the HPV school entry requirement adoption process in PR from 
different perspectives, such as the perspective of parents with adolescent children, or staff from 
the school system. This can contribute to seeing the whole picture of the HPV vaccine school-
entry requirement adoption process. Also, for a comprehensive content analysis of the newspaper 
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articles published in PR regarding the HPV vaccine school-entry requirement, future research 
should include the last five months of the 2018 year. Another area of interest would be to explore 
the misinformation regarding the HPV vaccine available in social media from PR. Lastly, future 
research should also look at the implementation process of the HPV vaccine school-entry 
requirement occurring in PR, taking into consideration HPV vaccination outcomes for evaluation 
of the policy.  
Moreover, this study also has several practice implications. The study identified the 
relevant factors that facilitated the adoption process of an HPV vaccine school-entry 
requirement. Thus, messages could be created to raise awareness and support among parents and 
other key stakeholders towards this type of population-based strategy. Public health practitioners 
should also consider the importance multisector collaborations, that work cohesively towards the 
same goal and with the same message. Additionally, for the messaging and ultimately the 
adoption of these policies to be facilitated. Thus, having local epidemiological data seems to be 
meaningful for the decision makers, as well as, been purposeful in aligning the messages with 
the values of the policymakers. The timing of educational programs and interventions should 
also be considered, as it can potentially facilitate the process of adoption of similar policies. 
Also, the people in power and key administrative staff should also be considered and influenced 
to facilitate the adoption process. Public health practitioners and advocates of immunization 
policies can use this information to develop action plans for their states.   
Finally, this research could impact public health policy in several ways. This study of 
PR’s HPV vaccine school-entry requirement provides an overview of an adoption process that 
recently took place and could inform other states and public health practitioners interested in 
making the HPV vaccine mandatory. This study also provides insight into the policies that may 
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need to be in place prior to the adoption of an HPV vaccine school-entry requirement. For 
instance, in the case of PR, a policy that made the month of January the cervical cancer 
prevention month, was used to create awareness among the population. As the participants of this 
study asserted, creating awareness of the issue before the HPV vaccine school-entry requirement 
was adopted may have contributed to the facilitation of the process. Additionally, the process 
that occurred in PR, in which the requirement was adopted via the DOH can also serve as an 
example to other states in which going through the Legislature may seem a difficult policy 
creation process. Lastly, findings from this study can inform other HPV vaccine policy initiatives 
to improve HPV vaccination rates across the US and target the prevention of HPV-related 
cancers.   
Summary 
The purpose of this study was to understand the macro-level factors that influenced the 
adoption of the HPV vaccine school-entry requirement in PR during the summer of 2018. MSA 
was useful to identify factors and understand the process that took place in PR for the HPV 
vaccine school-entry requirement to be created. Policy entrepreneurs actively guided the 
intersection of local problems, politics, and policies to educate the population and prevent cancer 
in PR. This timely look at the facilitators and barriers of the HPV vaccine school-entry provides 
practical information about the process of adopting a cancer prevention policy-based strategy. 
Findings from this study can inform other states and public health practitioners interested in 
adopting HPV vaccine policy initiatives to improve HPV vaccination rates across the US and 
target the prevention of HPV-related cancers. 
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Tables and Figures 
 
Table 1: Information regarding available HPV vaccines 
Type Name Manufacturer FDA approval 
Year 
recommended 
for routine 
vaccination 
HPV strains covered by each vaccine 
     6 11 16 18 31 33 45 52 58 
2vHPV Cervarix® GlaxoSmithKline 2009 F 2009 F   X X      
4vHPV Gardasil® Merck and Co, Inc. 
2006 F 2006 F 
X X X X      
2009 M 2011 M 
9valent  Gardasil-9® Merck and Co, Inc. 2014 B 2015 B X X X X X X X X X 
Note: M = males, F = females, B = both sexes (Markowitz et al., 2014, Petrosky et al., 2015) 
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Table 2: Studies about stakeholders’ reasons and factors associated with HPV vaccine school-entry requirement in the US: Studies’ 
characteristics (N=25) 
Authors, year Type of Stakeholder Location Study Design* Methodology Date data 
collected 
Sample size Theory 
Tissot et al. 
(2007) 
 
 
 
Pediatricians Three-state 
region: Ohio, 
Indiana, 
Kentucky 
QL  semi-
structured 
interviews 
2005 31 For data analysis – 
Framework analysis 
Kahn et al. 
(2009) 
Primary care 
physicians 
Texas QT  web survey 2008 1,122 Model informed by 
Theory of Planned 
Behavior, the 
Awareness-to-adherence 
model and diffusion 
model 
 
Millen et al. 
(2009) 
Emergency 
department patients 
Boston, 
Massachusetts 
QT  researcher 
administered 
survey 
 
2007 387 None mentioned 
Sanderson et al. 
(2009) 
HPV+ and HPV- 
Latina mothers 
 
Texas QT researcher 
administered 
survey 
2007-08 405 Mentioned in discussion 
– HBM (findings align 
with constructs)  
Colgrove et al. 
(2010)† 
Multiple: mostly 
policymakers, 
industry, medical 
prof. orgs., 
advocacy groups 
6 states: 
California, 
Indiana, New 
Hampshire, 
New York, 
Texas, 
Virginia, and at 
National level 
 
QL Key 
informant 
interviews 
(face to face 
and phone) 
2008-09 73 None mentioned 
(potentially the same as 
Abiola et al. 2013, since 
same 
database/participants) 
Data analysis: thematic 
content analysis  
Ferris, Horn, 
and Waller 
(2010)†† 
Parents/guardians 
of children 9-17 
years old 
Atlanta, 
Georgia and 
North Augusta, 
South Carolina 
QT self-
administered 
survey 
2008 325 None mentioned 
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Table 2: (continued)       
Authors, year Type of Stakeholder Location Study Design* Methodology Date data 
collected 
Sample size Theory 
Kahan 2010 National sample of 
American adults 
 
(did not specified if 
had to be parents) 
National panel 
sample 
Exp. 
3 conditions 
(1.no 
argument, 
2.unattributed 
arguments, 
3.culturally 
identifiable 
advocated) 
Online 
experiments  
April and August 
of 2007 
1,538 
(n1=254, 
n2=252, 
n3=1,032) 
Cultural 
Cognition/cultural 
theory of risk 
For data collection: 
previously validated 
scales, and new ones  
 
Rebecca B. 
Perkins, Pierre-
Joseph, 
Marquez, Iloka, 
and Clark 
(2010) 
 
Parents of girls 11 to 
18 (included ethnic 
minorities) 
 
Boston, 
Massachusetts 
 
QL/qt- with 
demographic 
data 
 
Interviews, 
Likert scale 
 
2007-08 
 
73 
 
Data analysis: informed 
by grounded theory and 
content analysis  
 
St John et al. 
(2010) ††† 
 
News media and 
parents/guardians of 
girls 9-13 
 
Virginia 
 
M 
 
Thematic 
analysis of 
Virginia 
newspapers 
 
8 focus 
groups with 
parents 
 
 
Stories from Jan. 
2006-08. 
 
 
2008 
 
 
29  
 
 
 
 
33 
 
Journalistic framing  
Yeganeh, 
Curtis, and Kuo 
(2010) 
 
 
 
Parents/guardians 
(all females) of girls 
ages 11-17 (mostly 
Latino) 
Los Angeles, 
California 
QT Researcher 
administered 
survey 
2008 95 None mentioned 
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Table 2: (continued)       
Authors, year Type of Stakeholder Location Study Design* Methodology Date data 
collected 
Sample size Theory 
Carlos 2011 
(Study looks at 
intent to 
follow/comply 
with HPV 
vaccination 
laws) 
 
Protocol 
published in 
2010 
Mothers/caretakers 
(25-55 years old) of 
females 9 to 17 
engaging in breast & 
cervical cancer 
screening 
Chicago, 
Illinois (urban 
site – mostly 
black)  
 
Southeastern, 
Michigan 
(suburban site – 
mostly white) 
 
QT mail-based 
self-
administered 
survey 
3/4 years after 
HPV vaccine 
approval  
Dec. 1, 2007 – 
Nov. 30, 2008 
(retrospectively 
identified) 
 
937 Data collection: 
previously used scales 
based on the Health 
Belief Model  
Robitz et al. 
(2011) 
Parents (mostly 
Hisp. Or AA) of 11 
to 18 years old girls 
from communities 
with high-risk for 
cervical cancer 
 
Los Angeles, 
California 
QT Telephone 
survey 
2007-08 484 None mentioned 
J. S. Smith et 
al. (2011) 
Parents/guardians of 
girls 10 to 18 years 
old 
 
Southeastern 
North Carolina 
QT Telephone 
survey 
2007 866 Survey based on 
constructs of HBM 
Sara E. Abiola, 
James 
Colgrove, and 
Michelle M. 
Mello 
(2013)†** 
Multiple: mostly 
policymakers, 
industry, medical 
prof. orgs., 
advocacy groups  
6 states: 
California, 
Indiana, New 
Hampshire, 
New York, 
Texas, 
Virginia, and at 
National level  
QL Newspaper 
articles and 
archival 
materials. 
Key 
informant 
interviews 
(face to face 
and phone). 
2006-08 
 
 
 
 
2008-09 
- 
 
 
 
 
73 
Multiple Streams Model 
(Theory) 
Data analysis: thematic 
content analysis 
R. B. Perkins et 
al. (2013) 
Low income and 
minority 
parents/guardians of 
boys 11 to 17 years 
old 
Boston, 
Massachusetts 
QL/qt with 
demographic 
data  
Interviews  2010-2011*  
“prior to 
universal 
recommendation 
for boys” 
120 Health Belief Model 
(perceived severity, 
perceived susceptibility, 
perceived benefits, and 
perceived barriers) 
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Table 2: (continued)       
Authors, year Type of Stakeholder Location Study Design* Methodology Date data 
collected 
Sample size Theory 
Pitts and Tufts 
(2013) ††† 
Parents/guardians 4th 
to 7th grade (9 to 13) 
girls 
Virginia QL 8 Focus 
Groups  
2008 33 For data analysis: 
thematic analytic 
procedures 
Nan et al.,  
(2014) 
 
(asked about 
HPV vaccine 
mandate for 
girls only) 
Undergraduate 
students 18 to 29 
Northeastern, 
US 
Exp. 
 
Web-based  Not reported: 
estimated to be 
2012 (p. 34), 
asked about girls 
only law 
559 
Gain =292, 
loss =267 
Cultural theory of Risk 
(cultural worldviews) 
and message framing 
theory (gained framed vs 
loss framed)  
some constructs of the 
Health Belief Model 
 
Pierre Joseph, 
Belizaire, et al. 
(2014) 
Minority men 18 to 
22 years old 
Boston, 
Massachusetts  
QL In-person 
surveys with 
open-ended 
questions  
2010-11 89 Health Belief Model – 
questions 
Data analysis: grounded 
theory and content 
analysis  
 
Pierre Joseph, 
Clark, et al. 
(2014) 
Minority women 18 
to 22 years old 
Boston, 
Massachusetts 
M In-person 
survey, semi-
structure 
interview, 
medical 
record review 
 
2007-09 132 Health Belief Model – 
qualitative questions 
Data analysis: grounded 
theory and content 
analysis  
M. L. Smith et 
al. (2014) 
18 to 22 college 
students  
Texas QT Online survey  Not reported 
(probably same 
as Wilson, 2016) 
 
1,322 None mentioned 
Califano et al. 
(2016) 
(ask about HPV 
vaccine school-
entry for all 
aged 11 to 12 
years old) 
 
Physicians 
(pediatricians and 
family physicians) 
National panel 
sample 
QT Online survey 2014 775 None mentioned  
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Table 2: (continued)       
Authors, year Type of Stakeholder Location Study Design* Methodology Date data 
collected 
Sample size Theory 
Calo et al., 
(2016) 
(asked about 
HPV vaccine 
school-entry for 
all 11 to 12 
year olds) 
 
Parents of 11 to 17-
year-old children 
National panel 
sample 
QT Web-based 
survey 
Nov. 2014 to Jan. 
2015 
1,501 None mentioned – look 
at the literature to look 
for predictors, scale for 
psychologic reactance, 
items from the Carolina 
HPV immunization 
attitudes and beliefs 
scale, item for vaccine 
importance 
Vercruysse et 
al. (2016) 
(asked about 
HPV vaccine 
school-entry for 
children to go 
to high and 
middle school) 
 
Parents of 11 to 17-
year old girls and 
health care providers 
Boston, 
Massachusetts  
QL/qt – chi-
squares 
Semi-
structured 
interviews 
2012-13 129(parents) 
34(providers) 
Health Belief Model and 
Transtheoretical model – 
for the questions 
Wilson and 
Smith (2016) 
College female 
students  
2 large Texas 
universities 
QT Internet-
delivered 
questionnaire 
Feb. 2011 to 
March 2011 
1,105 None mentioned – for 
data collection they used 
previously validated 
items.  
 
 Note: * QL = qualitative, QT = quantitative, M = mixed methods, Exp. = experimantal.  † = same dataset/participants, †† = same dataset/participants, ††† = 
same dataset/participants. ** This study is mostly about the policy formation process, but some opinions about school-entry requirements are discussed, 
thus, was included.    
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Table 3: Studies about stakeholders’ reasons and factors associated with an HPV vaccine school-entry requirement in the US: Main 
findings (N=25) 
Author, year Type of stakeholder Support Against 
 
Tissot et al. (2007) Pediatricians Maximize public health impact on immunization HPV not casually transmitted, concerned about 
long-term safety and efficacy of vaccines 
 
Kahn et al. (2009) Primary care 
physicians 
Effective strategy for vaccine uptake, access, 
policy guided by PH impact of vaccination, 
parents can opt-out (religious, philosophical and 
other) 
Patients not covered by Medicaid or VFC may 
not be able to get vaccine, public poor 
understanding of HPV and the vaccine, not 
enough data on long-term efficacy, parents’ 
autonomy, clinicians experience with vaccine is 
limited, HPV not casually transmitted, risky 
sexual behaviors 
 
Millen et al. (2009) Emergency 
department patients 
Higher support among those who knew that HPV 
was STD 
Support was not higher among those who have 
heard of HPV or that knew it causes cervical 
cancer 
Sanderson et al. (2009) HPV+ and HPV- 
Latina mothers 
Majority HPV+ and HPV- in favor of Texas law, 
HPV+ more than twice likely  
 
Colgrove et al. (2010)† Multiple: mostly 
policymakers, 
industry, medical prof. 
orgs., advocacy groups 
Cervical cancer severity, efficacy of the vaccine, 
mandate promote uptake equity (less motivated or 
knowledgeable parents)  
8 factors: 5 – based on the characteristics of the 
vaccine (newness of the vaccine, sexually 
transmitted nature of HPV, HPV not 
transmittable in classroom, discomfort with 
involvement of the vaccine manufacturer, price) 
3 – based on the vaccine policymaking process 
(government coercion, anti-vaccine activism, 
policymaking process) 
 
Ferris et al. (2010)†† Parents/guardians 
of children 9-17 years 
old 
Characteristic of parents – low SES, history of 
HPV-related disease, understand children 
susceptibility, interested in the HPV vaccine, 
know HPV vaccine reduces risk cervical cancer. 
Parents more likely to comply – children ages 12 
to 14, knew vaccine reduces risks of genital warts 
and cervical cancer 
 
In a scenario that HPV vaccine was required most 
allowed to vaccinate their children, those who 
don’t – autonomy 
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Table 3: (continued)    
Author, year Type of stakeholder Support Against 
 
Horn et al. (2010)†† Parents/guardians 
of children 9-17 years 
old 
 
Most supported mandatory vaccine programs but 
only 43% if HPV vaccine included 
Infringement on their rights, vaccine not well 
studied, vaccine has many side effects 
Kahan 2010  “when subjects see the argument, they are 
disposed to reject being made by the advocate 
whose values they share, and the argument they 
are predisposed to accept being made by the 
advocate whose values they repudiate, 
polarization shrinks to the point of disappearing.” 
(P. 509) 
“The results of the experiment suggest that 
disagreements about the risks and benefits of 
HPV vaccination are shaped by cultural values, 
which exert their influence through the biased 
assimilation of information and through 
attributions of information-source credibility.” (p. 
512) 
 
No argument condition: 
Hierarchy correlated positively with risk 
(participants perceived > risk as 
they became more hierarchical and < risk as they 
became more egalitarian) 
unattributed arguments condition:  
“subjects exposed to arguments became more 
concerned about risk as their worldviews became 
more individualistic and less concerned as their 
worldviews became more communitarian.” (p. 
508) 
Rebecca B. Perkins et al. 
(2010) 
Parents of girls 11 to 
18 (included ethnic 
minorities)  
62% of parents in favor but varied by ethnicity 
only 11% of Caucasians endorsed it, immigrants 
more likely to support. Reasons: to prevent 
cervical cancer, protect from sexually active 
adolescents, PH intervention good for all 
 
Personal choice, transmission not through social 
contact, new vaccine with side effects 
St John et al. (2010)††† News media and 
parents/guardians of 
girls 9-13 
This study is about an existing mandate. News: 
legislation aspects, opt-out amendment by the 
governor, support from the legislature, based on 
discourse from experts (lacked parents 
discussion), supporters – prevent 
Focus groups: positive about the HPV vaccine  
 
News: concerns about marketing and lobbying of 
vaccine, recent approval by the FDA, not long on 
the market, critics – bill too quick 
Focus groups: skeptical of the motivations, 
concerns pharma lobbying, opt-out as a ploy to 
get to agree, lack of information, HPV 
vaccination should be a personal choice 
Yeganeh et al. (2010) Parents/guardians (all 
females) of girls ages 
11-17 (mostly Latino) 
64% agree with the mandate, 89% would get 
daughter vaccinated. More likely to support if 
thought vaccines were safe, had pap test in the 
last year, already vaccinated daughter, Latino.  
 
20% disagree, 15% unsure.  
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Table 3: (continued)    
Author, year Type of stakeholder Support Against 
 
Carlos 2011 Mothers/caretakers 
(25-55 years old) of 
females 9 to 17 
engaging in breast & 
cervical cancer 
screening 
Low intent 22.2%, undecided (14.3%), and high 
intent 63.5%.* 
When looking only at mothers of 11 to 12 years 
old – 29.3% low intent, 12% undecided, 58.7% 
high intent  
Univariate analyses – individual knowledge and 
attitudes, vaccination benefits, belief daughter 
medical provider recommends, daughter is 
sexually active or soon will be higher odds to 
intent to comply with the mandate 
Multivariate model – high vaccine benefits 
*scale had 11 items, collapse into 3 groups  
 
Univariate analyses – demographics not 
associated 
Univariate analyses – safety concerns, daughter 
too young, and religious and moral beliefs had 
lower odds of intention to comply.  
Multivariate model – high safety concerns, 
daughter too young for vaccination,  
  
Robitz et al. (2011) Parents (mostly 
Hispanic or African 
American) of 11 to 18 
years old girls from 
communities with 
high-risk for cervical 
cancer 
59% thought the law was a good idea, mostly 
were Hispanics responding in Spanish, daughter’s 
HPV-vaccinated or intent to vaccine, belief the 
HPV vaccine works well. 
Agreement increased to 92% when including 
participants who think the law is ok if parents can 
opt-out.  
 
African American less likely to support, belief 
vaccine not work well, daughters not vaccinated 
or no intent, HPV vaccine is too new 
 
J. S. Smith et al. (2011) Parents/guardians of 
girls 10 to 18 years old 
47% agree to HPV-school entry laws, agreement 
increased to 84% when opt-out mentioned 
Predictors to support – daughters had initiated or 
intent to get the HPV vaccine, belief HPV 
vaccine effective against cervical cancer, 
beneficial if given at young age, regret if 
daughters not vaccinated and got HPV, belief that 
all children should get it.  
 
Less likely to support predictors – concerns HPV 
vaccine safety, causing health lasting problems, 
daughter might initiate sex, belief HPV vaccine 
pushed by drug companies, new vaccine, decision 
is for parents alone 
Sara E. Abiola et al. (2013) 
†** 
Multiple: mostly 
policymakers, 
industry, medical prof. 
orgs., advocacy groups 
Effective policy entrepreneurship – policy (any) 
would likely succeed  
Factors against compulsory measures: HPV is 
sexually transmitted (not spread through social 
contact, girls would perceive can engage in sex, 
make parents have sexual intimacy conversations 
when not ready or willing) concerns of the new 
vaccine’s safety and efficacy, vaccine 
manufacturer too involved in the policy process 
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Table 3: (continued)    
Author, year Type of stakeholder Support Against 
 
R. B. Perkins et al. (2013) Low income and 
minority 
parents/guardians of 
boys 11 to 17 years 
old 
Prevention and protection, protect child, public 
health, perceived severity of HPV. 
 
All participants (supporters and not) thought 
requirements should be for males and females. 
 
Personal choice, lack of information, not 
transmissible by casual contact, depends on age 
of the child 
 
 
 
Pitts and Tufts (2013)††† Parents/guardians 4th 
to 7th grade (9 to 13) 
girls 
This study is about an existing mandate. Positive 
about the opt-out option 
Parental rights and decision, HPV sexually 
transmitted, not enough research on the vaccine, 
not known long term efficacy of the vaccine, lack 
knowledge about the mandate, need for education 
 
Nan et al., (2014) 
 
(asked about HPV vaccine 
mandate for girls only) 
Undergraduate 
students 18 to 29 
(ask about the mandate 
for girls on only) 
Having the HPV vaccine predicted more 
perceived benefit and less risk 
Individualism-communitarianism – no prediction 
of benefits or risk.  
Pre-exposure attitudes, having the HPC vaccine 
strong predictor of support 
Support – loss-framed message support among 
the hierarchical, egalitarians supported policies 
with a gain-framed message  
 
Female students perceived the mandate less 
beneficial and riskier than males 
Blacks perceived greater risk 
Stronger hierarchical worldview predicted less 
benefit and perceived more risk of the HPV 
vaccine mandate 
Females, Hierarchical worldview showed less 
support 
 
Pierre Joseph, Belizaire, et 
al. (2014) 
Minority men 18 to 22 
years old 
Latino (72%) and Haitian (58%) more pro-
mandate, next Caucasian (57%) and African 
American (55%) 
Important for public health, benefit victims of 
sexual abuse 
 
Might promote promiscuity, beliefs “Christian 
scientists” 
There might be some ethnic differences in 
supporting/against the HPV vaccine. 
Pierre Joseph, Clark, et al. 
(2014) 
Minority women 18 to 
22 years old 
Mostly supported because adolescents are 
engaging in sexual activity and parents don’t 
know, public health concerns 
 
Personal choice, left to parents, students are not 
having sex in school  
M. L. Smith et al. (2014) 18 to 22 college 
students 
57.8% supported HPV vaccination mandates for 
both genders. 48.9% supported mandates for ages 
18 to 26, 48.4% for ages 12 to 17, and 15.1% for 
ages 9 to 11. 
Mostly non-white, and engage in sex, friends had 
HPV vaccine 
42% did not support HPV vaccination mandates 
for boys or girls  
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Table 3: (continued)    
Author, year Type of stakeholder Support Against 
 
Califano et al. (2016) 
(ask about HPV vaccine 
school-entry for all aged 
11 to 12 years old) 
Physicians 
(pediatricians and 
family physicians) 
47% agree to HPV vaccine for school entrance, 
18% with opt-out provisions only,  
74% with or without opt-out  
Predictors: in practice longer than 20 years, 
giving quality HPV recommendation, HPV is as 
important as Tdap and meningococcal 
 
Only 12% did not agree under any circumstances  
Calo et al., (2016) 
(ask about HPV vaccine 
school-entry for all aged 
11 to 12 years old) 
Parents of 11 to 17-
year-old children 
21% parents agree that laws are a good idea 
When opt-out options were included agreement 
increased - 57% 
Factors (without opt-out) in multivariate model: 
Hispanic parents, HPV vaccine was as or more 
important than other vaccines, HPV vaccine 
effective in prevention cervical cancer, it would 
be hard to find a clinic or provider where they 
could afford it 
Factors (with opt-out) in multivariate model: 
believed HPV prevents cervical cancer and HPV 
vaccine was as or more important than other 
vaccines. 
 
54% disagree 
 
Disagreement 21% 
Factors (without opt-out) in multivariate model: 
believed HPV vaccine was pushed by drug 
companies to make money, resided in the 
Midwest states compared to Northeast states 
Factors (with opt-out) in multivariate model: no 
other variable associated. 
Vercruysse et al. (2016) 
(asked about HPV vaccine 
school-entry for children to 
go to high and middle 
school) 
Parents of 11 to 17-
year-old girls and 
health care providers 
Parents: overall prevention or protection of their 
child’s health, support of other vaccines, the 
benefits overweighed risks, and the protection 
adolescents from STIs 
Providers: a third favored this mandate option, 
mentioned the common good and improving 
vaccination rates 
This study also addressed parents and providers 
attitudes - school-based programs.  
 
Parents: limitation to parents’ autonomy, lack of 
transmission through casual contact, a new 
vaccine, and adolescents not been sexually active 
Providers: worried that implementation could be 
challenging and costly, society not ready and lack 
transmission through casual contact 
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Table 3: (continued)    
Author, year Type of stakeholder Support Against 
 
Wilson and Smith (2016) College female 
students  
13% supported HPV vaccine mandates for 9 to 
11, 47.5% for aged 11-17 
Reasons: (agree/strongly agree) 
61% protect the public from disease, 51% to 
lower societal health-care costs, 70% to promote 
women’s health concerns, and 19.5% to make 
casual sex safer. 
Participants characteristics associated – those 
who completed the HPV vaccine 
Participants supported mandates for both age-
groups: sexually active, had Pap test, and had 
more friends who reported receiving the HPV 
series 
Participants who supported mandates for 12–17 
years old were single & engaged in sexual 
activity 
Beliefs associated mandates 9 to 11 years – HPV 
prevented by using condom, and getting a vaccine 
Mandate for 12 to 17-year-old - HPV is 
preventable by getting a vaccine aged 9–11  
significant larger proportion of participants 
completed the HPV vaccination supports for all 
reasons  
 
 
 
59.5% believe mandates violate personal 
freedom, 47.0% believe mandates violate parental 
rights.   
25% reported government is untrustworthy, 
safety concerns and 51.2% because of costs  
 
 
 
 
 
 
 
 
 
 
 
 
small proportion is against vaccination mandates  
Note: † = same dataset/participants, †† = same dataset/participants. ** This study is mostly about the policy formation process, but some opinions about school-
entry requirements are discussed.    
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Table 4: Additional exemplary quotes by theme 
Theme Sub-theme Quote Spanish Quote English 
Problems Indicators  “Las estadísticas dicen que, "Ocho de cada 10 personas 
van a verse afectadas en el virus", y yo acabo de tener 
un infográfico, que dice que, "Una de cada 54 personas 
va a padecer con cáncer cervical asociado al VPH en 
Puerto Rico". […] Nosotros somos más altos en HVP 
que en Estados Unidos, tenemos más cáncer, por 
ejemplo, 4.6 es la incidencia de cáncer cervical en 
Estados Unidos, en Puerto Rico creo es un 11.”—002 
 
“Statistics say that, “Eight out of ten people will be 
affected by the virus”, and I just had an infographic that 
said, “One out of 54 people in Puerto Rico will suffer from 
HPV related cervical cancer.” [...] We are higher on HPV 
than in the United States, we have more cancer, for 
example, 4.6 is the cervical cancer incidence in the United 
States, in Puerto Rico, I believe it is 11.”—2, Non-profit 
Focusing events  “yo te diría que un trabajo de muchos años; claro, en 
VOCES, desde que se constituyó ha tenido un rol bien 
importante la coalición porque ellos conformaron un 
grupo de paneles de expertos y desarrollaron el informe 
que habla específicamente sobre el informe en relación 
al Virus de Papiloma Humano con este comité, este 
panel asesor.” –008  
 
“A work of many years I would say; clearly, in VOCES, 
since its founding, the coalition has had a very important 
role because they formed a group of experts and 
developed the report that specifically talks about the 
report in relation to the Human Papillomavirus with this 
committee, this advising panel.” –008, Other 
Feedback “Ahora mismo, hoy te puedo decir que hemos sido 
reconocidos recientemente, Puerto Rico obtuvo un 
premio en los Estados Unidos porque es uno de los 
países donde tiene una alta incidencia de vacunación. 
Así que yo creo que eso es positivo, pero tenemos que 
aspirar a un poquito más.” – 021 
 
“Right now, today I can say that we have been recently 
recognized, Puerto Rico obtained an award because it is 
one of the countries in which there is a high vaccination 
rate. So, I believe that is positive, but we need to aspire to 
a bit more.” –021, Government 
Policy Soup of ideas “El proyecto de ley de la cámara 1303 apoya todos los 
esfuerzos que está haciendo el secretario de salud, no 
habla específicamente de la vacuna VPH, habla de 
todas las vacunas y de cómo mejorar el acceso a todas 
las vacunas, por ejemplo, con un reporte de la 
administración de cada vacuna para tener un sistema 
epidemiológico completo que nos va a permitir hacer 
proyecciones de qué regiones de las isla están más 
protegidas, tienen una inmunidad más completa, en caso 
de brote estamos mejor preparados para entrar a 
proteger, esos sectores que estén más vulnerables.” –
005 
“The HR bill 1303 supports all the efforts that the 
secretary of health is doing it does not specifically talks of 
the HPV vaccine, it talks about all vaccines and how can 
access be improved for all vaccines, for example, with a 
report of each vaccine administered so that we have a 
complete epidemiological system that will allow us to 
create projections of which island regions are protected 
more, have a more complete immunity, in case of an 
outbreak we are better prepared to go in [and] protect the 
most vulnerable sectors.” –005, Other 
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Table 4: (continued)   
Theme Sub-theme Quote Spanish Quote English 
Policy Technical 
Feasibility  
“En Puerto Rico hay una peculiaridad bien importante y 
es que quien decide las vacunas y las dosis que se van a 
requerir para admisión escolares, es el secretario de 
Salud. “En otros estados es la legislatura. Aquí es un 
proceso que se ha determinado desde 1974, desde 
nuestro primer mandato legislativo en vacunación, que 
es una jurisdicción exclusiva de quien tiene la expertise 
en materia de salud científica.” –005  
 
“In Puerto Rico there is a very important distinctiveness 
and that is that the one who decides the vaccines and the 
dosages that will be required for school entrance, is the 
secretary of health. In other states it is the legislature. 
Here it is a process that has been determined since 1974, 
since our first legislative immunization law, which is an 
exclusive jurisdiction of who has the expertise on the field 
of scientific health.” –005, Other 
 
Value 
acceptability  
“Así que dentro de los primeros 10 cánceres, vamos a 
poner tanto en hombres como en mujeres, cánceres 
asociados a VPH son las primeras razones de muerte. 
Por ende, esto es un asunto de salud pública que hay 
que atender.” —002 
 
“So in the first 10 cancers, including in men as in women, 
HPV-related cancers are the first [number one] causes of 
death. Hence, this is a public health matter that needs to 
be addressed.”—002, Non-profit 
Level of 
integration 
“Hubo un consenso, uniforme de todos los 
participantes, de que en Puerto Rico se debía promover 
el uso de la vacuna y que, eventualmente, si queríamos 
bajar nuestras tasas de incidencia del virus, debíamos 
promocionar también que fuese uno de los requisitos de 
admisión escolar, ¿por qué? Porque durante las edades 
que es más efectiva crear la inmunidad en el cuerpo 
contra ese virus es las edades de adolescencia.” –005  
 
“Hubo un consenso, uniforme de todos los participantes, 
de que en Puerto Rico se debía promover el uso de la 
vacuna y que, eventualmente, si queríamos bajar nuestras 
tasas de incidencia del virus, debíamos promocionar 
también que fuese uno de los requisitos de admisión 
escolar. Why? Because it is the most effective during the 
ages of adolescence to create immunity in the body 
against that virus.” –005, Other 
Politics  Pressure-groups 
campaigns  
“Muchos padres han hecho este comentario, pero no les 
gusta que se sientan obligados, que es obligatorio, que 
es mandado, por eso es que se usa la palabra requisito, 
no mandatorio.” –010  
“Many parents have made this comment, but they do not 
like feeling forced, that it is mandatory, that it is 
mandated, that is why the word requirement is used, not 
mandatory.” –010, Government 
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Table 4: (continued)   
Theme Sub-theme Quote Spanish Quote English 
Politics Administrative or 
legislative 
turnover 
 
“No solamente en las esferas de salud, sino también las 
esferas legislativas o en las esferas organizacionales, 
gubernamentales, en este caso el Departamento de 
Salud, para que ahora se tome la decisión de cuán 
importante es incluir la vacuna del virus del papiloma 
humano como una vacuna requisito, considerarlo y 
ahora de acuerdo al secretario de Salud que salió la 
carta hace poco del schedule de vacuna para este nuevo 
donde, se incluye. Entiendo que todos estos esfuerzos 
han ayudado a que otras esferas, como son estas, hayan 
tomado el interés genuino y se hayan dado la tarea a 
conocer un poco más, al punto de ahora tengamos un 
secretario que sí está apoyando lo que es el requisito en 
la vacuna.” –018  
 
“Not only in the health sectors, but also in the legislative 
sectors or in the  organizational sectors, governmental, in 
this case the Department of Health in order to make the 
decision now of how important it is to include the human 
papillomavirus vaccine as a required vaccine, consider it 
and now in accordance to the Secretary of Health a 
vaccine schedule announcement was recently released for 
this new, where it is included.  I understand that all of 
these efforts have helped other sectors, like these ones, 
take a genuine interest and take the task of getting to know 
a bit more, to the extent that now we have a secretary that 
is supporting the vaccine requirement.” –018, Non-profit 
Policy window  “[…] este año pasado nos sentamos con el secretario de 
Salud y con el Programa de Vacunación y demostramos 
que se habían cubierto todas las áreas que habíamos 
establecido, y que ya estábamos listos para dar el paso. 
No solamente estábamos listos para dar el paso, sino 
que era un momento importante […]” –002  
 
“[…] this past year we sat with the Secretary of Health 
and with the Vaccination Program, and we demonstrated 
that we had covered all the areas that we had established, 
and that we were ready to take the step. Not only were we 
ready for taking the step, but it was [also] an important 
moment.” –002, Non-profit 
Policy 
Entrepreneurs 
Non-profit 
organizations  
“El Departamento de Salud, VOCES, que es la coalición 
de vacunación, el Centro Compresivo del Cáncer, las 
asociaciones que tienen que ver con cáncer cervical y 
eso, la Coalición de Cáncer de Puerto Rico, ese tipo de 
organizaciones o grupos. –011” 
 
“The Department of Health, VOCES, which is the 
vaccination coalition, the Comprehensive Cancer Center, 
the cervical cancer related associations and that, the 
Cancer Coalition of Puerto Rico, that type of 
organizations or groups.” –011, Government  
Academia “Lo que ha pasado en Puerto Rico es que esto se ha 
seguido investigando y en la medida que tú tienes más 
investigación, más información; y me refiero, por 
ejemplo, a los estudios que ha hecho el Centro 
Comprensivo de Cáncer.” 
“What has happened in Puerto Rico is that there has been 
ongoing research and as you have more research, more 
information; and I am referring to, for example, the 
studies conducted by the Comprehensive Cancer Center.” 
Medical 
professional 
organizations 
“Obviamente tiene el endoso del presidente del Colegio 
de Médicos que es la asociación privada del sector 
privado más importante de salud en Puerto Rico, más el 
endoso de todas las organizaciones pediátricas.”—004  
 
“Obviously, it has the endorsement from the president of 
the College of Physicians, which is the most important 
private health association in Puerto Rico, plus the 
endorsement of all the pediatrics organizations.”—004, 
Researcher 
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Table 4: (continued)   
Theme Sub-theme Quote Spanish Quote English 
Policy 
Entrepreneurs 
Government  “Colaboramos mucho también con el programa de 
vacunación del Departamento de Salud. Yo creo que 
todas esas conversaciones han llegado también al 
secretario, y por eso es que se hace esta 
recomendación.” –014  
 
“We also collaborated a lot with the Department of 
Health’s vaccination program. I think all of those 
conversations have also reached the secretary, and for 
that it is why this recommendation is being made.” –014, 
Researcher 
 
Private sector “Sí, el sector privado también, no cabe duda de que 
hemos tenido un apoyo increíble de todos los 
sectores.”—005 
 
“Yes, the private sector too, there is no doubt that we have 
had an incredible support from all the sectors.” –005, 
Other 
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Table 5: Timeline of policies and strategies leading to the HPV vaccine school-entry requirement 
in PR 
Date Policy, Strategy or Event Description 
July 23rd, 
1974 
Act 235: Compulsory Immunization 
of students  
 
First immunization law in PR* 
Sept. 25th, 
1983 
Act 25: Immunization Law Current immunization law* 
 
Jan. 20th, 
2010 
Act 9: Insurance coverage  Private health insurance companies must cover the HPV 
vaccine for girls ages 11 to 18* 
 
Sept. 15th, 
2012 
Act 255: Amendment to Act 9 of 
2010 
To include 11 to 18 boys to the HPV vaccine health 
insurance coverage* 
 
January 
2015 
Rhaiza López Plumey Passing and Interview video posted on social media 
 
May 2015 VOCES HPV Advisory Panel 
Report 
Sponsored by VOCES* 
 
 
June 19th, 
2015 
Act 91 To declare the first week of August “The week of HPV 
awareness and prevention.” 
 
June 12th, 
2017 
DOH announcement The HPV vaccine was going to be required for school-
entry for the 2018-2019 academic year* 
 
Summer 
2017 
Education and promotion 
campaigns 
By non-profit organizations, such as VOCES and the DOH 
 
June 20th, 
2017 
Act 36: Make the month of January 
the “Cervical Cancer Prevention 
Month.”  
 
Jan. 27 “Cancer Prevention Day” TEAL day 
 
Aug. 30th, 
2017 
HR Bill 537: Investigation  To order the Health committee of the HR to investigate the 
efficacy and safety of the HPV vaccine. Approved on Sept. 
15th, 2017 
 
Nov. 1st, 
2017 
HR Bill 1303: New immunization 
law 
To create a new immunization law for minors and students. 
Petitioned by VOCES 
 
Feb. 8th, 
2018 
HR Bill 1303 and  
HR Resolution 537 - investigation 
Public hearings 
 
 
May 2nd, 
2018 
HR Bill 1576 Petitioned by an anti-vaccination group 
 
June 11th, 
2018 
HR Resolution 537 – investigation 
published 
Concludes that the DOH’s determination to include the 
HPV vaccine to the school required vaccine schedule 
aligns with the medical community position.  
 
May 30th, 
2018 
DOH announcement  HPV vaccine school-entry requirement* 
Notes: HR – House of Representatives, DOH – Dept. of Health, specific dates were obtained from the HR bills or announcements, * policies or 
strategies known by the researcher before data collection 
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Table 6: Number of news articles published by year 
Year Frequency Percent 
2015 
2016 
2017 
2018* 
Total 
65 22.7 
92 32.2 
82 28.7 
47 16.4 
286 100.0 
*Note: until July 31st, 2018 
 
Table 7: Overall distribution of newspaper articles by primary focus 
Primary Focus Frequency Percent 
Educational/informative about HPV & HPV vaccine 68 23.8 
Advertisement 48 16.8 
Vaccines in general 32 11.2 
Cervical cancer/screening 31 10.8 
HPV vaccine school-entry 19 6.6 
Health in general 17 5.9 
Cancer in general 17 5.9 
Other HPV-related cancers 12 4.2 
Scientific/Research advancements 9 3.1 
About STIs including HIV 8 2.8 
School-entry/Other policies 8 2.8 
DOH/government announcement 7 2.4 
Reforma/Obamacare/insurance 3 1.0 
Contraceptives 3 1.0 
Other Focus 2 0.7 
Rhaiza López Plumey 2 0.7 
Total 286 100 
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Table 8: Articles published for each primary focus category by year 
Focus 2015 2016 2017 2018* Total  
Educational/informative about HPV & HPV 
vaccine 14 25 18 11 68 
Advertisement 4 22 13 9 48 
Vaccines in general 12 7 6 7 32 
Cervical cancer/screening 4 15 9 3 31 
HPV vaccine school-entry 1 0 13 5 19 
Health in general 5 5 5 2 17 
Cancer in general 5 7 3 2 17 
Other HPV-related cancers 3 3 6 0 12 
Scientific/Research advancements 4 3 0 2 9 
About STIs including HIV 4 1 3 0 8 
School-entry/Other policies 2 1 2 3 8 
DOH/government announcement 2 2 1 2 7 
Salud/Obamacare/insurance 2 0 1 0 3 
Contraceptives 3 0 0 0 3 
Other Focus 0 0 1 1 2 
Rhaiza 0 1 1 0 2 
Total 65 92 82 47 286 
*Note: until July 31st, 2018 
 
Table 9: Number of articles that mentioned the HPV vaccine school-entry requirement published 
by year and newspaper source 
Source 
Year  
2015 2016 2017 2018* Total 
 El Nuevo Dia 1 0 9 10 20 
Endi.com 1 0 2 1 4 
Vocero 0 0 2 2 4 
vocero.com 0 0 3 3 6 
Total 2 0 16 16 34 
*Note: until July 31st, 2018 
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Table 10: Type of argument included in the articles that mentioned the HPV vaccine school-
entry requirement by year of publication 
Type of argument 
Year 
Total 2015 2017 2018* 
Against 
In favor of 
Both arguments 
Other 
0 3 2 5 
2 10 8 20 
0 1 4 5 
0 2 2 4 
Total 2 16 16 34 
*Note: until July 31st, 2018 
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